@NP	Olfactory ensheathing cells , olfactory nerve fibroblasts and biomatrices	1
@NP	Olfactory ensheathing cells	1
@NP	olfactory nerve fibroblasts	30
@NP	biomatrices	62
@NP	long-distance axon regrowth and functional recovery	85
@NP	the dorsally hemisected adult rat spinal cord R.	140
@NP	the dorsally hemisected adult rat spinal cord	140
@NP	R.	186
@NP	Deumens a , , G.C.	189
@NP	Deumens	189
@NP	a , , G.C.	197
@NP	a ,	197
@NP	G.C.	202
@NP	Koopmans a , b , W.M.M.	207
@NP	Koopmans a	207
@NP	b	218
@NP	W.M.M.	221
@NP	Honig b , F.P.T.	228
@NP	Honig b	228
@NP	F.P.T.	237
@NP	Hamers c , V.	244
@NP	Hamers c	244
@NP	V.	254
@NP	Maquet d , R.	257
@NP	Maquet d	257
@NP	R.	267
@NP	Jérôme d , H.W.M.	270
@NP	Jérôme d	270
@NP	H.W.M.	280
@NP	Steinbusch a , E.A.J.	287
@NP	Steinbusch a	287
@NP	E.A.J.	301
@NP	Joosten b	308
@NP	a Department of Psychiatry	318
@NP	a Department	318
@NP	Psychiatry	334
@NP	Neuropsychology	349
@NP	Division Neuroscience	366
@NP	European Graduate School of Neuroscience -LRB- EURON -RRB-	389
@NP	European Graduate School	389
@NP	Neuroscience -LRB- EURON -RRB-	417
@NP	Neuroscience	417
@NP	EURON	431
@NP	University of Maastricht , P.O.	439
@NP	University	439
@NP	Maastricht , P.O.	453
@NP	Box 616 , 6200	470
@NP	MD	484
@NP	Maastricht	488
@NP	The Netherlands b Department of Anesthesiology	500
@NP	The Netherlands b Department	500
@NP	Anesthesiology	532
@NP	Academic Hospital Maastricht , P.O.	548
@NP	Academic Hospital Maastricht	548
@NP	P.O.	578
@NP	CS axon regrowth	1219
@NP	large lesion gaps	1243
@NP	we	1262
@NP	a multifactorial transplantation strategy	1270
@NP	an OEC/ONF continuum in spinal cords	1322
@NP	an OEC/ONF continuum	1322
@NP	spinal cords	1346
@NP	a 2-mm-long dorsal hemisection lesion gap	1364
@NP	This strategy	1407
@NP	the use of aligned OEC/ONF	1430
@NP	the use	1430
@NP	aligned OEC/ONF	1441
@NP	poly -LRB- D , L -RRB-	1457
@NP	poly	1457
@NP	lactide biomatrix bridges within the lesion gap	1467
@NP	lactide biomatrix bridges	1467
@NP	the lesion gap	1500
@NP	OEC/ONF injections at 1 mm rostral and caudal	1519
@NP	OEC/ONF injections	1519
@NP	1 mm rostral and caudal	1541
@NP	1 mm rostral	1541
@NP	caudal	1558
@NP	the lesion gap	1568
@NP	the effects of this complete strategy	1601
@NP	the effects	1601
@NP	this complete strategy	1616
@NP	control animals	1640
@NP	injections	1670
@NP	culture medium rostral and caudal	1686
@NP	culture medium rostral	1686
@NP	caudal	1713
@NP	the lesion gap	1723
@NP	our multifactorial intervention	1753
@NP	an enhanced presence	1797
@NP	injured CS axons	1821
@NP	the lesion gap	1858
@NP	65.0 ± 12.8 % in transplanted animals versus 13.1 ± 3.9 % in control animals	1874
@NP	65.0	1874
@NP	transplanted animals versus 13.1 ± 3.9 % in control animals	1890
@NP	transplanted animals	1890
@NP	13.1 ± 3.9 %	1918
@NP	13.1 ±	1918
@NP	control animals	1933
@NP	No regrowth of these axons	1951
@NP	No regrowth	1951
@NP	these axons	1966
@NP	the lesion site	1999
@NP	a lack of OEC/ONF survival	2040
@NP	a lack	2040
@NP	OEC/ONF survival	2050
@NP	the biomatrices	2070
@NP	a 10-fold increase	2100
@NP	neurofilament-positive axon ingrowth	2122
@NP	the lesion site as compared to untreated control animals	2164
@NP	the lesion site	2164
@NP	untreated control animals	2195
@NP	the use of quantitative gait analysis	2240
@NP	the use	2240
@NP	quantitative gait analysis	2251
@NP	a modest recovery in stride length and swing speed of the hind limbs	2279
@NP	a modest recovery	2279
@NP	stride length	2300
@NP	speed of the hind limbs	2324
@NP	speed	2324
@NP	the hind limbs	2333
@NP	multifactorial strategies	2371
@NP	repair of large spinal lesion gaps	2424
@NP	repair	2424
@NP	large spinal lesion gaps	2434
@NP	we	2460
@NP	the combined use of OEC/ONF and poly -LRB- D , L -RRB- - lactide biomatrices	2477
@NP	the combined use	2477
@NP	OEC/ONF and poly -LRB- D , L -RRB- - lactide biomatrices	2497
@NP	OEC/ONF and poly	2497
@NP	lactide biomatrices	2519
@NP	Introduction Axonal disruption	2560
@NP	the key factor	2594
@NP	respect to functional loss	2614
@NP	respect	2614
@NP	functional loss	2625
@NP	spinal cord injury -LRB- SCI -RRB-	2647
@NP	spinal cord injury	2647
@NP	SCI	2667
@NP	Spontaneous regeneration of severed axons	2673
@NP	Spontaneous regeneration	2673
@NP	severed axons	2701
@NP	the injuryinduced disbalance	2749
@NP	growth-promoting and growthinhibiting factors	2786
@NP	the spinal cord environment -LRB- Fawcett , 1997 -RRB-	2835
@NP	the spinal cord environment	2835
@NP	Fawcett	2864
@NP	1997	2873
@NP	Transplantation of growth-promoting grafts	2880
@NP	Transplantation	2880
@NP	growth-promoting grafts	2899
@NP	this balance	2975
@NP	experimental conditions	2994
@NP	axon regrowth and functional recovery -LRB- Deumens et al. , 2005 -RRB-	3040
@NP	axon regrowth and functional recovery	3040
@NP	axon regrowth	3040
@NP	Deumens	3079
@NP	et al. , 2005	3087
@NP	et al.	3087
@NP	2005	3095
@NP	the last decade	3105
@NP	mixed cultures	3122
@NP	olfactory ensheathing cells	3140
@NP	OEC	3169
@NP	olfactory nerve fibroblasts	3178
@NP	ONF	3207
@NP	purified OEC cultures	3216
@NP	a possible therapeutic tool	3270
@NP	experimental SCI research -LRB- Raisman , 2001 -RRB-	3301
@NP	experimental SCI research	3301
@NP	Raisman , 2001	3328
@NP	Raisman	3328
@NP	2001	3337
@NP	OEC	3361
@NP	the mammalian olfactory system	3375
@NP	they	3413
@NP	olfactory axon regeneration	3428
@NP	the lifespan	3467
@NP	the organism -LRB- Ramon-Cueto and Avila , 1998 -RRB-	3483
@NP	the organism	3483
@NP	Ramon-Cueto and Avila , 1998	3497
@NP	Ramon-Cueto	3497
@NP	Avila , 1998	3513
@NP	Avila	3513
@NP	1998	3520
@NP	a process	3527
@NP	the presence of ONF -LRB- Raisman , 2001 -RRB-	3585
@NP	the presence	3585
@NP	ONF -LRB- Raisman , 2001 -RRB-	3601
@NP	ONF	3601
@NP	Raisman , 2001	3606
@NP	Raisman	3606
@NP	2001	3615
@NP	The CST	4241
@NP	a low regenerative response	4266
@NP	injury -LRB- Joosten , 1997 -RRB-	4300
@NP	injury	4300
@NP	Joosten	4308
@NP	1997	4317
@NP	regrowth of injured CS axons	4333
@NP	regrowth	4333
@NP	injured CS axons	4345
@NP	transplantation of mixed OEC/ONF	4388
@NP	transplantation	4388
@NP	mixed OEC/ONF	4407
@NP	OEC cultures	4434
@NP	the injured spinal cord tissue	4452
@NP	the spinal cord injury models	4484
@NP	small spinal lesion gaps	4531
@NP	the injured human spinal cord	4560
@NP	large cystic cavities	4591
@NP	long-distance axon regrowth	4636
@NP	Long-distance axon regeneration of olfactory axons	4665
@NP	Long-distance axon regeneration	4665
@NP	olfactory axons	4700
@NP	both OEC and ONF -LRB- Li et al. , 2005 -RRB-	4749
@NP	OEC	4754
@NP	ONF -LRB- Li et al. , 2005 -RRB-	4762
@NP	ONF	4762
@NP	Li	4767
@NP	et al. , 2005	4770
@NP	et al.	4770
@NP	2005	4778
@NP	we	4796
@NP	transplanted OEC/ONF cultures	4817
@NP	repair of injured CS axons across large spinal lesion gaps	4855
@NP	repair	4855
@NP	injured CS axons across large spinal lesion gaps	4865
@NP	injured CS axons	4865
@NP	large spinal lesion gaps	4889
@NP	regrowth of injured CS axons across large lesion gaps	4924
@NP	regrowth	4924
@NP	injured CS axons across large lesion gaps	4936
@NP	injured CS axons	4936
@NP	large lesion gaps	4960
@NP	a growth-stimulating source , such as OEC / ONF	4999
@NP	a growth-stimulating source	4999
@NP	OEC / ONF	5036
@NP	OEC	5036
@NP	ONF	5041
@NP	a physical substrate to bridge the lesion gap	5055
@NP	the lesion gap	5086
@NP	the use of millions of autologous growthpromoting cells	5120
@NP	the use	5120
@NP	millions of autologous growthpromoting cells	5131
@NP	millions	5131
@NP	autologous growthpromoting cells	5143
@NP	other bridges	5177
@NP	growth-promoting tissues -LRB- Coumans et al. , 2001 -RRB-	5220
@NP	growth-promoting tissues	5220
@NP	Coumans	5246
@NP	et al. , 2001	5254
@NP	et al.	5254
@NP	2001	5262
@NP	growthpromoting cells	5269
@NP	extracellular matrix molecules -LRB- Li et al. , 2003 -RRB-	5301
@NP	extracellular matrix molecules	5301
@NP	Li	5333
@NP	et al. , 2003	5336
@NP	et al.	5336
@NP	2003	5344
@NP	organic bridges -LRB- Schnell and Schwab , 1993 -RRB-	5355
@NP	organic bridges	5355
@NP	Schnell and Schwab	5372
@NP	1993	5392
@NP	the present study	5402
@NP	a multifactorial transplantation strategy including a physical bridge	5421
@NP	a multifactorial transplantation strategy	5421
@NP	a physical bridge	5473
@NP	an OEC/ONF continuum in rat spinal cords	5510
@NP	an OEC/ONF continuum	5510
@NP	rat spinal cords	5534
@NP	large lesion gaps	5556
@NP	dorsal hemisection	5581
@NP	CS axon regrowth	5623
@NP	Schnell and Schwab	5641
@NP	1990 ; Schnell et al. , 1994 ; Grill et al. , 1997 ; GrandPre et al.	5661
@NP	1990	5661
@NP	Schnell et al. , 1994 ; Grill et al. , 1997 ; GrandPre et al.	5667
@NP	Schnell	5667
@NP	et al. , 1994 ; Grill et al. , 1997 ; GrandPre et al.	5675
@NP	et al. , 1994	5675
@NP	et al.	5675
@NP	1994	5683
@NP	Grill et al. , 1997	5689
@NP	Grill	5689
@NP	et al. , 1997	5695
@NP	et al.	5695
@NP	1997	5703
@NP	GrandPre et al.	5709
@NP	GrandPre	5709
@NP	et al.	5718
@NP	2002	5726
@NP	we	5733
@NP	a 2-mm-long dorsal hemisection lesion	5741
@NP	OEC/ONF	5788
@NP	biomatrix complexes	5796
@NP	directional neurite growth	5852
@NP	Deumens	5889
@NP	et al. , 2004	5897
@NP	et al.	5897
@NP	2004	5905
@NP	the 2-mmlong dorsal hemisection	5943
@NP	lesion gaps	5975
@NP	addition	5991
@NP	OEC/ONF suspensions	6001
@NP	rostral and caudal	6035
@NP	the thoracic lesion site	6057
@NP	Migration	6083
@NP	OEC/ONF	6096
@NP	transplantation	6110
@NP	the injured spinal cord , as has been previously reported	6131
@NP	the injured spinal cord	6131
@NP	Li	6189
@NP	et al. , 1997 , 1998	6192
@NP	et al.	6192
@NP	1997	6200
@NP	1998	6206
@NP	a continuum of OEC/ONF	6229
@NP	a continuum	6229
@NP	OEC/ONF	6244
@NP	the injured spinal cord	6255
@NP	the effect	6298
@NP	this multifactorial treatment	6312
@NP	OEC/ONF -- biomatrix complexes and OEC/ONF cell injections	6352
@NP	OEC/ONF	6352
@NP	biomatrix complexes and OEC/ONF cell injections	6360
@NP	biomatrix complexes	6360
@NP	OEC/ONF cell injections	6384
@NP	control animals	6409
@NP	a graft	6441
@NP	the lesion site	6456
@NP	culture medium injections	6485
@NP	rostral and caudal	6511
@NP	the injury site	6533
@NP	We	6550
@NP	our multifactorial transplantation strategy	6570
@NP	regrowth	6625
@NP	injured CS axons across the large spinal lesion site	6637
@NP	injured CS axons	6637
@NP	the large spinal lesion site	6661
@NP	recovery of impaired body functions	6707
@NP	recovery	6707
@NP	impaired body functions	6719
@NP	Materials and methods	6745
@NP	Materials	6745
@NP	methods	6759
@NP	General All	6767
@NP	experimental procedures	6779
@NP	the recommendations	6831
@NP	the European Commission	6854
@NP	European Communities Council Directive of 24 November 1986 ; 86/609 / EEC	6879
@NP	European Communities Council Directive of 24 November 1986 ; 86/609 /	6879
@NP	European Communities Council Directive	6879
@NP	24 November 1986 ; 86/609 /	6921
@NP	24 November 1986	6921
@NP	86/609	6939
@NP	EEC	6947
@NP	protocols	6957
@NP	the Committee	6984
@NP	Animal Research of the Maastricht University	7001
@NP	Animal Research	7001
@NP	the Maastricht University	7020
@NP	DEC 2004-030	7047
@NP	this study	7065
@NP	every attempt	7077
@NP	the number of animals and their suffering	7112
@NP	the number	7112
@NP	animals and their suffering	7126
@NP	animals	7126
@NP	their suffering	7138
@NP	Male Lewis rats	7155
@NP	inbred , animal facilities of Maastricht University	7172
@NP	inbred , animal facilities	7172
@NP	Maastricht University	7201
@NP	7 weeks old	7225
@NP	7 weeks	7225
@NP	200 -- 250 g in body weight	7238
@NP	200	7238
@NP	250 g in body weight	7242
@NP	250 g	7242
@NP	body weight	7251
@NP	CatWalk behavioral testing	7284
@NP	Hamers	7312
@NP	et al. , 2001 ; Koopmans et al. , 2005	7319
@NP	et al.	7319
@NP	2001 ; Koopmans et al.	7327
@NP	2001	7327
@NP	Koopmans et al.	7333
@NP	Koopmans	7333
@NP	et al.	7342
@NP	2005	7350
@NP	they	7362
@NP	three consecutive runs	7390
@NP	hesitation	7421
@NP	the age of 9 weeks	7436
@NP	the age	7436
@NP	9 weeks	7447
@NP	the animals	7456
@NP	the CatWalk	7496
@NP	preoperative CatWalk data	7518
@NP	a dorsal hemisection of the spinal cord	7551
@NP	a dorsal hemisection	7551
@NP	the spinal cord	7575
@NP	T11/T12	7608
@NP	animals	7621
@NP	two groups	7656
@NP	one group -LRB- n = 10 -RRB-	7668
@NP	one group	7668
@NP	n	7679
@NP	10	7683
@NP	OEC/ONF -- biomatrix transplants	7696
@NP	OEC/ONF	7696
@NP	biomatrix transplants	7704
@NP	the lesion site and OEC/ONF suspensions	7731
@NP	the lesion site	7731
@NP	OEC/ONF suspensions	7751
@NP	the rostral and caudal cord stumps	7776
@NP	the rostral	7776
@NP	caudal cord stumps	7792
@NP	the other group -LRB- n = 8 -RRB-	7816
@NP	the other group	7816
@NP	n	7833
@NP	8	7837
@NP	transplants	7856
@NP	the lesion site	7873
@NP	injections of culture medium	7903
@NP	injections	7903
@NP	culture medium	7917
@NP	the rostral and caudal host stumps	7937
@NP	the rostral	7937
@NP	caudal host stumps	7953
@NP	this	7979
@NP	the animals	7985
@NP	the Basso -- Beattie -- Bresnahan locomotor rating scale	8028
@NP	Beattie	8038
@NP	Basso	8081
@NP	et al. , 1995	8087
@NP	et al.	8087
@NP	1995	8095
@NP	the CatWalk gait analysis for 9 weeks	8105
@NP	the CatWalk gait analysis	8105
@NP	9 weeks	8135
@NP	the CS tract	8162
@NP	an additional surgery	8176
@NP	6 weeks	8215
@NP	injury	8229
@NP	Nine weeks	8237
@NP	SCI	8254
@NP	the animals	8259
@NP	histological analysis	8305
@NP	the postoperative period	8339
@NP	histological analysis	8375
@NP	the researchers	8398
@NP	the treatment	8428
@NP	OEC/ONF cultures	8443
@NP	The isolation of mixed OEC/ONF cultures	8460
@NP	The isolation	8460
@NP	mixed OEC/ONF cultures	8477
@NP	syngeneic cells	8511
@NP	the outer two glomerular layers of adult rat	8532
@NP	the outer two glomerular layers	8532
@NP	adult rat	8567
@NP	olfactory bulbs	8577
@NP	that described previously -LRB- Li et al. , 1998 -RRB-	8610
@NP	that	8610
@NP	Li et al. , 1998	8637
@NP	Li	8637
@NP	et al.	8640
@NP	1998	8648
@NP	a method	8672
@NP	Ramon-Cueto and co-workers -LRB- Ramon-Cueto and Nieto - Sampedro , 1992 -RRB-	8694
@NP	Ramon-Cueto	8694
@NP	co-workers -LRB- Ramon-Cueto and Nieto - Sampedro , 1992 -RRB-	8710
@NP	co-workers	8710
@NP	Ramon-Cueto and Nieto - Sampedro , 1992	8722
@NP	Ramon-Cueto and Nieto	8722
@NP	Ramon-Cueto	8722
@NP	Nieto	8738
@NP	Sampedro , 1992	8745
@NP	Sampedro	8745
@NP	1992	8755
@NP	9-week-old Lewis rats	8771
@NP	inbred ; animal facilities of Maastricht University	8794
@NP	inbred	8794
@NP	animal facilities of Maastricht University	8802
@NP	animal facilities	8802
@NP	Maastricht University	8823
@NP	the olfactory bulbs	8868
@NP	meninges	8918
@NP	the outer olfactory nerve fiber and glomerular layers	8934
@NP	the outer olfactory nerve fiber	8934
@NP	glomerular layers	8970
@NP	The tissue	9014
@NP	small fragments	9038
@NP	trypsin	9073
@NP	0.1 % in phosphate-buffered saline ; Gibco/Invitrogen , Breda , The Netherlands	9082
@NP	0.1 %	9082
@NP	phosphate-buffered saline ; Gibco/Invitrogen , Breda , The Netherlands	9090
@NP	phosphate-buffered saline	9090
@NP	Gibco/Invitrogen , Breda , The Netherlands	9117
@NP	Gibco/Invitrogen , Breda	9117
@NP	The Netherlands	9142
@NP	37 °C for 15 min	9162
@NP	37 °C	9162
@NP	15 min	9171
@NP	Trypsinization	9179
@NP	addition of culture medium	9209
@NP	addition	9209
@NP	culture medium	9221
@NP	Dulbecco 's	9237
@NP	Eagle 's medium	9257
@NP	Eagle 's	9257
@NP	DMEM/NUT mix F12 ; Gibco/Invitrogen	9273
@NP	DMEM/NUT mix F12	9273
@NP	Gibco/Invitrogen	9291
@NP	Breda , The Netherlands	9309
@NP	Breda	9309
@NP	The Netherlands	9316
@NP	glutamax-I	9338
@NP	10 %	9367
@NP	fetal calf serum -LRB- Bodinco , Alkmaar , The Netherlands -RRB-	9383
@NP	fetal calf serum	9383
@NP	Bodinco	9401
@NP	Alkmaar	9410
@NP	The Netherlands	9419
@NP	antibiotics -LRB- 100 U/ml penicillin and 100 μg/ml streptomycin -RRB-	9440
@NP	antibiotics	9440
@NP	100 U/ml penicillin and 100 μg/ml streptomycin	9453
@NP	100 U/ml penicillin	9453
@NP	100 μg/ml streptomycin	9477
@NP	the only culture	9505
@NP	this study	9537
@NP	The tissue	9549
@NP	culture medium	9582
@NP	1 ml culture medium	9614
@NP	single cell dissociation	9641
@NP	mechanical trituration	9682
@NP	The cells	9706
@NP	PLL-coated Petri dishes	9731
@NP	a density of 200,000 cells in 2 ml of culture medium per Petri dish	9758
@NP	a density	9758
@NP	200,000 cells in 2 ml of culture medium per Petri dish	9771
@NP	200,000 cells	9771
@NP	2 ml of culture medium per Petri dish	9788
@NP	2 ml	9788
@NP	culture medium per Petri dish	9796
@NP	culture medium	9796
@NP	Petri dish	9815
@NP	The cells	9827
@NP	4	9852
@NP	5 days before half of the culture medium	9854
@NP	5 days	9854
@NP	half of the culture medium	9868
@NP	half	9868
@NP	the culture medium	9876
@NP	the culture medium	9922
@NP	every 2 days	9955
@NP	It	9969
@NP	this protocol	9986
@NP	mixed cultures	10008
@NP	OEC and ONF	10039
@NP	Li	10052
@NP	et al. , 1997 ; Deumens et al. , 2004	10055
@NP	et al.	10055
@NP	1997 ; Deumens et al.	10063
@NP	1997	10063
@NP	Deumens et al.	10069
@NP	Deumens	10069
@NP	et al.	10077
@NP	2004	10085
@NP	these cultures	10103
@NP	OEC/ONF cultures	10132
@NP	Poly	10150
@NP	lactide matrices Poly -LRB- D , L -RRB-	10160
@NP	lactide matrices	10160
@NP	Poly -LRB- D , L -RRB-	10177
@NP	Poly	10177
@NP	lactide with inherent viscosity of 1.62 dl/g	10187
@NP	lactide	10187
@NP	inherent viscosity of 1.62 dl/g	10200
@NP	inherent viscosity	10200
@NP	1.62 dl/g	10222
@NP	Purac Biochem -LRB- Gorinchem , The Netherlands -RRB-	10251
@NP	Purac Biochem	10251
@NP	Gorinchem	10266
@NP	The Netherlands	10277
@NP	diblock poly -LRB- D,L-lactide-b-polyethylene oxide -RRB- -LRB- PLA-b-PEO -RRB-	10297
@NP	diblock poly -LRB- D,L-lactide-b-polyethylene oxide -RRB-	10297
@NP	diblock poly	10297
@NP	D,L-lactide-b-polyethylene oxide	10310
@NP	PLA-b-PEO	10345
@NP	a PLA block of approximately 4000 of molecular weight	10371
@NP	a PLA block	10371
@NP	approximately 4000 of molecular weight	10386
@NP	approximately 4000	10386
@NP	molecular weight	10408
@NP	ring-opening polymerization of D,L-lactide	10444
@NP	ring-opening polymerization	10444
@NP	D,L-lactide	10475
@NP	PEO-monomethyl-ether -LRB- with molecular weight	10492
@NP	PEO-monomethyl-ether	10492
@NP	molecular weight	10519
@NP	approximately 5000 , supplied by Sigma ,	10540
@NP	approximately 5000	10540
@NP	Sigma	10572
@NP	Uithoorn , The Netherlands	10579
@NP	Uithoorn	10579
@NP	The Netherlands	10589
@NP	Polymer foams	10607
@NP	a mixture of PLA	10640
@NP	a mixture	10640
@NP	PLA	10653
@NP	10	10668
@NP	% of PLA-b-PEO amphiphilic copolymer -LRB- PLA/PLA-b-PEO -RRB- .	10674
@NP	%	10674
@NP	PLA-b-PEO amphiphilic copolymer -LRB- PLA/PLA-b-PEO -RRB-	10679
@NP	PLA-b-PEO amphiphilic copolymer	10679
@NP	PLA/PLA-b-PEO	10712
@NP	Polymer foams with an aligned pore structure	10728
@NP	Polymer foams	10728
@NP	an aligned pore structure	10747
@NP	freeze-drying	10790
@NP	polymer solutions , as previously described	10807
@NP	polymer solutions	10807
@NP	Maquet	10851
@NP	et al. , 2001	10858
@NP	et al.	10858
@NP	2001	10866
@NP	The polymer	10873
@NP	dimethylcarbonate	10902
@NP	a 5	10929
@NP	% polymer solution .	10936
@NP	%	10936
@NP	polymer solution	10938
@NP	The solution	10956
@NP	immersion	10991
@NP	liquid nitrogen	11006
@NP	solvent crystallization	11041
@NP	the frozen system	11072
@NP	a vacuum pump	11107
@NP	the solvent	11126
@NP	sublimation at − 10 °C and 10 − 2 Torr	11153
@NP	sublimation at − 10 °C	11153
@NP	sublimation	11153
@NP	− 10 °C	11168
@NP	10 − 2 Torr	11178
@NP	10 −	11178
@NP	2 Torr	11181
@NP	48 h	11195
@NP	the drying temperature	11201
@NP	0 °C	11241
@NP	the drying process	11249
@NP	The foams	11283
@NP	room temperature	11315
@NP	Small polymer rods -LRB- 1 × 1 × 10 mm -RRB-	11333
@NP	Small polymer rods	11333
@NP	1 × 1 × 10 mm	11353
@NP	1 ×	11353
@NP	1 × 10 mm	11357
@NP	1 ×	11357
@NP	10 mm	11361
@NP	the freeze-dried foams using a razor blade	11382
@NP	the freeze-dried foams	11382
@NP	a razor blade	11411
@NP	UV exposure for 15 min	11443
@NP	UV exposure	11443
@NP	15 min	11459
@NP	OEC/ONF on poly -LRB- D , L -RRB-	11467
@NP	OEC/ONF	11467
@NP	poly -LRB- D , L -RRB-	11478
@NP	poly	11478
@NP	lactide matrices	11488
@NP	OEC/ONF cultures	11505
@NP	10 days -LRB- Days in vitro 10 ; DIV10 -RRB-	11551
@NP	10 days	11551
@NP	Days in vitro 10 ; DIV10	11560
@NP	Days	11560
@NP	vitro 10 ; DIV10	11568
@NP	vitro 10	11568
@NP	vitro	11568
@NP	10	11574
@NP	DIV10	11578
@NP	the Petri dishes	11605
@NP	a 5-min incubation	11625
@NP	0.1 %	11647
@NP	Fluka BioChemika , Buchs , Switzerland	11674
@NP	Fluka BioChemika	11674
@NP	Buchs , Switzerland	11692
@NP	37 °C	11724
@NP	Trypsinization	11730
@NP	culture medium	11763
@NP	a 10-min centrifugation at 1200 rpm	11785
@NP	a 10-min centrifugation	11785
@NP	1200 rpm	11812
@NP	the pellet	11822
@NP	culture medium	11852
@NP	OEC/ONF cultures	11868
@NP	the surface area of the PLA/PLA-b-PEO matrices	11904
@NP	the surface area	11904
@NP	the PLA/PLA-b-PEO matrices	11924
@NP	a density of about 40,000 cells per cm2	11954
@NP	a density	11954
@NP	40,000 cells per cm2	11973
@NP	40,000 cells	11973
@NP	cm2	11990
@NP	these substrates for 4 days	12007
@NP	these substrates	12007
@NP	4 days	12028
@NP	This protocol	12036
@NP	aligned OEC/ONF	12058
@NP	biomatrix complexes as described previously -LRB- Deumens et al. , 2004 -RRB-	12074
@NP	biomatrix complexes	12074
@NP	Deumens	12119
@NP	et al. , 2004	12127
@NP	et al.	12127
@NP	2004	12135
@NP	Prelabeling	12142
@NP	OEC/ONF	12157
@NP	transplantation	12172
@NP	One day	12188
@NP	transplantation	12203
@NP	both the OEC/ONF cultures and the OEC/ONF	12220
@NP	the OEC/ONF cultures	12225
@NP	the OEC/ONF	12250
@NP	biomatrix complexes	12262
@NP	Hoechst	12303
@NP	This	12312
@NP	a 40	12329
@NP	60-min incubation at 37 °C in 2 μg/ml	12338
@NP	60-min incubation	12338
@NP	37 °C in 2 μg/ml	12359
@NP	37 °C	12359
@NP	2 μg/ml	12367
@NP	Hoechst 33342 -LRB- Sigma , Uithoorn , The Netherlands -RRB- in culture medium	12375
@NP	Hoechst 33342 -LRB- Sigma , Uithoorn , The Netherlands -RRB-	12375
@NP	Hoechst 33342	12375
@NP	Sigma	12390
@NP	Uithoorn	12397
@NP	The Netherlands	12407
@NP	culture medium	12427
@NP	the OEC/ONF cultures and OEC/ONF -- biomatrices	12455
@NP	the OEC/ONF cultures and OEC/ONF	12455
@NP	biomatrices	12488
@NP	culture medium	12529
@NP	Surgeries General	12545
@NP	every operation	12567
@NP	i.e.	12584
@NP	SCI , transplantation , and CS tract labeling -RRB-	12589
@NP	SCI	12589
@NP	transplantation	12594
@NP	CS tract labeling	12615
@NP	animals	12635
@NP	intraperitoneal -LRB- i.p. -RRB- injections	12652
@NP	Buprenorfine	12691
@NP	Temgesic 0.1 ml/animal	12705
@NP	Temgesic	12705
@NP	0.1 ml/animal	12714
@NP	Schering-Plough , Utrecht , The Netherlands	12729
@NP	Schering-Plough	12729
@NP	Utrecht	12746
@NP	The Netherlands	12755
@NP	One hour	12773
@NP	the injection	12788
@NP	the animals	12803
@NP	a mixture of 1	12838
@NP	a mixture	12838
@NP	1	12851
@NP	2 % halothane -LRB- Abbott , Hoofddorp , The Netherlands -RRB-	12853
@NP	2 % halothane	12853
@NP	Abbott	12867
@NP	Hoofddorp	12875
@NP	The Netherlands	12886
@NP	O2/N2O -LRB- 1:2 -RRB-	12907
@NP	O2/N2O	12907
@NP	1:2	12915
@NP	an ophthalmic ointment	12924
@NP	Visagel -LRB- Eurovet , Bladel , The Netherlands -RRB-	12948
@NP	Visagel	12948
@NP	Eurovet	12957
@NP	Bladel	12966
@NP	The Netherlands	12974
@NP	the eyes	13007
@NP	the operation	13041
@NP	the beginning of every operation	13059
@NP	the beginning	13059
@NP	every operation	13076
@NP	the hair overlying the operation area	13093
@NP	the hair	13093
@NP	the operation area	13112
@NP	the skin	13146
@NP	Bethadine	13173
@NP	the end of every operation	13187
@NP	the end	13187
@NP	every operation	13198
@NP	the muscles and skin	13215
@NP	animals	13253
@NP	awake	13281
@NP	their home cages	13308
@NP	At least 1 h	13326
@NP	their awakening	13345
@NP	the animals	13362
@NP	another i.p. injection	13383
@NP	Buprenorfine	13411
@NP	SCI , transplantation Laminectomy	13425
@NP	SCI	13425
@NP	transplantation Laminectomy	13430
@NP	the spinal cord	13477
@NP	T11/T12	13508
@NP	The dura mater	13517
@NP	the use of microscissors	13549
@NP	the use	13549
@NP	microscissors	13560
@NP	the dorsal half of the spinal cord	13574
@NP	the dorsal half	13574
@NP	the spinal cord	13593
@NP	two spinal levels	13624
@NP	2 mm	13643
@NP	an aspiration device	13661
@NP	the dorsal part of the spinal cord in between the two cuts	13683
@NP	the dorsal part	13683
@NP	the spinal cord in between the two cuts	13702
@NP	the spinal cord	13702
@NP	the two cuts	13729
@NP	The depth of the lesion	13755
@NP	The depth	13755
@NP	the lesion	13768
@NP	1.2 mm	13783
@NP	care	13795
@NP	the dorsal part of the CS tract	13831
@NP	the dorsal part	13831
@NP	the CS tract	13850
@NP	the ventral-most part of the dorsal funiculus	13874
@NP	the ventral-most part	13874
@NP	the dorsal funiculus	13899
@NP	This lesion	13921
@NP	descending rubrospinal axons	13944
@NP	the dorsal component of the CS tract	13974
@NP	the dorsal component	13974
@NP	the CS tract	13998
@NP	all ascending dorsal column axons	14012
@NP	all	14012
@NP	dorsal column axons	14026
@NP	local spinal sensory neurites	14051
@NP	The experimental group	14082
@NP	10 animals	14118
@NP	an OEC/ONF -- biomatrix transplant	14139
@NP	an OEC/ONF	14139
@NP	biomatrix transplant	14150
@NP	the thoracic lesion site which was then covered with DuraFilm	14176
@NP	the thoracic lesion site	14176
@NP	DuraFilm	14229
@NP	addition	14242
@NP	OEC/ONF suspensions	14252
@NP	100,000 cells/μl ; 2 μl per injection site ; 1 injection site/stump	14273
@NP	100,000 cells/μl	14273
@NP	2 μl per injection site ; 1 injection site/stump	14291
@NP	2 μl per injection site	14291
@NP	2 μl	14291
@NP	injection site	14300
@NP	1 injection site/stump	14316
@NP	the rostral and caudal cord stumps	14359
@NP	the rostral	14359
@NP	caudal cord stumps	14375
@NP	a distance of 1 mm	14397
@NP	a distance	14397
@NP	1 mm	14411
@NP	the lesion site	14421
@NP	a depth of 1.2 mm	14444
@NP	a depth	14444
@NP	1.2 mm	14455
@NP	The control group	14463
@NP	8 animals	14494
@NP	injections of culture medium	14514
@NP	injections	14514
@NP	culture medium	14528
@NP	the rostral and caudal cord stumps -LRB- 2 μl per injection site -RRB-	14548
@NP	the rostral	14548
@NP	caudal cord stumps -LRB- 2 μl per injection site -RRB-	14564
@NP	caudal cord stumps	14564
@NP	2 μl per injection site	14584
@NP	2 μl	14584
@NP	injection site	14593
@NP	a distance of 1 mm	14612
@NP	a distance	14612
@NP	1 mm	14626
@NP	the lesion site	14636
@NP	a depth of 1.2 mm	14659
@NP	a depth	14659
@NP	1.2 mm	14670
@NP	These culture injections	14678
@NP	possible damage induced by the injection procedure	14728
@NP	possible damage	14728
@NP	the injection procedure	14755
@NP	The control animals	14780
@NP	a transplant	14816
@NP	the lesion site	14834
@NP	CS tract labeling A dental drill	14851
@NP	CS tract labeling A	14851
@NP	dental drill	14871
@NP	burr holes	14901
@NP	both sides of the cranium overlying the sensorimotor cortices	14915
@NP	both sides	14915
@NP	the cranium overlying the sensorimotor cortices	14929
@NP	the cranium	14929
@NP	the sensorimotor cortices	14951
@NP	The anterograde neuronal tracer biotin dextran amine	14978
@NP	BDA ; MW 10,000 ; Molecular Probes/Invitrogen	15032
@NP	BDA	15032
@NP	MW 10,000 ; Molecular Probes/Invitrogen	15037
@NP	MW 10,000	15037
@NP	Molecular Probes/Invitrogen	15048
@NP	Breda , The Netherlands	15077
@NP	Breda	15077
@NP	The Netherlands	15084
@NP	the sensorimotor cortex	15126
@NP	a depth of 2 mm	15153
@NP	a depth	15153
@NP	2 mm	15164
@NP	the cortical surface	15174
@NP	both sides	15198
@NP	10 % in 0.1 M phosphate-buffered saline -LRB- PBS -RRB-	15210
@NP	10 %	15210
@NP	0.1 M phosphate-buffered saline -LRB- PBS -RRB-	15217
@NP	0.1 M phosphate-buffered saline	15217
@NP	PBS	15250
@NP	pH 7.2 ; 1.5 μl/3 injections / hemisphere	15256
@NP	pH 7.2	15256
@NP	1.5 μl/3 injections / hemisphere	15264
@NP	1.5 μl/3 injections	15264
@NP	hemisphere	15285
@NP	The needle	15298
@NP	place for 1 min	15321
@NP	place	15321
@NP	1 min	15331
@NP	Histological analysis At 9 weeks after SCI/3 weeks after CS tract tracing	15371
@NP	Histological analysis	15371
@NP	9 weeks	15396
@NP	SCI/3 weeks	15410
@NP	CS tract	15428
@NP	the rats	15446
@NP	an overdose of Nembutal -LRB- 150 mg/kg body weight ; i.p. injection -RRB-	15464
@NP	an overdose	15464
@NP	Nembutal -LRB- 150 mg/kg body weight ; i.p. injection -RRB-	15479
@NP	Nembutal	15479
@NP	150 mg/kg body weight	15489
@NP	injection	15517
@NP	They	15529
@NP	ice-cold 4 % paraformaldehyde in 0.1 M phosphate buffer -LRB- pH 7.4 -RRB-	15568
@NP	ice-cold 4 % paraformaldehyde	15568
@NP	0.1 M phosphate buffer -LRB- pH 7.4 -RRB-	15600
@NP	0.1 M phosphate buffer	15600
@NP	pH 7.4	15624
@NP	perfusion	15639
@NP	the spinal cords and the brains	15650
@NP	the spinal cords	15650
@NP	the brains	15671
@NP	post-fixed in cold 4 %	15699
@NP	post-fixed	15699
@NP	cold 4 %	15713
@NP	cold	15713
@NP	paraformaldehyde overnight	15730
@NP	The following day	15758
@NP	the tissue	15777
@NP	10 % sucrose in PBS -LRB- 0.1 M ; pH 7.6 -RRB-	15807
@NP	10 % sucrose	15807
@NP	PBS -LRB- 0.1 M ; pH 7.6 -RRB-	15822
@NP	PBS	15822
@NP	0.1 M ; pH 7.6	15827
@NP	0.1 M	15827
@NP	pH 7.6	15834
@NP	overnight	15851
@NP	4 °C	15864
@NP	the tissue	15875
@NP	25 % sucrose in PBS	15906
@NP	25 % sucrose	15906
@NP	PBS	15921
@NP	3 days	15938
@NP	4 °C	15948
@NP	this cryo-protection procedure	15959
@NP	the brain and 2.5-cmlong spinal cord pieces including the lesion site	15991
@NP	the brain and 2.5-cmlong spinal cord pieces	15991
@NP	the lesion site	16045
@NP	− 80 °C	16087
@NP	a cryostat	16100
@NP	the spinal cord pieces	16112
@NP	sagittal sections of 25 μm	16154
@NP	sagittal sections	16154
@NP	25 μm	16175
@NP	this way	16186
@NP	a total of about 120 sections	16196
@NP	a total	16196
@NP	about 120 sections	16207
@NP	spinal cord	16244
@NP	The sections	16257
@NP	gelatin chrome-alumn	16298
@NP	Sigma	16320
@NP	Uithoorn	16327
@NP	The Netherlands	16337
@NP	coated glass slides	16354
@NP	− 20 °C	16388
@NP	Alternate sections	16395
@NP	immunohistochemistry	16433
@NP	the following antibodies	16460
@NP	mouse anti-p75-NGF receptor -LRB- 1:10,000 ; Chemicon , Hampshire , UK -RRB-	16486
@NP	mouse anti-p75-NGF receptor	16486
@NP	1:10,000 ; Chemicon , Hampshire , UK	16515
@NP	1:10,000	16515
@NP	Chemicon , Hampshire , UK	16525
@NP	mouse antineurofilament RT97	16551
@NP	anti-RT97 ; 1:100 ; Hybridoma Bank , Iowa City , IA , USA	16581
@NP	anti-RT97	16581
@NP	1:100 ; Hybridoma Bank , Iowa City , IA , USA	16592
@NP	1:100	16592
@NP	Hybridoma Bank , Iowa City , IA , USA	16599
@NP	Hybridoma Bank	16599
@NP	Iowa City , IA , USA	16615
@NP	rabbit anti-GFAP -LRB- 1:1000 ; DAKO -RRB-	16636
@NP	rabbit anti-GFAP	16636
@NP	1:1000 ; DAKO	16654
@NP	1:1000	16654
@NP	DAKO	16662
@NP	rabbit anti-GAP43 / B50	16669
@NP	rabbit anti-GAP43	16669
@NP	B50	16687
@NP	generous gift from Leo van Halewijn	16692
@NP	generous gift	16692
@NP	Leo van Halewijn	16711
@NP	Utrecht University , The Netherlands	16729
@NP	Utrecht University	16729
@NP	The Netherlands	16749
@NP	rabbit-serotonin -LRB- Prof.	16771
@NP	Dr.	16795
@NP	H.	16799
@NP	Steinbusch , Maastricht University , The Netherlands -RRB- .	16802
@NP	Steinbusch , Maastricht University	16802
@NP	Netherlands	16841
@NP	Secondary antibodies used	16855
@NP	Secondary antibodies	16855
@NP	streptavidin	16886
@NP	Cy3	16899
@NP	1:2000	16904
@NP	the BDA-labeled CS axons	16916
@NP	Jackson ImmunoResearch Europe Ltd. , Cambridgeshire , UK	16942
@NP	Jackson ImmunoResearch Europe Ltd.	16942
@NP	Cambridgeshire , UK	16978
@NP	Cy3-conjugated donkey anti-mouse	16999
@NP	1:800 ; Jackson ImmunoResearch Europe Ltd.	17033
@NP	1:800	17033
@NP	Jackson ImmunoResearch Europe Ltd.	17040
@NP	Cambridgeshire , UK	17076
@NP	Cambridgeshire	17076
@NP	UK	17092
@NP	Alexa	17097
@NP	488-conjugated goat antimouse	17103
@NP	1:100 ; Molecular Probes/Invitrogen	17134
@NP	1:100	17134
@NP	Molecular Probes/Invitrogen	17141
@NP	Breda , The Netherlands	17170
@NP	Breda	17170
@NP	The Netherlands	17177
@NP	Alexa 488-conjugated goat anti-rabbit	17199
@NP	1:100 ; Molecular Probes/Invitrogen	17238
@NP	1:100	17238
@NP	Molecular Probes/Invitrogen	17245
@NP	Breda , The Netherlands	17274
@NP	Breda	17274
@NP	The Netherlands	17281
@NP	Antibodies	17299
@NP	0.3 % Triton X-100 in Tris-buffered saline -LRB- TBS-T -RRB-	17326
@NP	0.3 % Triton X-100	17326
@NP	Tris-buffered saline -LRB- TBS-T -RRB-	17347
@NP	Tris-buffered saline	17347
@NP	TBS-T	17369
@NP	All primary antibody incubations	17377
@NP	overnight at room temperature	17415
@NP	overnight	17415
@NP	room temperature	17428
@NP	All secondary antibody incubations	17446
@NP	1.5 h at room temperature	17486
@NP	1.5 h	17486
@NP	room temperature	17495
@NP	double staining protocols	17516
@NP	the primary antibodies	17543
@NP	a mixture	17579
@NP	the incubation with the Cy3-labeled secondary antibody	17593
@NP	the incubation	17593
@NP	the Cy3-labeled secondary antibody	17613
@NP	the incubation	17664
@NP	the Alexalabeled secondary antibody	17684
@NP	all antibody incubations	17728
@NP	the washing steps	17754
@NP	10 min TBS-T	17785
@NP	10 min TBS	17799
@NP	TBS-T without Triton X-100	17811
@NP	TBS-T	17811
@NP	Triton X-100	17825
@NP	10 min TBS-T	17844
@NP	All other washing steps	17858
@NP	All other	17858
@NP	steps	17876
@NP	three times 10 min TBS	17891
@NP	three times	17891
@NP	10 min TBS	17903
@NP	Hoechst stainings	17919
@NP	a 30-min incubation in Hoechst 33342	17938
@NP	a 30-min incubation	17938
@NP	Hoechst 33342	17961
@NP	Sigma	17976
@NP	Uithoorn	17983
@NP	The Netherlands	17993
@NP	Every sixth section	18020
@NP	p75	18056
@NP	p75 and Hoechst	18083
@NP	p75	18083
@NP	Hoechst	18091
@NP	GFAP / BDA-labeled CS axons , GAP43/BDA-labeled CS axons , GFAP / neurofilament	18100
@NP	GFAP	18100
@NP	BDA-labeled CS axons , GAP43/BDA-labeled CS axons , GFAP	18106
@NP	BDA-labeled CS axons	18106
@NP	GAP43/BDA-labeled CS axons	18128
@NP	GFAP	18156
@NP	neurofilament	18162
@NP	GFAP/serotonin	18180
@NP	Stained sections	18196
@NP	an Olympus AX-70 microscope using epifluorescent illumination	18233
@NP	an Olympus AX-70 microscope	18233
@NP	epifluorescent illumination	18267
@NP	The microscope	18296
@NP	a × 20 objective and a × 10 projection lens	18329
@NP	a × 20 objective	18329
@NP	a × 10 projection lens	18349
@NP	The signal for Alexa 488 -LRB- green -RRB-	18372
@NP	The signal for Alexa 488	18372
@NP	The signal	18372
@NP	Alexa 488	18387
@NP	a narrow band MNIBA-type FITC filter	18424
@NP	Chroma Technology Corp	18462
@NP	Rockingham	18486
@NP	VT , USA	18498
@NP	the signal for Cy3 -LRB- red -RRB-	18508
@NP	the signal	18508
@NP	Cy3 -LRB- red -RRB-	18523
@NP	Cy3	18523
@NP	red	18528
@NP	a MNG filter -LRB- Chroma Technology Corp , Rockingham , VT , USA -RRB-	18552
@NP	a MNG filter	18552
@NP	Chroma Technology Corp	18566
@NP	Rockingham	18590
@NP	VT , USA	18602
@NP	the signal for Hoechst -LRB- blue -RRB-	18616
@NP	the signal for Hoechst	18616
@NP	the signal	18616
@NP	Hoechst	18631
@NP	a U-MNIBA filter -LRB- Chroma Technology Corp , Rockingham , VT , USA -RRB-	18665
@NP	a U-MNIBA filter	18665
@NP	Chroma Technology Corp	18683
@NP	Rockingham	18707
@NP	VT , USA	18719
@NP	Pictures	18729
@NP	the	18741
@NP	sections	18753
@NP	a magnification of ×	18775
@NP	a magnification	18775
@NP	×	18794
@NP	a Sony Power HAD 3CCD Color Video Camera or an Olympus F-view	18801
@NP	a Sony Power HAD 3CCD Color Video Camera	18801
@NP	an Olympus F-view	18845
@NP	CCD camera -LRB- Paes , Zoeterwoude , The Netherlands -RRB-	18870
@NP	CCD camera	18870
@NP	Paes	18882
@NP	Zoeterwoude	18888
@NP	The Netherlands	18901
@NP	All pictures	18919
@NP	the image analyzing system analySIS Vers	18951
@NP	the image	18951
@NP	system analySIS Vers	18971
@NP	3.0	18993
@NP	Soft Imaging System , Münster ,	18999
@NP	Soft Imaging System	18999
@NP	Münster	19020
@NP	Quantitative analysis CS axon growth All sections with BDA-labeled CS axons	19040
@NP	Quantitative analysis CS	19040
@NP	axon growth	19065
@NP	All sections with BDA-labeled CS axons	19077
@NP	All sections	19077
@NP	BDA-labeled CS axons	19095
@NP	quantitative analysis	19135
@NP	250-μm-wide boxes	19158
@NP	four different locations in the spinal cord sections	19191
@NP	four different locations	19191
@NP	the spinal cord sections	19219
@NP	indications in Fig. 4	19254
@NP	indications	19254
@NP	Fig. 4	19269
@NP	The first box	19278
@NP	the dorsal gray/white matter at 2.5 -- 3 mm rostral to the injury site	19306
@NP	the dorsal gray/white matter at 2.5	19306
@NP	the dorsal gray/white matter	19306
@NP	2.5	19338
@NP	3 mm rostral to the injury site	19342
@NP	3 mm rostral	19342
@NP	the injury site	19358
@NP	the rostral reference	19394
@NP	The second box	19418
@NP	the dorsal gray/white matter directly rostral	19447
@NP	the dorsal gray/white matter	19447
@NP	the injury site	19496
@NP	The third box	19513
@NP	the gray matter underneath the lesion site	19541
@NP	the gray matter	19541
@NP	the lesion site	19568
@NP	only few axons	19591
@NP	the lesion site	19630
@NP	the box	19647
@NP	the area where most BDA immunoreactivity was found	19669
@NP	the area	19669
@NP	most BDA immunoreactivity	19684
@NP	The fourth box	19721
@NP	the gray matter caudal	19750
@NP	the injury site	19776
@NP	the position where most BDA immunoreactivity could be found	19802
@NP	the position	19802
@NP	most BDA immunoreactivity	19821
@NP	The few BDA-immunoreactive CS axons	19863
@NP	the caudal gray matter within 10 mm	19931
@NP	the caudal gray matter	19931
@NP	10 mm	19961
@NP	the caudal edge of the lesion site	19972
@NP	the caudal edge	19972
@NP	the lesion site	19991
@NP	All four boxes	20008
@NP	all the sections containing BDA-labeled CS axons	20040
@NP	all the sections	20040
@NP	BDA-labeled CS axons	20068
@NP	The percentage	20090
@NP	each box	20108
@NP	BDA-immunoreactive axons -LRB- `` BDA immunoreactivity occupation '' -RRB-	20129
@NP	BDA-immunoreactive axons	20129
@NP	BDA	20156
@NP	immunoreactivity occupation ''	20160
@NP	immunoreactivity	20160
@NP	occupation ''	20177
@NP	the box values in all the sections	20208
@NP	the box values	20208
@NP	all the sections	20226
@NP	the efficiency of BDA CS tract tracing	20262
@NP	the efficiency	20262
@NP	BDA CS tract tracing	20280
@NP	BDA CS tract	20280
@NP	animals	20327
@NP	the BDA immunoreactivity at the rostral reference	20336
@NP	the BDA immunoreactivity	20336
@NP	the rostral reference	20364
@NP	the 100 % reference value of BDA-labeled axons of each animal	20399
@NP	the 100 % reference value	20399
@NP	BDA-labeled axons of each animal	20427
@NP	BDA-labeled axons	20427
@NP	each animal	20448
@NP	The BDA immunoreactivity values of boxes 2 , 3 , and 4	20461
@NP	The BDA immunoreactivity values	20461
@NP	boxes 2 , 3 , and 4	20496
@NP	boxes	20496
@NP	2 , 3 , and 4	20502
@NP	that of the rostral reference	20541
@NP	that	20541
@NP	the rostral reference	20549
@NP	A similar quantification method	20572
@NP	others -LRB- Goldshmit et al. , 2004 -RRB-	20637
@NP	others	20637
@NP	Goldshmit	20645
@NP	et al. , 2004	20655
@NP	et al.	20655
@NP	2004	20663
@NP	Double staining CS axons	20670
@NP	GAP43/B50 All sections double-stained for CS axons and GAP43/B50	20699
@NP	GAP43/B50	20699
@NP	All sections double-stained for CS axons and GAP43/B50	20709
@NP	All sections	20709
@NP	CS axons and GAP43/B50	20741
@NP	BDA-labeled CS axons	20792
@NP	transplanted and/or control animals	20845
@NP	transplanted	20845
@NP	control animals	20865
@NP	Axon growth	20882
@NP	the lesion/graft site	20899
@NP	Every sixth section of five transplanted and five control animals	20921
@NP	Every sixth section	20921
@NP	five transplanted and five control animals	20944
@NP	five transplanted	20944
@NP	five control animals	20966
@NP	GFAP and neurofilament	21010
@NP	the degree of neurofilament-positive axon growth	21053
@NP	the degree	21053
@NP	neurofilament-positive axon growth	21067
@NP	the lesion/graft site	21107
@NP	Similar	21130
@NP	the quantitative analysis	21141
@NP	the BDA-labeled CS tract	21170
@NP	the neurofilament immunoreactivity within the total lesion/graft site	21196
@NP	the neurofilament immunoreactivity	21196
@NP	the total lesion/graft site	21238
@NP	GFAP staining	21280
@NP	the lesion / graft site	21326
@NP	the lesion	21326
@NP	graft site	21338
@NP	the percentage	21357
@NP	the total lesion/graft site	21375
@NP	neurofilament immunoreactivity -LRB- `` NF immunoreactivity occupation '' -RRB-	21415
@NP	neurofilament immunoreactivity	21415
@NP	NF	21448
@NP	immunoreactivity occupation ''	21451
@NP	immunoreactivity	21451
@NP	occupation ''	21468
@NP	all sections	21506
@NP	transplanted and control animals	21541
@NP	transplanted	21541
@NP	control animals	21558
@NP	raphespinal axons	21607
@NP	the axons	21636
@NP	the graft/lesion site	21658
@NP	a double staining of GFAP/serotonin	21681
@NP	a double staining	21681
@NP	GFAP/serotonin	21702
@NP	Functional testing	21732
@NP	Basso -- Beattie -- Bresnahan -LRB- BBB -RRB-	21751
@NP	Basso -- Beattie -- Bresnahan	21751
@NP	Beattie	21757
@NP	BBB	21776
@NP	locomotor rating scale This locomotor test assesses locomotor performance	21781
@NP	locomotor rating scale	21781
@NP	This locomotor test	21804
@NP	locomotor performance	21833
@NP	the hind limbs	21858
@NP	a score that ranges from 0 to 21 -LRB- Basso et al. , 1995 -RRB-	21877
@NP	a score	21877
@NP	0 to 21	21902
@NP	Basso	21911
@NP	et al. , 1995	21917
@NP	et al.	21917
@NP	1995	21925
@NP	The BBB test	21932
@NP	the recommendations	21972
@NP	an observation time of approximately 4 min	21997
@NP	an observation time	21997
@NP	approximately 4 min	22020
@NP	two investigators which were blind to the treatment	22047
@NP	two investigators	22047
@NP	the treatment	22085
@NP	The scores of the left and right hind limbs	22100
@NP	The scores	22100
@NP	the left and right hind limbs	22114
@NP	the BBB score of the animal	22171
@NP	the BBB score	22171
@NP	the animal	22188
@NP	The BBB test	22200
@NP	the day of the operation	22245
@NP	the day	22245
@NP	the operation	22256
@NP	the following days postoperatively -LRB- DPO -RRB-	22277
@NP	the following days postoperatively	22277
@NP	the following days	22277
@NP	DPO	22313
@NP	1 , 2 , 3 , 7 , 14 , 21 , 28 , 35 , 42 , 49 , 56 , and 63	22319
@NP	1	22319
@NP	2	22322
@NP	3	22325
@NP	7	22328
@NP	14	22331
@NP	21	22335
@NP	28	22339
@NP	35	22343
@NP	42	22347
@NP	49 , 56 , and 63	22351
@NP	CatWalk gait analysis This locomotor test	22367
@NP	CatWalk gait analysis	22367
@NP	This locomotor test	22389
@NP	an easy and objective analysis	22416
@NP	static and dynamic locomotor parameters , such as stride length	22455
@NP	static and dynamic locomotor parameters	22455
@NP	stride length	22504
@NP	base of support	22519
@NP	base	22519
@NP	support	22527
@NP	interlimb coordination	22536
@NP	/ stance phases	22569
@NP	stance	22571
@NP	Details on the CatWalk set-up	22586
@NP	Details	22586
@NP	the CatWalk set-up	22597
@NP	Hamers et al. , 2001 ; Koopmans et al. , 2005	22640
@NP	Hamers	22640
@NP	et al. , 2001 ; Koopmans et al. , 2005	22647
@NP	et al. , 2001	22647
@NP	et al.	22647
@NP	2001	22655
@NP	Koopmans et al. , 2005	22661
@NP	Koopmans	22661
@NP	et al. , 2005	22670
@NP	et al.	22670
@NP	2005	22678
@NP	the animals	22694
@NP	about 2 weeks	22722
@NP	a glass runway	22745
@NP	hesitation	22768
@NP	this training period	22787
@NP	the animals	22809
@NP	the CatWalk test via a 12 g/day food restriction protocol	22840
@NP	the CatWalk test	22840
@NP	a 12 g/day food restriction protocol	22861
@NP	24 h before testing	22902
@NP	24 h	22902
@NP	testing	22914
@NP	the animals	22923
@NP	food	22952
@NP	Small food pellets	22958
@NP	Noyes Precision	22978
@NP	PJPPP-0045 ; Sandown Chemical Ltd. , Hampton , UK	23002
@NP	PJPPP-0045	23002
@NP	Sandown Chemical Ltd. , Hampton , UK	23014
@NP	Sandown Chemical Ltd.	23014
@NP	Hampton , UK	23037
@NP	located at the end of the glass runway	23050
@NP	the end of the glass	23061
@NP	the end	23061
@NP	the glass	23072
@NP	a reward	23102
@NP	analysis	23116
@NP	three uninterrupted runs	23126
@NP	CatWalk-based BBB scale	23162
@NP	Koopmans et al. , 2005	23211
@NP	Koopmans	23211
@NP	et al.	23220
@NP	2005	23228
@NP	the coordination parameter	23235
@NP	the CatWalk , the regularity index -LRB- RI -RRB- ,	23276
@NP	the CatWalk	23276
@NP	the regularity index -LRB- RI -RRB-	23289
@NP	the regularity index	23289
@NP	RI	23311
@NP	the BBB scoring	23340
@NP	the BBB	23340
@NP	brief	23360
@NP	the RI grades	23367
@NP	the degree	23381
@NP	coordination	23395
@NP	the number	23411
@NP	normal step sequence patterns	23425
@NP	four	23469
@NP	the total number of paw placements	23486
@NP	the total number	23486
@NP	paw placements	23506
@NP	100 %	23539
@NP	Koopmans et al. , 2005	23545
@NP	Koopmans	23545
@NP	et al.	23554
@NP	2005	23562
@NP	Crossings of the glass runway with an RI of 100 %	23569
@NP	Crossings	23569
@NP	the glass runway with an RI of 100 %	23582
@NP	the glass runway	23582
@NP	an RI of 100 %	23604
@NP	an RI	23604
@NP	100 %	23613
@NP	three , two , one , or none of the CatWalk	23649
@NP	three	23649
@NP	two	23656
@NP	one	23661
@NP	none of the CatWalk	23669
@NP	none	23669
@NP	the CatWalk	23677
@NP	no coordination	23747
@NP	the BBB score	23788
@NP	the animal at that testing day , respectively -LRB- Koopmans et al. , 2005 -RRB-	23805
@NP	the animal at that testing day , respectively	23805
@NP	the animal at that testing day	23805
@NP	the animal	23805
@NP	that testing day	23819
@NP	Koopmans	23851
@NP	et al. , 2005	23860
@NP	et al.	23860
@NP	2005	23868
@NP	Results Fig. 1 .	23876
@NP	Results	23876
@NP	Fig. 1	23885
@NP	Hoechst-prelabeled OEC/ONF	23906
@NP	host cells	23950
@NP	the lesion site	23966
@NP	One day	23983
@NP	transplantation	24000
@NP	OEC/ONF	24017
@NP	Hoechst 33342	24046
@NP	-LRB- A -RRB- S100β immunostained	24061
@NP	-LRB- A -RRB- S100β	24061
@NP	-LRB- A -RRB-	24061
@NP	S100β	24065
@NP	Hoechst-prelabeled OEC/ONF	24089
@NP	the day	24125
@NP	transplantation -LRB- examples of S100β immunostaining -LRB- arrowheads -RRB-	24136
@NP	transplantation	24136
@NP	examples of S100β immunostaining -LRB- arrowheads -RRB-	24153
@NP	examples	24153
@NP	S100β immunostaining -LRB- arrowheads -RRB-	24165
@NP	S100β immunostaining	24165
@NP	arrowheads	24187
@NP	Hoechst staining	24203
@NP	arrows	24221
@NP	-LRB- B , C -RRB- Prelabeled OEC/ONF	24244
@NP	B , C	24245
@NP	B	24245
@NP	C	24248
@NP	a limited area -LRB- around the injection site -RRB- rostral	24281
@NP	the injection site	24304
@NP	the injury site at 9 weeks after injury/transplantation	24335
@NP	the injury site	24335
@NP	9 weeks after injury/transplantation	24354
@NP	9 weeks	24354
@NP	injury/transplantation	24368
@NP	The dotted line in panel B	24392
@NP	The dotted line	24392
@NP	panel B	24411
@NP	the spinal cord	24430
@NP	the arrow	24447
@NP	the location of the lesion site	24467
@NP	the location	24467
@NP	the lesion site	24483
@NP	d , dorsal	24500
@NP	d	24500
@NP	dorsal	24503
@NP	v , ventral	24511
@NP	v	24511
@NP	ventral	24514
@NP	r , rostral	24523
@NP	r	24523
@NP	rostral	24526
@NP	c , caudal	24535
@NP	c	24535
@NP	caudal	24538
@NP	panel C	24546
@NP	an enlargement of the box shown in panel B.	24557
@NP	an enlargement	24557
@NP	the box shown in panel B.	24575
@NP	the box	24575
@NP	panel B.	24592
@NP	-LRB- D -RRB- Transplanted	24601
@NP	-LRB- D -RRB-	24601
@NP	Hoechst-prelabeled cells -LRB- blue -RRB- in the injection area	24618
@NP	Hoechst-prelabeled cells -LRB- blue -RRB-	24618
@NP	Hoechst-prelabeled cells	24618
@NP	blue	24644
@NP	the injection area	24653
@NP	note	24673
@NP	a proportion of the cells	24683
@NP	a proportion	24683
@NP	the cells	24699
@NP	p75-NGF receptor -LRB- red -RRB-	24732
@NP	p75-NGF receptor	24732
@NP	red	24750
@NP	Arrows	24756
@NP	a few Hoechst-prelabeled cells with p75-NGF receptor immunoreactivity	24772
@NP	a few Hoechst-prelabeled cells	24772
@NP	p75-NGF receptor immunoreactivity	24808
@NP	-LRB- E -RRB-	24843
@NP	Hoechst	24847
@NP	staining of the OEC/ONF	24855
@NP	staining	24855
@NP	the OEC/ONF	24867
@NP	biomatrix complex within the lesion site	24879
@NP	biomatrix complex	24879
@NP	the lesion site	24904
@NP	all these Hoechst-positive cells	24921
@NP	all	24921
@NP	these Hoechst-positive cells	24925
@NP	host cells	24971
@NP	note	24983
@NP	the Hoechst staining	24993
@NP	any prelabeled cells	25031
@NP	cells that are labeled after sacrificing the animals	25062
@NP	cells	25062
@NP	the animals	25103
@NP	Identification	25121
@NP	Hoechst-stained -LRB- blue -RRB- host cells	25152
@NP	the biomatrix complex	25193
@NP	a subpopulation of the cells	25216
@NP	a subpopulation	25216
@NP	the cells	25235
@NP	p75-NGF receptor -LRB- red -RRB-	25267
@NP	p75-NGF receptor	25267
@NP	red	25285
@NP	Scale bars in A -- C , E , and F	25291
@NP	Scale bars	25291
@NP	A -- C , E , and F	25305
@NP	C , E , and F	25307
@NP	C	25307
@NP	E	25310
@NP	F	25317
@NP	200 μm	25323
@NP	scale bar in panel D	25331
@NP	scale bar	25331
@NP	panel D	25344
@NP	100 μm	25355
@NP	Fig. 2 .	25364
@NP	Fig.	25364
@NP	2	25369
@NP	Transplantation	25372
@NP	OEC/ONF-biomatrix complexes	25391
@NP	dorsal hemisection injury sites	25422
@NP	a laminectomy of the low-thoracic spinal cord -LRB- A -RRB-	25461
@NP	a laminectomy	25461
@NP	the low-thoracic spinal cord -LRB- A -RRB-	25478
@NP	the low-thoracic spinal cord	25478
@NP	A	25508
@NP	a 2-mm-long dorsal hemisection gap	25512
@NP	B	25557
@NP	Hereafter , OEC/ONF suspensions	25561
@NP	Hereafter	25561
@NP	OEC/ONF suspensions	25572
@NP	1 mm rostral and 1 mm caudal to the injury site	25609
@NP	1 mm rostral	25609
@NP	1 mm caudal to the injury site	25626
@NP	1 mm caudal	25626
@NP	the injury site	25641
@NP	approximate injection sites	25658
@NP	arrowheads	25703
@NP	an aligned OEC/ONF	25719
@NP	biomatrix complex	25738
@NP	the lesion gap -LRB- C -RRB-	25774
@NP	the lesion gap	25774
@NP	C	25790
@NP	This complex	25794
@NP	a Dura Film covering -LRB- not shown -RRB-	25825
@NP	a Dura Film	25825
@NP	Fig. 3 .	25859
@NP	Fig.	25859
@NP	3	25864
@NP	Neurofilament IR fiber ingrowth into the graft/lesion site .	25867
@NP	Neurofilament IR fiber ingrowth	25867
@NP	the graft/lesion site	25904
@NP	The graft/lesion site	25927
@NP	the schematic representation in panel A	25980
@NP	the schematic representation	25980
@NP	panel A	26012
@NP	the asterisk in panel A	26021
@NP	the asterisk	26021
@NP	panel A	26037
@NP	the approximate location of the section shown in panel B.	26056
@NP	the approximate location	26056
@NP	the section shown in panel B.	26084
@NP	the section	26084
@NP	panel B.	26105
@NP	GFAP immunostaining	26114
@NP	the border of the graft/lesion site	26155
@NP	the border	26155
@NP	the graft/lesion site	26169
@NP	Numerous neurofilament IR fibers	26192
@NP	the GFAP-IR tissue -LRB- arrow in panel B -RRB-	26247
@NP	the GFAP-IR tissue	26247
@NP	arrow in panel B	26267
@NP	arrow	26267
@NP	panel B	26276
@NP	the graft/lesion site -LRB- B -RRB-	26299
@NP	the graft/lesion site	26299
@NP	B	26322
@NP	control animals	26329
@NP	neurofilament IR fibers	26346
@NP	the GFAP-IR tissue	26382
@NP	the outer circumferences of the lesion gap	26420
@NP	the outer circumferences	26420
@NP	the lesion gap	26448
@NP	Quantification of neurofilament IR fiber ingrowth into the graft/lesion site	26464
@NP	Quantification	26464
@NP	neurofilament IR fiber ingrowth into the graft/lesion site	26482
@NP	neurofilament IR fiber ingrowth	26482
@NP	the graft/lesion site	26519
@NP	a 10-fold increase	26548
@NP	transplanted versus control animals -LRB- C -RRB-	26570
@NP	transplanted	26570
@NP	control animals -LRB- C -RRB-	26590
@NP	control animals	26590
@NP	C	26607
@NP	Serotonin immunohistochemistry	26611
@NP	serotonergic fibers	26653
@NP	the graft/lesion site -LRB- indicated with an asterisk -RRB- -LRB- D -RRB-	26682
@NP	the graft/lesion site -LRB- indicated with an asterisk -RRB-	26682
@NP	the graft/lesion site	26682
@NP	an asterisk	26720
@NP	D	26734
@NP	Arrowheads in panel B	26738
@NP	Arrowheads	26738
@NP	panel B	26752
@NP	parts of the PLA/PLA-b-PEO biomatrix material ; R , rostral ; C , caudal	26769
@NP	parts of the PLA/PLA-b-PEO biomatrix material	26769
@NP	parts	26769
@NP	the PLA/PLA-b-PEO biomatrix material	26778
@NP	R , rostral	26816
@NP	R	26816
@NP	rostral	26819
@NP	C , caudal	26828
@NP	C	26828
@NP	caudal	26831
@NP	P <	26840
@NP	P	26840
@NP	<	26842
@NP	0.05	26844
@NP	Fig. 4 .	26851
@NP	Fig.	26851
@NP	4	26856
@NP	BDA-IR corticospinal axon response to OEC/ONF intervention .	26859
@NP	BDA-IR	26859
@NP	corticospinal axon response to OEC/ONF intervention	26866
@NP	corticospinal axon response	26866
@NP	OEC/ONF intervention	26897
@NP	BDA-IR corticospinal axons	26919
@NP	the graft/lesion site	26972
@NP	very few	27004
@NP	the lesion	27029
@NP	the caudal host	27049
@NP	spinal cord	27065
@NP	No labeled corticospinal axons	27078
@NP	the graft/lesion site	27120
@NP	-LRB- A -RRB- Sagittal spinal cord section of an OEC/ONF-transplanted animal .	27143
@NP	-LRB- A -RRB-	27143
@NP	Sagittal spinal cord section of an OEC/ONF-transplanted animal	27147
@NP	Sagittal spinal cord section	27147
@NP	an OEC/ONF-transplanted animal	27179
@NP	The dotted line	27211
@NP	the delineation of the spinal cord	27238
@NP	the delineation	27238
@NP	the spinal cord	27257
@NP	the OEC/ONF -- biomatrix complex	27274
@NP	the OEC/ONF	27274
@NP	biomatrix complex	27286
@NP	the lesion site	27322
@NP	The four boxes	27339
@NP	the boxes used in the quantitative analysis	27364
@NP	the boxes	27364
@NP	the quantitative analysis	27382
@NP	-LRB- B -RRB- A significantly higher BDA-IR	27409
@NP	-LRB- B -RRB-	27409
@NP	A significantly higher BDA-IR	27413
@NP	the injury site -LRB- box 2 -RRB- in transplanted animals versus control animals	27474
@NP	the injury site -LRB- box 2 -RRB-	27474
@NP	the injury site	27474
@NP	box 2	27491
@NP	transplanted animals versus control animals	27501
@NP	transplanted animals	27501
@NP	control animals	27529
@NP	BDA/GFAP-stained sagittal section	27550
@NP	an OEC/ONF-transplanted animal ; many BDA-labeled corticospinal axons	27587
@NP	an OEC/ONF-transplanted animal	27587
@NP	many BDA-labeled corticospinal axons	27619
@NP	rostral	27661
@NP	the graft/lesion site	27672
@NP	asterisk in panel C	27695
@NP	asterisk	27695
@NP	panel C	27707
@NP	the graft/lesion site	27725
@NP	D , E	27749
@NP	D	27749
@NP	E	27752
@NP	BDA/GAP43-stained sagittal sections	27755
@NP	OEC/ONF-transplanted animals	27794
@NP	corticospinal axons rostral	27844
@NP	the graft/lesion site	27875
@NP	GAP43 IR -LRB- D -RRB-	27905
@NP	GAP43 IR	27905
@NP	D	27915
@NP	numerous GAP43 IR fibers	27923
@NP	the graft/lesion site	27967
@NP	note that panel E is in the middle of the graft/lesion site	27990
@NP	note	27990
@NP	panel E	28000
@NP	the middle of the graft/lesion site	28014
@NP	the middle	28014
@NP	the graft/lesion site	28028
@NP	E	28052
@NP	asterisk in panel D	28056
@NP	asterisk	28056
@NP	panel D	28068
@NP	the graft/lesion site	28086
@NP	-LRB- F -RRB- BDA-labeled corticospinal axon -LRB- arrow -RRB-	28109
@NP	-LRB- F -RRB- BDA-labeled corticospinal axon	28109
@NP	-LRB- F -RRB-	28109
@NP	BDA-labeled corticospinal axon	28113
@NP	arrow	28145
@NP	the caudal gray matter of an OEC/ONF-transplanted animal ; these caudal fibers	28167
@NP	the caudal gray matter of an OEC/ONF-transplanted animal	28167
@NP	the caudal gray matter	28167
@NP	an OEC/ONF-transplanted animal	28193
@NP	these caudal fibers	28225
@NP	one or two transplanted and control animals	28264
@NP	one	28264
@NP	two transplanted and control animals	28271
@NP	two transplanted	28271
@NP	control animals	28292
@NP	Scale bars	28309
@NP	100 μm	28324
@NP	Fig. 5 .	28333
@NP	Fig.	28333
@NP	5	28338
@NP	Behavioral effects of OEC/ONF intervention .	28341
@NP	Behavioral effects	28341
@NP	OEC/ONF intervention	28363
@NP	The acute OEC/ONF transplantation	28385
@NP	an effect on gross locomotion	28432
@NP	an effect	28432
@NP	gross locomotion	28445
@NP	the outcome	28478
@NP	the BBB locomotor scale	28493
@NP	A	28518
@NP	the CatWalk-based BBB scale	28525
@NP	B	28554
@NP	Fine locomotor parameters	28558
@NP	the CatWalk gait analysis	28599
@NP	a significant difference	28632
@NP	acute OEC/ONF transplantation at 9 weeks	28663
@NP	acute OEC/ONF transplantation	28663
@NP	9 weeks	28696
@NP	injury : stride length	28710
@NP	injury	28710
@NP	stride length	28718
@NP	speed of the hind limbs	28742
@NP	speed	28742
@NP	the hind limbs	28751
@NP	transplanted versus control animals -LRB- C , D -RRB-	28797
@NP	transplanted	28797
@NP	control animals -LRB- C , D -RRB-	28817
@NP	control animals	28817
@NP	P < 0.05 .	28842
@NP	P	28842
@NP	< 0.05 .	28844
@NP	<	28844
@NP	0.05 .	28846
@NP	OEC/ONF cultures The mixed OEC/ONF cultures	28853
@NP	OEC/ONF cultures	28853
@NP	The mixed OEC/ONF cultures	28870
@NP	those described previously -LRB- Li et al. , 1998 -RRB-	28915
@NP	those	28915
@NP	Li et al. , 1998	28943
@NP	Li	28943
@NP	et al.	28946
@NP	1998	28954
@NP	The cultures	28961
@NP	two main cell populations : the OEC and the ONF	28984
@NP	two main cell populations	28984
@NP	the OEC and the ONF	29011
@NP	the OEC	29011
@NP	the ONF	29023
@NP	The OEC population	29032
@NP	spindle-shaped cells co-expressing p75-NGF receptor and S100β	29072
@NP	spindle-shaped cells	29072
@NP	p75-NGF receptor and S100β	29107
@NP	OEC	29148
@NP	the GFAP protein	29162
@NP	The ONF population	29211
@NP	multiple cell types	29243
@NP	a flattened fibroblast-like morphology	29268
@NP	Immunoreactivity for fibronectin and GFAP in the ONF population	29308
@NP	Immunoreactivity	29308
@NP	fibronectin and GFAP in the ONF population	29329
@NP	fibronectin and GFAP	29329
@NP	the ONF population	29353
@NP	the presence of fibroblasts and astrocytes	29382
@NP	the presence	29382
@NP	fibroblasts and astrocytes	29398
@NP	the time in culture	29453
@NP	the time	29453
@NP	culture	29465
@NP	the relative contribution of OEC/ONF	29474
@NP	the relative contribution	29474
@NP	OEC/ONF	29503
@NP	Deumens et al. , 2004	29522
@NP	Deumens	29522
@NP	et al.	29530
@NP	2004	29538
@NP	which	29545
@NP	either a higher ONF proliferation as compared toOEC	29563
@NP	either a higher ONF proliferation	29563
@NP	toOEC	29609
@NP	a down-regulation of the p75 - NGF receptor by OEC	29618
@NP	a down-regulation of the p75	29618
@NP	a down-regulation	29618
@NP	the p75	29639
@NP	NGF receptor by OEC	29648
@NP	NGF receptor	29648
@NP	OEC	29664
@NP	advancing time	29673
@NP	the presence	29691
@NP	serum	29707
@NP	the culture medium	29716
@NP	Franceschini and Barnett	29760
@NP	1996	29786
@NP	the time of transplantation -LRB- i.e. after 14 days in vitro -RRB-	29796
@NP	the time	29796
@NP	transplantation -LRB- i.e. after 14 days in vitro -RRB-	29808
@NP	transplantation	29808
@NP	i.e. after 14 days in vitro	29825
@NP	i.e.	29825
@NP	14 days in vitro	29836
@NP	14 days	29836
@NP	the cultures	29855
@NP	10 % OEC	29884
@NP	selective immunostaining for either S100β or p75-NGF receptor	29902
@NP	selective immunostaining	29902
@NP	either S100β or p75-NGF receptor	29931
@NP	S100β	29938
@NP	p75-NGF receptor	29947
@NP	Prelabeling of the OEC/ONF cultures with Hoechst 1 day prior to transplantation	29965
@NP	Prelabeling	29965
@NP	the OEC/ONF cultures with Hoechst 1 day prior to transplantation	29980
@NP	the OEC/ONF cultures	29980
@NP	Hoechst	30006
@NP	1 day	30014
@NP	transplantation	30029
@NP	all the cells	30063
@NP	the presence of a stained -LRB- blue -RRB- nucleus -LRB- Fig. 1A -RRB-	30098
@NP	the presence	30098
@NP	a stained -LRB- blue -RRB- nucleus -LRB- Fig. 1A -RRB-	30114
@NP	a	30114
@NP	-LRB- blue -RRB- nucleus -LRB- Fig. 1A -RRB-	30124
@NP	-LRB- blue -RRB- nucleus	30124
@NP	Fig. 1A	30140
@NP	SCI , transplantation Eighteen animals	30150
@NP	SCI	30150
@NP	transplantation Eighteen animals	30155
@NP	transplantation	30155
@NP	Eighteen animals	30171
@NP	a 2-mm-long dorsal hemisection injury	30197
@NP	T11/T12 -LRB- Fig. 2 -RRB-	30238
@NP	T11/T12	30238
@NP	Fig. 2	30247
@NP	Ten animals	30256
@NP	an OEC/ONF	30285
@NP	biomatrix	30296
@NP	the lesion gap -LRB- Fig. 2 -RRB-	30329
@NP	the lesion gap	30329
@NP	Fig. 2	30345
@NP	OEC/ONF injections	30379
@NP	the host tissue rostral and caudal	30403
@NP	the host tissue rostral	30403
@NP	caudal	30431
@NP	this lesion gap	30441
@NP	Eight control animals	30458
@NP	culture medium injections	30494
@NP	the same locations	30523
@NP	the host tissue	30545
@NP	all eighteen animals	30571
@NP	a significant drop	30599
@NP	body weight	30621
@NP	5 %	30640
@NP	the first week postoperatively	30647
@NP	the first week	30647
@NP	they	30679
@NP	body weight	30695
@NP	the weeks	30710
@NP	the two groups of animals	30745
@NP	the two groups	30745
@NP	animals	30763
@NP	a significant difference in body weight	30787
@NP	a significant difference	30787
@NP	body weight	30815
@NP	any time point in the study -LRB- data not shown -RRB-	30830
@NP	any time point	30830
@NP	the study -LRB- data not shown -RRB-	30848
@NP	the study	30848
@NP	data not shown	30859
@NP	data	30859
@NP	Transplants within the spinal cord	30876
@NP	Transplants	30876
@NP	the spinal cord	30895
@NP	9 weeks	30914
@NP	the SCI and acute transplantation or control intervention	30928
@NP	the SCI	30928
@NP	acute transplantation or control intervention	30940
@NP	the animals	30987
@NP	the time	31019
@NP	the paraformaldehyde-fixed spinal cords from the transplanted animals	31042
@NP	the paraformaldehyde-fixed spinal cords	31042
@NP	the transplanted animals	31087
@NP	the OEC/ONF -- biomatrix complexes	31113
@NP	the OEC/ONF	31113
@NP	biomatrix complexes	31125
@NP	the lesion sites	31169
@NP	a stiff connective tissue bridge	31200
@NP	the graft/lesion site	31241
@NP	This connective tissue complicated the procedure of taking the	31264
@NP	This connective tissue	31264
@NP	the procedure of taking the	31299
@NP	the procedure	31299
@NP	the	31323
@NP	spinal cord	31335
@NP	the animals	31354
@NP	this procedure	31376
@NP	much care	31412
@NP	histological analysis of sagittal spinal cord sections	31423
@NP	histological analysis	31423
@NP	sagittal spinal cord sections	31448
@NP	the OEC/ONF -- biomatrix complex	31490
@NP	the OEC/ONF	31490
@NP	biomatrix complex	31502
@NP	a large extent disconnected from the host spinal tissue in many animals	31527
@NP	a large extent	31527
@NP	the host spinal tissue in many animals	31560
@NP	the host spinal tissue	31560
@NP	many animals	31586
@NP	a disconnection	31609
@NP	the complex and the underlying host spinal tissue	31652
@NP	the complex	31652
@NP	the underlying host spinal tissue	31668
@NP	a disconnection between the complex and the rostral and caudal host tissue	31703
@NP	a disconnection	31703
@NP	the complex and the rostral and caudal host tissue	31727
@NP	the complex	31727
@NP	the rostral and caudal host tissue	31743
@NP	nearly all transplanted animals	31791
@NP	many complex remnants	31837
@NP	the inner of the complexes	31880
@NP	the inner	31880
@NP	the complexes	31893
@NP	partly complex degradation	31919
@NP	control animals	31950
@NP	the lesion site	31967
@NP	any tissue	31997
@NP	Hoechst-prelabeled OEC/ONF	32022
@NP	the levels of the rostral and caudal injection sites	32074
@NP	the levels	32074
@NP	the rostral and caudal injection sites	32088
@NP	the rostral	32088
@NP	caudal injection sites	32104
@NP	none	32132
@NP	the biomatrix complexes	32158
@NP	The Hoechst-prelabeled OEC/ONF rostral and caudal to the lesion gap	32183
@NP	The Hoechst-prelabeled OEC/ONF rostral and caudal	32183
@NP	the lesion gap	32236
@NP	a relatively small area of the spinal cord	32273
@NP	a relatively small area	32273
@NP	the spinal cord	32300
@NP	the injection sites	32335
@NP	little or no migration	32361
@NP	the surrounding host tissue	32389
@NP	Figs. 1B -- D	32418
@NP	Figs. 1B	32418
@NP	D	32427
@NP	many yellowish crystalloid autofluorescent macrophages	32440
@NP	Bunn	32496
@NP	et al. , 2002	32501
@NP	et al.	32501
@NP	2002	32509
@NP	the host spinal cord tissue , viable transplanted Hoechst-prelabeled OEC/ONF	32532
@NP	the host spinal cord tissue	32532
@NP	viable transplanted Hoechst-prelabeled OEC/ONF	32561
@NP	those macrophages	32636
@NP	their blue fluorescence under UV illumination	32665
@NP	their blue fluorescence	32665
@NP	UV illumination	32695
@NP	addition	32715
@NP	a subpopulation of the transplanted Hoechst-prelabeled OEC/ONF	32725
@NP	a subpopulation	32725
@NP	the transplanted Hoechst-prelabeled OEC/ONF	32744
@NP	the p75-NGF receptor -LRB- Fig. 1D -RRB-	32811
@NP	the p75-NGF receptor	32811
@NP	Fig. 1D	32833
@NP	both transplanted and control animals	32846
@NP	both	32846
@NP	transplanted and control animals	32851
@NP	transplanted	32851
@NP	control animals	32868
@NP	small , but clearly visible cavities -LRB- with a diameter of about 100 μm -RRB-	32885
@NP	small , but clearly visible cavities	32885
@NP	a diameter of about 100 μm	32927
@NP	a diameter	32927
@NP	100 μm	32947
@NP	rostral and caudal	32975
@NP	the injury site	32997
@NP	a similar extent	33016
@NP	all animals	33036
@NP	the result of the injection procedure	33062
@NP	the result	33062
@NP	the injection procedure	33076
@NP	they	33103
@NP	located at approximately 1 mm rostral and caudal	33113
@NP	approximately 1 mm	33124
@NP	the lesion gap	33165
@NP	no transplanted Hoechst-prelabeled OEC/ONF	33190
@NP	the OEC/ONF -- biomatrix complexes in the graft/lesion sites	33267
@NP	the OEC/ONF	33267
@NP	biomatrix complexes in the graft/lesion sites	33280
@NP	biomatrix complexes	33280
@NP	the graft/lesion sites	33303
@NP	a histological Hoechst staining	33327
@NP	the animals	33391
@NP	host cells	33426
@NP	the transplanted complexes	33451
@NP	it	33485
@NP	many host cells	33508
@NP	the biomatrix complexes -LRB- Fig. 1E -RRB-	33532
@NP	the biomatrix complexes	33532
@NP	Fig. 1E	33557
@NP	Additional immunostaining	33567
@NP	a subpopulation of these invading cells	33617
@NP	a subpopulation	33617
@NP	these invading cells	33636
@NP	them	33699
@NP	Schwann cells -LRB- Fig. 1F -RRB-	33719
@NP	Schwann cells	33719
@NP	Fig. 1F	33734
@NP	The identity of the rest of the invading cells	33744
@NP	The identity	33744
@NP	the rest of the invading cells	33760
@NP	the rest	33760
@NP	the invading cells	33772
@NP	Ingrowth of axons into the graft/lesion site	33808
@NP	Ingrowth	33808
@NP	axons into the graft/lesion site	33820
@NP	axons	33820
@NP	the graft/lesion site	33831
@NP	axon regrowth	33872
@NP	we	33894
@NP	axons	33928
@NP	the transplanted OEC/ONF -- biomatrix complex	33945
@NP	the transplanted OEC/ONF	33945
@NP	biomatrix complex	33971
@NP	we	33994
@NP	a general neurofilament -LRB- NF -RRB- staining	34017
@NP	NF	34042
@NP	control animals	34059
@NP	there	34076
@NP	an NF-positive fiber passing the GFAP-positive scar	34099
@NP	an NF-positive fiber	34099
@NP	the GFAP-positive scar	34128
@NP	NF-positive fiber growth into the lesion site	34161
@NP	NF-positive fiber growth	34161
@NP	the lesion site	34191
@NP	the outer circumferences	34225
@NP	the lesion -LRB- i.e. at the border of the lesion gap -RRB-	34253
@NP	the lesion	34253
@NP	i.e. at the border of the lesion gap	34265
@NP	i.e.	34265
@NP	the border of the lesion gap	34273
@NP	the border	34273
@NP	the lesion gap	34287
@NP	sharp contrast to this	34307
@NP	sharp contrast	34307
@NP	this	34325
@NP	numerous NF-positive fibers	34331
@NP	the OEC/ONF -- biomatrix complexes of transplanted animals -LRB- Fig. 3B -RRB-	34386
@NP	the OEC/ONF	34386
@NP	biomatrix complexes of transplanted animals -LRB- Fig. 3B -RRB-	34399
@NP	biomatrix complexes	34399
@NP	transplanted animals -LRB- Fig. 3B -RRB-	34422
@NP	transplanted animals	34422
@NP	Fig. 3B	34444
@NP	the DuraFilm	34468
@NP	the grafts	34490
@NP	a quantitative analysis	34508
@NP	the complex	34555
@NP	the lesion site	34602
@NP	we	34619
@NP	the ingrowth	34631
@NP	NF-positive fibers -LRB- `` NF immunoreactivity occupation '' -RRB-	34647
@NP	NF-positive fibers	34647
@NP	NF	34668
@NP	immunoreactivity occupation ''	34671
@NP	immunoreactivity	34671
@NP	occupation ''	34688
@NP	the complete lesion gap	34704
@NP	irrespective of the degree in which the complex filled up this lesion gap	34729
@NP	irrespective	34729
@NP	the degree in which the complex filled up this lesion gap	34745
@NP	the degree	34745
@NP	the complex	34765
@NP	this lesion gap	34787
@NP	the GFAP-positive scar	34811
@NP	the graft/lesion site -LRB- Fig. 3A -RRB-	34847
@NP	the graft/lesion site	34847
@NP	Fig. 3A	34870
@NP	The size of the graft	34880
@NP	The size	34880
@NP	the graft	34892
@NP	lesion site , as demarcated by the GFAP-IR boundary ,	34903
@NP	lesion site	34903
@NP	the GFAP-IR boundary	34933
@NP	OEC/ONF-transplanted animals and control animals -LRB- data not shown -RRB-	34978
@NP	OEC/ONF-transplanted animals and control animals	34978
@NP	OEC/ONF-transplanted animals	34978
@NP	control animals	35011
@NP	data not shown	35028
@NP	data	35028
@NP	The occupation of the graft/lesion site by NF-positive fibers	35045
@NP	The occupation	35045
@NP	the graft/lesion site by NF-positive fibers	35063
@NP	the graft/lesion site	35063
@NP	NF-positive fibers	35088
@NP	0.41 ± 0.11 % in transplanted animals versus 0.05 ±	35111
@NP	0.41 ±	35111
@NP	0.11 %	35118
@NP	transplanted animals versus 0.05 ±	35127
@NP	transplanted animals	35127
@NP	0.05 ±	35155
@NP	0.02 %	35162
@NP	control animals	35171
@NP	Fig. 3C , P < 0.05	35188
@NP	Fig. 3C , P <	35188
@NP	Fig. 3C	35188
@NP	P <	35197
@NP	P	35197
@NP	<	35199
@NP	0.05	35201
@NP	serotonin immunostaining	35217
@NP	serotonergic fibers in the intact spinal tissue -LRB- Fig. 3D -RRB-	35264
@NP	serotonergic fibers	35264
@NP	the intact spinal tissue -LRB- Fig. 3D -RRB-	35287
@NP	the intact spinal tissue	35287
@NP	Fig. 3D	35313
@NP	the graft / lesion site	35323
@NP	the graft	35323
@NP	lesion site	35334
@NP	serotonin-immunoreactive fibers -LRB- data not shown -RRB-	35371
@NP	serotonin-immunoreactive fibers	35371
@NP	data not shown	35404
@NP	data	35404
@NP	CS axon response BDA labeling of the CS tract	35421
@NP	CS axon response BDA labeling	35421
@NP	the CS tract	35454
@NP	nine	35485
@NP	ten transplanted animals	35497
@NP	seven	35529
@NP	eight control animals	35542
@NP	BDA-labeled CS axons	35565
@NP	the graft/lesion site -LRB- Figs. 4A , C , D -RRB-	35620
@NP	the graft/lesion site	35620
@NP	Figs. 4A	35643
@NP	C	35653
@NP	D	35656
@NP	Most of these axons	35660
@NP	Most	35660
@NP	these axons	35668
@NP	the host/graft interface -LRB- Figs. 4A , C , D -RRB-	35708
@NP	the host/graft interface	35708
@NP	Figs. 4A	35734
@NP	C	35744
@NP	D	35747
@NP	No BDA-labeled CS axons	35751
@NP	the graft	35802
@NP	any of the animals	35815
@NP	any	35815
@NP	the animals	35822
@NP	a BDA-labeled CS axon	35849
@NP	the graft/lesion site	35895
@NP	one or two of the transplanted and control animals	35921
@NP	one or two of the transplanted	35921
@NP	one or two	35921
@NP	the transplanted	35935
@NP	control animals	35956
@NP	this	35973
@NP	the case caudal	35987
@NP	the lesion site -LRB- Fig. 4E -RRB-	36006
@NP	the lesion site	36006
@NP	Fig. 4E	36023
@NP	The anterograde labeling efficiency	36033
@NP	the animals	36090
@NP	BDA immunoreactivity at the rostral reference	36103
@NP	BDA immunoreactivity	36103
@NP	the rostral reference	36127
@NP	12.3 % at maximum and 0.15 % at minimum	36153
@NP	12.3 % at maximum	36153
@NP	12.3 %	36153
@NP	maximum	36162
@NP	0.15 % at minimum	36174
@NP	0.15 %	36174
@NP	minimum	36183
@NP	No statistically significant differences in BDAlabeled CS axons	36192
@NP	No statistically significant differences	36192
@NP	BDAlabeled CS axons	36236
@NP	the two groups of animals	36277
@NP	the two groups	36277
@NP	animals	36295
@NP	These values	36304
@NP	the 100 % reference values with respect	36330
@NP	the 100 % reference values	36330
@NP	respect	36361
@NP	the BDA immunoreactivity occupation measures rostral , underneath ,	36372
@NP	the BDA immunoreactivity occupation measures	36372
@NP	caudal to the lesion	36442
@NP	caudal	36442
@NP	the lesion	36452
@NP	Quantification	36464
@NP	BDA immunoreactivity occupation at the four different locations	36482
@NP	BDA immunoreactivity occupation	36482
@NP	the four different locations	36517
@NP	statistical testing usingANOVAR with Bonferroni	36550
@NP	statistical testing usingANOVAR	36550
@NP	Bonferroni	36587
@NP	hoc	36603
@NP	there	36619
@NP	an overall difference	36629
@NP	BDA immunoreactivity	36654
@NP	the respective locations -LRB- Location : F1 ,14 = 504.85 , P < 0.001 -RRB-	36680
@NP	the respective locations	36680
@NP	Location : F1 ,14 = 504.85	36706
@NP	Location	36706
@NP	F1 ,14 = 504.85	36716
@NP	F1 ,14	36716
@NP	504.85	36724
@NP	P < 0.001	36732
@NP	P	36732
@NP	< 0.001	36734
@NP	<	36734
@NP	0.001	36736
@NP	Fig. 4B	36744
@NP	a reduction	36758
@NP	BDA immunoreactivity -LRB- 1 -RRB-	36773
@NP	BDA immunoreactivity	36773
@NP	1	36795
@NP	rostral to the lesion site	36807
@NP	rostral	36807
@NP	the lesion site	36818
@NP	the lesion site	36850
@NP	the lesion	36850
@NP	site	36861
@NP	-LRB- 3 -RRB- caudal to the lesion site as compared to the rostral reference in	36871
@NP	caudal	36875
@NP	the lesion site as compared to the rostral reference in	36885
@NP	the lesion site	36885
@NP	the rostral reference in	36916
@NP	the rostral reference	36916
@NP	transplanted and control animals	36946
@NP	transplanted	36946
@NP	control animals	36963
@NP	addition	36983
@NP	an overall group difference	36993
@NP	Group : F1 ,14 = 12.09 , P < 0.01	37032
@NP	Group	37032
@NP	F1 ,14 = 12.09 , P < 0.01	37039
@NP	F1 ,14 = 12.09 , P <	37039
@NP	F1 ,14	37039
@NP	= 12.09 , P <	37045
@NP	12.09 , P	37047
@NP	12.09	37047
@NP	P	37054
@NP	0.01	37058
@NP	A significantly -LRB- P < 0.01 -RRB-	37065
@NP	A significantly	37065
@NP	P < 0.01	37082
@NP	P	37082
@NP	< 0.01	37084
@NP	<	37084
@NP	0.01	37086
@NP	higher BDA immunoreactivity	37092
@NP	rostral	37142
@NP	the lesion/graft site in transplanted animals -LRB- 65.0 ± 12.8 % -RRB-	37153
@NP	the lesion/graft site	37153
@NP	transplanted animals -LRB- 65.0 ± 12.8 % -RRB-	37178
@NP	transplanted animals	37178
@NP	65.0 ± 12.8 %	37200
@NP	65.0	37200
@NP	± 12.8 %	37205
@NP	animals	37237
@NP	13.1 ± 3.9 %	37246
@NP	13.1	37246
@NP	± 3.9 %	37251
@NP	We	37260
@NP	the higher BDA immunoreactivity directly rostral to the injury site	37277
@NP	the higher BDA immunoreactivity	37277
@NP	the injury site	37329
@NP	a sprouting response by the injured CS axons	37359
@NP	a sprouting response	37359
@NP	the injured CS axons	37383
@NP	a reduction in CS axon die-back	37405
@NP	a reduction	37405
@NP	CS axon die-back	37420
@NP	a combination of these two options	37441
@NP	a combination	37441
@NP	these two options	37458
@NP	the CS axons approaching the host/graft interface	37502
@NP	the CS axons	37502
@NP	the host/graft interface	37527
@NP	axons	37567
@NP	a BDA/GAP43 double staining	37574
@NP	All the	37617
@NP	nine transplanted	37625
@NP	seven control animals with a good BDA labeling of the CS tract staining	37647
@NP	seven control animals	37647
@NP	a good BDA labeling of the CS tract staining	37674
@NP	a good BDA labeling	37674
@NP	the CS tract staining	37697
@NP	GAP43	37737
@NP	positive BDA-immunoreactive axons	37744
@NP	positive	37744
@NP	BDA-immunoreactive axons	37753
@NP	none of the transplanted or control animals	37782
@NP	none of the transplanted	37782
@NP	none	37782
@NP	the transplanted	37790
@NP	control animals	37810
@NP	we	37830
@NP	such axons -LRB- Fig. 4D -RRB-	37841
@NP	such axons	37841
@NP	Fig. 4D	37853
@NP	the transplantation effect	37879
@NP	the injured CS axons rostral	37909
@NP	the lesion site most likely	37941
@NP	the lesion site	37941
@NP	a reduced die-back	37978
@NP	Functional outcome BBB locomotor rating scale The spinal cord injury	37998
@NP	Functional outcome BBB locomotor rating scale	37998
@NP	Functional outcome	37998
@NP	BBB locomotor rating scale	38017
@NP	The spinal cord injury	38044
@NP	functional impairment of the animals	38079
@NP	functional impairment	38079
@NP	the animals	38104
@NP	the first day after injury	38120
@NP	the first day	38120
@NP	injury	38140
@NP	the majority of animals	38148
@NP	the majority	38148
@NP	animals	38164
@NP	this study	38186
@NP	plantar placement of their hind paws	38222
@NP	plantar placement	38222
@NP	their hind paws	38243
@NP	there	38269
@NP	extensive movements of the hip , the knee , and the ankle	38279
@NP	extensive movements	38279
@NP	the hip , the knee , and the ankle	38302
@NP	the hip	38302
@NP	the knee	38311
@NP	the ankle	38325
@NP	the first week after injury	38339
@NP	the first week	38339
@NP	injury	38360
@NP	all the animals	38368
@NP	plantar placement of the hind paws , many with weight support	38388
@NP	plantar placement	38388
@NP	the hind paws	38409
@NP	weight support	38434
@NP	3 weeks after injury	38453
@NP	3 weeks	38453
@NP	injury	38467
@NP	all the animals	38475
@NP	consistent weight	38498
@NP	plantar	38526
@NP	BBB score 11	38544
@NP	BBB	38544
@NP	score 11	38548
@NP	some of them	38563
@NP	some	38563
@NP	them	38571
@NP	occasional coordination	38586
@NP	the forelimbs and the hind limbs -LRB- BBB score 12 -RRB-	38618
@NP	the forelimbs	38618
@NP	the hind limbs -LRB- BBB score 12 -RRB-	38636
@NP	the hind limbs	38636
@NP	BBB score 12	38652
@NP	the 9 weeks post-injury	38678
@NP	9 weeks	38682
@NP	the animals	38703
@NP	the BBB locomotor test on a weekly basis	38732
@NP	the BBB locomotor test	38732
@NP	a weekly basis	38758
@NP	No difference	38774
@NP	BBB scores	38795
@NP	transplanted and control animals at any time point -LRB- Fig. 5A -RRB-	38823
@NP	transplanted and control animals	38823
@NP	any time point -LRB- Fig. 5A -RRB-	38859
@NP	any time point	38859
@NP	Fig. 5A	38875
@NP	most of the animals in both groups	38894
@NP	most	38894
@NP	the animals in both groups	38902
@NP	the animals	38902
@NP	both groups	38917
@NP	a BBB score of 11	38941
@NP	a BBB score	38941
@NP	11	38956
@NP	the third week	38964
@NP	the ninth week	38982
@NP	A BBB score of 11	38998
@NP	A BBB score	38998
@NP	11	39013
@NP	frequent to consistent weight	39025
@NP	plantar stepping without coordination -LRB- Basso et al. , 1995 -RRB-	39065
@NP	plantar	39065
@NP	coordination -LRB- Basso et al. , 1995 -RRB-	39090
@NP	coordination	39090
@NP	Basso	39104
@NP	et al. , 1995	39110
@NP	et al.	39110
@NP	1995	39118
@NP	CatWalk-based BBB scale	39125
@NP	the CatWalk gait analysis	39152
@NP	the RI	39179
@NP	an objective measure of coordination	39205
@NP	an objective measure	39205
@NP	coordination	39229
@NP	the CatWalk-based coordination data	39248
@NP	the BBB scores	39304
@NP	3 , 6 , and 9 weeks	39322
@NP	3	39322
@NP	6	39325
@NP	9 weeks	39332
@NP	injury	39346
@NP	the BBB scores	39354
@NP	Fig. 5B	39398
@NP	animals	39421
@NP	their BBB scores	39439
@NP	from 11.4 -LRB- DPO21 -RRB- , 11.8 -LRB- DPO42 -RRB- ,	39456
@NP	from 11.4 -LRB- DPO21 -RRB-	39456
@NP	from 11.4	39456
@NP	DPO21	39467
@NP	11.8 -LRB- DPO42 -RRB-	39475
@NP	and 11.4 -LRB- DPO63 -RRB-	39489
@NP	and 11.4	39489
@NP	DPO63	39499
@NP	15.2 -LRB- DPO21 -RRB- , 15.3 -LRB- DPO42 -RRB- , and 15.8 -LRB- DPO63 -RRB-	39509
@NP	15.2 -LRB- DPO21 -RRB-	39509
@NP	15.3 -LRB- DPO42 -RRB-	39523
@NP	15.8 -LRB- DPO63 -RRB-	39541
@NP	all statistically significant using a Student 's t test -LRB- P < 0.01 -RRB-	39555
@NP	all statistically significant	39555
@NP	a Student 's t test	39591
@NP	a Student 's	39591
@NP	P < 0.01	39611
@NP	P	39611
@NP	< 0.01	39613
@NP	<	39613
@NP	0.01	39615
@NP	control animals	39635
@NP	their BBB scores	39661
@NP	integration	39683
@NP	the CatWalk-based coordination data	39698
@NP	11.1 -LRB- DPO21 -RRB-	39740
@NP	11.8 -LRB- DPO42 -RRB-	39754
@NP	11.6 -LRB- DPO63 -RRB-	39772
@NP	15.4 -LRB- DPO21 -RRB- , 14.6 -LRB- DPO42 -RRB- , and 13.6 -LRB- DPO63 -RRB-	39788
@NP	15.4 -LRB- DPO21 -RRB-	39788
@NP	14.6 -LRB- DPO42 -RRB-	39802
@NP	13.6 -LRB- DPO63 -RRB-	39820
@NP	DPO63	39845
@NP	all these time points	39852
@NP	a Student 's t test -LRB- P < 0.01 -RRB-	39910
@NP	a Student 's t test	39910
@NP	a Student 's	39910
@NP	P < 0.01	39930
@NP	P	39930
@NP	< 0.01	39932
@NP	<	39932
@NP	0.01	39934
@NP	the BBB scores increased to a similar extent in both the transplanted	39947
@NP	the BBB scores	39947
@NP	a similar extent	39975
@NP	the transplanted	40000
@NP	control animals	40021
@NP	no significant difference	40038
@NP	the two groups	40087
@NP	integration of the CatWalk-based coordination data	40107
@NP	integration	40107
@NP	the CatWalk-based coordination data	40122
@NP	the BBB scores at any time point -LRB- Fig. 5B -RRB-	40163
@NP	the BBB scores	40163
@NP	any time point -LRB- Fig. 5B -RRB-	40181
@NP	any time point	40181
@NP	Fig. 5B	40197
@NP	CatWalk gait analysis Duration of walkway	40207
@NP	CatWalk gait analysis Duration	40207
@NP	walkway	40241
@NP	respect	40263
@NP	the CatWalk gait analysis	40274
@NP	it	40301
@NP	the duration of walkway crossing	40330
@NP	the duration	40330
@NP	walkway crossing	40346
@NP	walkway	40346
@NP	an influence on the locomotion of the animals -LRB- Koopmans et al. , 2005 -RRB-	40372
@NP	an influence	40372
@NP	the locomotion of the animals -LRB- Koopmans et al. , 2005 -RRB-	40388
@NP	the locomotion	40388
@NP	the animals -LRB- Koopmans et al. , 2005 -RRB-	40406
@NP	the animals	40406
@NP	Koopmans	40419
@NP	et al. , 2005	40428
@NP	et al.	40428
@NP	2005	40436
@NP	it	40454
@NP	identical durations	40475
@NP	walkway	40498
@NP	animal groups	40523
@NP	the various locomotor parameters	40552
@NP	Preoperative training on the CatWalk	40586
@NP	Preoperative training	40586
@NP	the CatWalk	40611
@NP	rapid runway crossings of 1.39 ± 0.07 s and 1.47 ± 0.06 s	40635
@NP	rapid runway crossings	40635
@NP	1.39 ± 0.07 s and 1.47 ± 0.06 s	40661
@NP	1.39 ± 0.07 s	40661
@NP	1.39 ±	40661
@NP	0.07 s	40668
@NP	1.47 ± 0.06 s	40679
@NP	1.47 ±	40679
@NP	0.06 s	40686
@NP	transplanted and control animals , respectively	40696
@NP	transplanted	40696
@NP	control animals , respectively	40713
@NP	control animals	40713
@NP	Three weeks	40744
@NP	injury	40762
@NP	the runway crossing	40770
@NP	the runway	40770
@NP	significantly to 2.11 ± 0.12 s and 2.45 ± 0.25 s	40800
@NP	significantly to 2.11 ± 0.12 s	40800
@NP	2.11 ± 0.12	40817
@NP	2.11 ±	40817
@NP	0.12	40824
@NP	2.45 ± 0.25 s	40835
@NP	2.45 ±	40835
@NP	0.25 s	40842
@NP	transplanted and control animals , respectively	40852
@NP	transplanted	40852
@NP	control animals , respectively	40869
@NP	control animals	40869
@NP	the 6 and 9 weeks postinjury time points	40903
@NP	6	40907
@NP	9 weeks	40913
@NP	there	40945
@NP	no further increase in runway crossing in both animal groups	40955
@NP	no further increase	40955
@NP	runway crossing in both animal groups	40978
@NP	runway	40978
@NP	animal groups	41002
@NP	A statistically significant increase	41017
@NP	time between the preoperative and postinjury time points	41066
@NP	time	41066
@NP	the preoperative and postinjury time points	41079
@NP	both animal groups	41126
@NP	Time : F3 ,39 = 7.37 , P < 0.001 ; and F3 ,31	41156
@NP	Time	41156
@NP	F3 ,39 = 7.37 , P < 0.001	41162
@NP	F3 ,39 = 7.37 , P <	41162
@NP	F3 ,39	41162
@NP	= 7.37 , P <	41168
@NP	7.37 , P	41170
@NP	7.37	41170
@NP	P	41176
@NP	0.001	41180
@NP	F3 ,31	41191
@NP	4.71	41199
@NP	P <	41205
@NP	P	41205
@NP	<	41207
@NP	0.01 ; 1-way ANOVA/Bonferroni	41209
@NP	0.01	41209
@NP	1-way ANOVA/Bonferroni	41215
@NP	hoc over four time points for transplanted and control animals , respectively	41243
@NP	hoc	41243
@NP	four time points for transplanted and control animals , respectively	41252
@NP	four time points	41252
@NP	transplanted and control animals , respectively	41273
@NP	transplanted	41273
@NP	control animals , respectively	41290
@NP	control animals	41290
@NP	no statistically significant difference in crossing time	41349
@NP	no statistically significant difference	41349
@NP	time	41401
@NP	the two animal groups	41424
@NP	any of the four time points	41449
@NP	any	41449
@NP	the four time points	41456
@NP	a legitimate comparison of data between the two groups	41489
@NP	a legitimate comparison	41489
@NP	data between the two groups	41516
@NP	data	41516
@NP	the two groups	41529
@NP	any given time point	41559
@NP	Stride length of hind limbs The stride length of the hind limbs	41581
@NP	Stride length	41581
@NP	hind limbs The stride length of the hind limbs	41598
@NP	hind limbs	41598
@NP	The stride length of the hind limbs	41609
@NP	The stride length	41609
@NP	the hind limbs	41630
@NP	the distance	41648
@NP	the print	41669
@NP	one hind paw	41682
@NP	one step cycle to the print of the same hind paw in the next step cycle	41698
@NP	one step cycle	41698
@NP	the print of the same hind paw in the next step cycle	41716
@NP	the print	41716
@NP	the same hind paw in the next step cycle	41729
@NP	the same hind paw	41729
@NP	the next step cycle	41750
@NP	injury	41778
@NP	the stride length of transplanted and control animals	41786
@NP	the stride length	41786
@NP	transplanted and control animals	41807
@NP	transplanted	41807
@NP	control animals	41824
@NP	148.1 ± 2.8 mm and 140.2 ± 2.6 mm	41844
@NP	148.1 ± 2.8 mm	41844
@NP	148.1 ±	41844
@NP	2.8 mm	41852
@NP	140.2 ± 2.6 mm	41863
@NP	140.2 ±	41863
@NP	2.6 mm	41871
@NP	n.s. ; Fig. 5C	41893
@NP	n.s.	41893
@NP	Fig. 5C	41899
@NP	the four different time points	41914
@NP	there	41946
@NP	a statistically significant decrease	41956
@NP	Time : F1 ,16 = 18.14	41994
@NP	Time	41994
@NP	F1 ,16 = 18.14	42000
@NP	F1 ,16	42000
@NP	18.14	42008
@NP	P < 0.01	42015
@NP	P	42015
@NP	< 0.01	42017
@NP	<	42017
@NP	0.01	42019
@NP	an overall significant difference	42039
@NP	the two groups -LRB- Group : F1 ,16 = 6.11 , P < 0.05 -RRB-	42094
@NP	the two groups	42094
@NP	Group : F1 ,16 = 6.11	42110
@NP	Group	42110
@NP	F1 ,16 = 6.11	42117
@NP	F1 ,16	42117
@NP	= 6.11	42123
@NP	P < 0.05	42131
@NP	P	42131
@NP	< 0.05	42133
@NP	<	42133
@NP	0.05	42135
@NP	the last time point in this study -LRB- i.e. 9 weeks post-injury -RRB-	42145
@NP	the last time point	42145
@NP	this study -LRB- i.e. 9 weeks post-injury -RRB-	42168
@NP	this study	42168
@NP	9 weeks	42185
@NP	Student 's t testing	42207
@NP	Student 's	42207
@NP	the stride length of the hind limbs in transplanted animals	42239
@NP	the stride length	42239
@NP	the hind limbs in transplanted animals	42260
@NP	the hind limbs	42260
@NP	transplanted animals	42278
@NP	control animals	42332
@NP	134.5 ± 3.1 mm and 122.5 ± 3.3 mm , respectively ; P < 0.05 ; Fig. 5C	42349
@NP	134.5 ± 3.1 mm	42349
@NP	134.5 ±	42349
@NP	3.1 mm	42357
@NP	122.5 ± 3.3 mm , respectively ; P < 0.05 ; Fig. 5C	42368
@NP	122.5 ± 3.3 mm , respectively	42368
@NP	122.5	42368
@NP	± 3.3 mm	42374
@NP	P < 0.05	42398
@NP	P <	42398
@NP	P	42398
@NP	0.05	42402
@NP	Fig. 5C	42408
@NP	Fig.	42408
@NP	5C	42413
@NP	Swing speed	42418
@NP	hind limbs	42433
@NP	This parameter	42444
@NP	the distance -LRB- stride length -RRB-	42468
@NP	the distance	42468
@NP	stride length	42482
@NP	the hind paw	42502
@NP	one step cycle and the time	42530
@NP	one step cycle	42530
@NP	the time	42549
@NP	swing duration	42559
@NP	it	42575
@NP	injury	42592
@NP	the swing speed of the hind limbs	42600
@NP	the swing speed	42600
@NP	the hind limbs	42619
@NP	1.20 ± 0.05 m/s	42638
@NP	1.15 ± 0.02 m/s for transplanted and control animals , respectively	42658
@NP	1.15 ± 0.02 m/s	42658
@NP	transplanted and control animals , respectively	42678
@NP	transplanted	42678
@NP	control animals , respectively	42695
@NP	control animals	42695
@NP	n.s.	42726
@NP	a tendency	42742
@NP	a difference	42770
@NP	the two animal groups -LRB- Group : F1 ,16 = 4.34 , P = 0.054 -RRB-	42791
@NP	the two animal groups	42791
@NP	Group : F1 ,16 = 4.34 , P = 0.054	42814
@NP	Group	42814
@NP	F1 ,16 = 4.34 , P = 0.054	42821
@NP	F1	42821
@NP	,16 = 4.34 , P = 0.054	42823
@NP	,16 = 4.34 , P	42823
@NP	4.34	42829
@NP	0.054	42839
@NP	all time points	42852
@NP	there	42869
@NP	a significant change in swing speed -LRB- Time : F1 ,16 = 9.47 , P < 0.01 -RRB-	42879
@NP	a significant change	42879
@NP	swing speed -LRB- Time : F1 ,16 = 9.47 , P < 0.01 -RRB-	42903
@NP	swing speed	42903
@NP	Time : F1 ,16 = 9.47	42916
@NP	Time	42916
@NP	F1 ,16 = 9.47	42922
@NP	F1 ,16	42922
@NP	9.47	42930
@NP	P < 0.01	42936
@NP	P	42936
@NP	< 0.01	42938
@NP	<	42938
@NP	0.01	42940
@NP	Student 's t tests	42947
@NP	Student 's	42947
@NP	the swing speed of the hind limbs	42977
@NP	the swing speed	42977
@NP	the hind limbs	42996
@NP	transplanted animal	43039
@NP	animals	43082
@NP	the end	43093
@NP	the experiment -LRB- i.e. 9 weeks after injury -RRB-	43104
@NP	the experiment	43104
@NP	i.e. 9 weeks after injury	43120
@NP	i.e.	43120
@NP	9 weeks after injury	43125
@NP	9 weeks	43125
@NP	injury	43139
@NP	Fig. 5D ; P < 0.05	43148
@NP	Fig. 5D	43148
@NP	P < 0.05	43157
@NP	P <	43157
@NP	P	43157
@NP	0.05	43161
@NP	inter-group changes	43177
@NP	both stride length of the hind limbs	43212
@NP	both stride length	43212
@NP	the hind limbs	43234
@NP	speed of the hind limbs	43259
@NP	speed	43259
@NP	the hind limbs	43268
@NP	there	43284
@NP	no change	43294
@NP	swing duration between the two animal groups -LRB- data not shown -RRB-	43307
@NP	swing duration	43307
@NP	the two animal groups	43330
@NP	data not shown	43353
@NP	data	43353
@NP	Discussion	43370
@NP	We	43381
@NP	the effect of a multifactorial acute transplantation strategy on axon regrowth	43392
@NP	the effect	43392
@NP	a multifactorial acute transplantation strategy on axon regrowth	43406
@NP	a multifactorial acute transplantation strategy	43406
@NP	axon regrowth	43457
@NP	large spinal lesion gaps	43478
@NP	This strategy	43504
@NP	an OEC/ONF continuum	43537
@NP	the injured spinal cord	43561
@NP	two aspects	43594
@NP	an aligned OEC/ONF	43607
@NP	biomatrix complex	43626
@NP	a 2-mm dorsal hemisection lesion site and additional OEC/ONF cell injections	43654
@NP	a 2-mm dorsal hemisection lesion site	43654
@NP	additional OEC/ONF cell injections	43696
@NP	1 mm rostral and 1 mm caudal	43734
@NP	1 mm rostral	43734
@NP	1 mm caudal	43751
@NP	the injury site	43766
@NP	Fig. 2	43783
@NP	We	43792
@NP	the transplanted OEC/ONF	43805
@NP	the injection areas	43842
@NP	the biomatrices	43874
@NP	the lesion gaps	43897
@NP	the surviving OEC/ONF in the injection areas	43927
@NP	the surviving OEC/ONF	43927
@NP	the injection areas	43952
@NP	these areas	43993
@NP	an OEC/ONF continuum	44013
@NP	we	44064
@NP	our transplantation strategy	44085
@NP	numerous axons	44125
@NP	the OEC/ONF -- biomatrix complex	44153
@NP	the OEC/ONF	44153
@NP	biomatrix complex	44165
@NP	None of these axons	44184
@NP	None	44184
@NP	these axons	44192
@NP	CS or raphespinal origin	44211
@NP	CS	44211
@NP	raphespinal origin	44217
@NP	BDA-labeled CS axons	44246
@NP	the graft	44281
@NP	any of the animals	44294
@NP	any	44294
@NP	the animals	44301
@NP	the transplantation strategy	44314
@NP	a clear increase of injured BDA-labeled CS axons	44355
@NP	a clear increase	44355
@NP	injured BDA-labeled CS axons	44375
@NP	the injury site	44424
@NP	This response of injured BDA-labeled CS axons	44441
@NP	This response	44441
@NP	injured BDA-labeled CS axons	44458
@NP	a reduced die-back of the axons as a result of the transplantation intervention	44499
@NP	a reduced die-back	44499
@NP	the axons as a result of the transplantation intervention	44521
@NP	the axons	44521
@NP	a result of the transplantation intervention	44534
@NP	a result	44534
@NP	the transplantation intervention	44546
@NP	none of these CS axons	44585
@NP	none	44585
@NP	these CS axons	44593
@NP	GAP43/B50 - positive	44612
@NP	GAP43/B50	44612
@NP	addition	44636
@NP	the transplantation strategy	44646
@NP	a recovery in stride length	44691
@NP	a recovery	44691
@NP	stride length	44705
@NP	speed of the hind limbs	44729
@NP	speed	44729
@NP	the hind limbs	44738
@NP	OEC vs.	44754
@NP	OEC	44754
@NP	vs.	44758
@NP	OEC/ONF	44762
@NP	there	44781
@NP	an ongoing discussion	44790
@NP	the optimal composition of olfactory ensheathing cell cultures	44818
@NP	the optimal composition	44818
@NP	olfactory ensheathing cell cultures	44845
@NP	regeneration	44908
@NP	axons	44924
@NP	an experimental spinal cord injury -LRB- Barnett and Chang , 2004 -RRB-	44941
@NP	an experimental spinal cord injury	44941
@NP	Barnett and Chang	44977
@NP	2004	44996
@NP	Acute transplantation of mixed OEC/ONF cultures	45003
@NP	Acute transplantation	45003
@NP	mixed OEC/ONF cultures	45028
@NP	regrowth of injured CS axons	45066
@NP	regrowth	45066
@NP	injured CS axons	45078
@NP	relatively small spinal lesion gaps -LRB- Li et al. , 1997 , 1998 -RRB-	45102
@NP	relatively small spinal lesion gaps	45102
@NP	Li	45139
@NP	et al. , 1997 , 1998	45142
@NP	et al.	45142
@NP	1997	45150
@NP	1998	45156
@NP	purified OEC cultures	45177
@NP	complete or incomplete transection sites , injured	45222
@NP	complete or incomplete transection sites	45222
@NP	CS axons	45272
@NP	the relatively small lesion gaps	45309
@NP	Ramon-Cueto	45343
@NP	et al. , 2000 ; Nash et al. , 2002	45355
@NP	et al.	45355
@NP	2000 ; Nash et al.	45363
@NP	2000	45363
@NP	Nash et al.	45369
@NP	Nash	45369
@NP	et al.	45374
@NP	2002	45382
@NP	these small lesion gaps	45423
@NP	CS axons	45456
@NP	the spinal cord surface	45501
@NP	the presence of meningeal fibroblasts -LRB- Ramon - Cueto et al. , 2000 -RRB-	45528
@NP	the presence	45528
@NP	meningeal fibroblasts -LRB- Ramon - Cueto et al. , 2000 -RRB-	45544
@NP	meningeal fibroblasts	45544
@NP	Ramon	45567
@NP	Cueto et al. , 2000	45574
@NP	Cueto	45574
@NP	et al.	45580
@NP	2000	45588
@NP	This	45595
@NP	a cooperation of the transplanted OEC with fibroblasts	45609
@NP	a cooperation	45609
@NP	the transplanted OEC with fibroblasts	45626
@NP	the transplanted OEC	45626
@NP	fibroblasts	45652
@NP	contrast to small spinal lesion gaps	45668
@NP	contrast	45668
@NP	small spinal lesion gaps	45680
@NP	large spinal lesion gaps	45706
@NP	long-distance axon regrowth	45739
@NP	Acute transplantation of purified OEC cultures	45768
@NP	Acute transplantation	45768
@NP	purified OEC cultures	45793
@NP	very few injured CS axons	45830
@NP	around large spinal lesion gaps -LRB- Chuah et al. , 2004 -RRB-	45866
@NP	around large spinal lesion gaps	45866
@NP	Chuah	45899
@NP	et al. , 2004	45905
@NP	et al.	45905
@NP	2004	45913
@NP	it	45930
@NP	OEC and ONF	45950
@NP	long-distance olfactory axon regeneration -LRB- Li et al. , 2005 -RRB-	45978
@NP	long-distance olfactory axon regeneration	45978
@NP	Li	46021
@NP	et al. , 2005	46024
@NP	et al.	46024
@NP	2005	46032
@NP	our multifactorial transplantation strategy	46051
@NP	the spinal cord , transplanted OEC	46098
@NP	the spinal cord	46098
@NP	OEC	46128
@NP	ONF	46133
@NP	long-distance regrowth of injured CS axons	46164
@NP	long-distance regrowth	46164
@NP	injured CS axons	46190
@NP	Multifactorial transplantation strategy and regrowth	46208
@NP	injured CS axons across large spinal gaps	46264
@NP	injured CS axons	46264
@NP	large spinal gaps	46288
@NP	repair of large spinal lesion gaps	46336
@NP	repair	46336
@NP	large spinal lesion gaps	46346
@NP	The long-distance axon regrowth , required in large spinal lesion gaps ,	46398
@NP	The long-distance axon regrowth	46398
@NP	large spinal lesion gaps	46443
@NP	influence	46476
@NP	at least three issues	46489
@NP	a continuum of growth-promoting cells within the spinal cord	46519
@NP	a continuum	46519
@NP	growth-promoting cells within the spinal cord	46534
@NP	growth-promoting cells	46534
@NP	the spinal cord	46564
@NP	CS axons	46589
@NP	grafts	46624
@NP	immature astrocytes in a collagen matrix	46643
@NP	immature astrocytes	46643
@NP	a collagen matrix	46666
@NP	the caudal host	46705
@NP	spinal cord -LRB- Joosten et al. , 2004 -RRB-	46721
@NP	spinal cord	46721
@NP	Joosten	46734
@NP	et al. , 2004	46742
@NP	et al.	46742
@NP	2004	46750
@NP	It	46757
@NP	this lack of CS axon re-entry into the host tissue	46779
@NP	this lack	46779
@NP	CS axon re-entry into the host tissue	46792
@NP	CS axon re-entry	46792
@NP	the host tissue	46814
@NP	the absence of transplanted cells in the host tissue	46848
@NP	the absence	46848
@NP	transplanted cells in the host tissue	46863
@NP	transplanted cells	46863
@NP	the host tissue	46885
@NP	the alignment of cells	46910
@NP	the alignment	46910
@NP	cells	46927
@NP	the large lesion gaps	46951
@NP	A specific organization of astrocytes	46974
@NP	A specific organization	46974
@NP	astrocytes	47001
@NP	utmost importance for the correct long-distance outgrowth of the CS tract	47039
@NP	utmost importance	47039
@NP	the correct long-distance outgrowth of the CS tract	47061
@NP	the correct long-distance outgrowth	47061
@NP	the CS tract	47100
@NP	development -LRB- Joosten and Gribnau , 1989 -RRB-	47120
@NP	development	47120
@NP	Joosten and Gribnau	47133
@NP	1989	47154
@NP	a clear orientation of transplanted OEC	47174
@NP	a clear orientation	47174
@NP	transplanted OEC	47197
@NP	directional host axon growth from the thalamus	47229
@NP	directional host axon growth	47229
@NP	the thalamus	47263
@NP	the hippocampus -LRB- Perez-Bouza et al. , 1998 -RRB-	47279
@NP	the hippocampus	47279
@NP	Perez-Bouza	47296
@NP	et al. , 1998	47308
@NP	et al.	47308
@NP	1998	47316
@NP	Third	47323
@NP	OEC and ONF	47336
@NP	long-distance olfactory axon regeneration -LRB- Li et al. , 2005 -RRB-	47358
@NP	long-distance olfactory axon regeneration	47358
@NP	Li	47401
@NP	et al. , 2005	47404
@NP	et al.	47404
@NP	2005	47412
@NP	the use of these mixed cultures	47419
@NP	the use	47419
@NP	these mixed cultures	47430
@NP	long-distance regrowth of axons severed by an SCI	47487
@NP	long-distance regrowth	47487
@NP	axons severed by an SCI	47513
@NP	axons	47513
@NP	an SCI	47530
@NP	our multifactorial transplantation strategy	47541
@NP	all these three issues	47586
@NP	all these	47586
@NP	three issues	47596
@NP	OEC/ONF	47632
@NP	transplanted	47645
@NP	the 2-mm dorsal hemisection lesion gap	47668
@NP	biomatrices	47720
@NP	the rostral and caudal host	47742
@NP	the rostral	47742
@NP	caudal host	47758
@NP	tissue	47770
@NP	Putative migration	47778
@NP	OEC/ONF	47800
@NP	the injured spinal cord , as described previously	47815
@NP	the injured spinal cord	47815
@NP	Li	47865
@NP	et al. , 1998	47868
@NP	et al.	47868
@NP	1998	47876
@NP	an OEC/ONF continuum	47899
@NP	OEC/ONF	47937
@NP	biomatrix complexes	47946
@NP	directional neurite outgrowth	47996
@NP	Deumens	48036
@NP	et al. , 2004	48044
@NP	et al.	48044
@NP	2004	48052
@NP	the lesion gaps	48082
@NP	Third , mixed OEC/ONF cultures	48099
@NP	Third	48099
@NP	mixed OEC/ONF cultures	48106
@NP	Our multifactorial transplantation intervention	48140
@NP	two main histological outcomes	48201
@NP	there	48240
@NP	an enhanced presence	48250
@NP	injured CS axons directly rostral to the spinal lesion gap -LRB- Fig. 4 -RRB-	48274
@NP	injured CS axons	48274
@NP	the spinal lesion gap -LRB- Fig. 4 -RRB-	48311
@NP	the spinal lesion gap	48311
@NP	Fig. 4	48334
@NP	numerous axon	48351
@NP	the OEC / ONF --	48376
@NP	the OEC	48376
@NP	ONF	48385
@NP	biomatrix complexes in the spinal lesion gaps -LRB- Fig. 3 -RRB-	48389
@NP	biomatrix complexes	48389
@NP	the spinal lesion gaps -LRB- Fig. 3 -RRB-	48412
@NP	the spinal lesion gaps	48412
@NP	Fig. 3	48436
@NP	these axons	48460
@NP	an aligned phenotype	48487
@NP	The enhanced presence of CS axons	48509
@NP	The enhanced presence	48509
@NP	CS axons	48534
@NP	the lesion gap	48563
@NP	a reduced die-back of injured CS axons	48590
@NP	a reduced die-back	48590
@NP	injured CS axons	48612
@NP	the injured CS axons	48637
@NP	GAP43/B50	48682
@NP	Die-back of injured CS axons	48693
@NP	Die-back	48693
@NP	injured CS axons	48705
@NP	injury	48753
@NP	the majority of CS axons	48772
@NP	the majority	48772
@NP	CS axons	48788
@NP	between 1 and 2.5 mm rostral	48811
@NP	the injury site at 8 -- 10 weeks after trauma	48843
@NP	the injury site at 8	48843
@NP	the injury site	48843
@NP	8	48862
@NP	10 weeks after trauma	48864
@NP	10 weeks	48864
@NP	trauma	48879
@NP	Pallini et al. , 1988 ; von Meyenburg et al. , 1998 ; Oudega et al. , 1999	48887
@NP	Pallini	48887
@NP	et al. , 1988 ; von Meyenburg et al. , 1998 ; Oudega et al. , 1999	48895
@NP	et al. , 1988	48895
@NP	et al.	48895
@NP	1988	48903
@NP	von Meyenburg et al. , 1998	48909
@NP	von Meyenburg	48909
@NP	et al. , 1998	48923
@NP	et al.	48923
@NP	1998	48931
@NP	Oudega et al. , 1999	48937
@NP	Oudega	48937
@NP	et al. , 1999	48944
@NP	et al.	48944
@NP	1999	48952
@NP	Our results	48959
@NP	sharp contrast	48978
@NP	those	48996
@NP	mixed OEC/ONF cultures	49031
@NP	small spinal lesion gaps	49057
@NP	regrowth	49103
@NP	CS axons	49115
@NP	the spinal lesion sites	49132
@NP	the caudal spinal tissue	49165
@NP	up to 1 cm -LRB- Li et al. , 1997 , 1998 -RRB-	49190
@NP	up to 1 cm	49190
@NP	Li	49202
@NP	et al. , 1997 , 1998	49205
@NP	et al.	49205
@NP	1997	49213
@NP	1998	49219
@NP	We	49226
@NP	three possibilities involved in the contrasting results	49237
@NP	three possibilities	49237
@NP	the contrasting results	49269
@NP	OEC/ONF transplants	49301
@NP	small lesion gaps -LRB- Li et al. , 1997 , 1998 , 2003 -RRB-	49341
@NP	small lesion gaps	49341
@NP	Li	49360
@NP	et al. , 1997 , 1998 , 2003	49363
@NP	et al.	49363
@NP	1997	49371
@NP	1998	49377
@NP	2003	49383
@NP	our study	49393
@NP	no Hoechst-prelabeled OEC/ONF	49404
@NP	the OEC/ONF	49451
@NP	biomatrix complexes transplanted into the large lesion gap -LRB- see below -RRB-	49463
@NP	biomatrix complexes	49463
@NP	the large lesion gap -LRB- see below -RRB-	49501
@NP	the large lesion gap	49501
@NP	the lesion model of Li and co-workers	49543
@NP	the lesion model	49543
@NP	Li and co-workers	49563
@NP	Li	49563
@NP	co-workers	49570
@NP	ours	49604
@NP	The level of the lesion	49610
@NP	The level	49610
@NP	the lesion	49623
@NP	i.e. high cervical vs. low thoracic	49644
@NP	i.e.	49644
@NP	low thoracic	49667
@NP	The capacity of an injured axon to regrow	49681
@NP	The capacity	49681
@NP	an injured axon to regrow	49697
@NP	an increasing distance	49741
@NP	the injury	49772
@NP	the soma of the injured neuron -LRB- Richardson et al. , 1984 -RRB-	49787
@NP	the soma	49787
@NP	the injured neuron -LRB- Richardson et al. , 1984 -RRB-	49799
@NP	the injured neuron	49799
@NP	Richardson	49819
@NP	et al. , 1984	49830
@NP	et al.	49830
@NP	1984	49838
@NP	this	49853
@NP	the extent of the lesion	49859
@NP	the extent	49859
@NP	the lesion	49873
@NP	i.e.	49894
@NP	lesion of the CS tract vs. 2 - mm-wide dorsal hemisection injury	49907
@NP	lesion of the CS tract	49907
@NP	lesion	49907
@NP	the CS tract	49917
@NP	2 - mm-wide dorsal hemisection injury	49934
@NP	injured CS axons	49981
@NP	small spinal lesion gaps	50016
@NP	one-way approaches	50047
@NP	OEC/ONF suspensions -LRB- Li et al. , 1998 -RRB-	50091
@NP	OEC/ONF suspensions	50091
@NP	Li	50112
@NP	et al. , 1998	50115
@NP	et al.	50115
@NP	1998	50123
@NP	long distance of injured CS axons across large lesion gaps	50130
@NP	long distance	50130
@NP	injured CS axons across large lesion gaps	50147
@NP	injured CS axons	50147
@NP	large lesion gaps	50171
@NP	additional interventions , such as the use of growth-promoting bridges	50201
@NP	additional interventions	50201
@NP	the use of growth-promoting bridges	50235
@NP	the use	50235
@NP	growth-promoting bridges	50246
@NP	these large lesion gaps	50278
@NP	such bridges	50312
@NP	growth-promoting cells and biodegradable matrices	50340
@NP	growth-promoting cells	50340
@NP	biodegradable matrices	50367
@NP	our study	50391
@NP	some disadvantages	50415
@NP	the specific combination	50437
@NP	OEC/ONF with poly -LRB- D , L -RRB-	50465
@NP	OEC/ONF	50465
@NP	poly -LRB- D , L -RRB-	50478
@NP	poly	50478
@NP	lactide matrices	50488
@NP	a lack of OEC/ONF survival on the matrices within the lesion site	50510
@NP	a lack	50510
@NP	OEC/ONF survival on the matrices within the lesion site	50520
@NP	OEC/ONF survival	50520
@NP	the matrices within the lesion site	50540
@NP	the matrices	50540
@NP	the lesion site	50560
@NP	a poor integration of the complexes into the host spinal tissue	50580
@NP	a poor integration	50580
@NP	the complexes into the host spinal tissue	50602
@NP	the complexes	50602
@NP	the host spinal tissue	50621
@NP	Third	50662
@NP	CS axon regrowth across a 2-mm-long lesion gap and into the caudal host tissue	50669
@NP	CS axon regrowth	50669
@NP	a 2-mm-long lesion gap	50693
@NP	the caudal host tissue	50725
@NP	more than the 9 weeks	50760
@NP	A 9-week period	50783
@NP	CS axon regrowth	50829
@NP	relatively small lesions -LRB- Li et al. , 1998 -RRB-	50853
@NP	relatively small lesions	50853
@NP	Li	50879
@NP	et al. , 1998	50882
@NP	et al.	50882
@NP	1998	50890
@NP	our data	50906
@NP	CS axons	50924
@NP	present almost exclusively rostral to the injury site	50933
@NP	the injury	50971
@NP	the time after injury	51001
@NP	the time	51001
@NP	injury	51016
@NP	the determining factor in the CS axon regrowth response	51030
@NP	the determining factor	51030
@NP	the CS axon regrowth response	51056
@NP	inter-group differences in CS axon regrowth	51096
@NP	inter-group differences	51096
@NP	CS axon regrowth	51123
@NP	rostral	51165
@NP	the injury site	51176
@NP	both OEC/ONF-transplanted animals and untreated control animals	51196
@NP	OEC/ONF-transplanted animals	51201
@NP	a few CS axons	51261
@NP	the gray matter underneath the lesion site	51293
@NP	the gray matter	51293
@NP	the lesion site	51320
@NP	the gray matter of the caudal spinal tissue	51347
@NP	the gray matter	51347
@NP	the caudal spinal tissue	51366
@NP	line with this	51395
@NP	line	51395
@NP	this	51405
@NP	others	51411
@NP	a similar CS axon regrowth response	51424
@NP	OEC transplantation	51466
@NP	large lesion gaps	51491
@NP	thoracic dorsal column transection -LRB- Chuah et al. , 2004 -RRB-	51525
@NP	thoracic dorsal column transection	51525
@NP	Chuah	51561
@NP	et al. , 2004	51567
@NP	et al.	51567
@NP	2004	51575
@NP	NF-positive axon growth into the lesion site	51593
@NP	NF-positive axon growth	51593
@NP	the lesion site	51622
@NP	we	51639
@NP	a spontaneous response of endogenous tissue repair	51660
@NP	a spontaneous response	51660
@NP	endogenous tissue repair	51686
@NP	dorsal hemisection injury	51717
@NP	the thoracic spinal cord of the rat -LRB- Brook et al. , 2000 -RRB-	51746
@NP	the thoracic spinal cord	51746
@NP	the rat -LRB- Brook et al. , 2000 -RRB-	51774
@NP	the rat	51774
@NP	Brook	51783
@NP	et al. , 2000	51789
@NP	et al.	51789
@NP	2000	51797
@NP	NF-positive fibers	51810
@NP	small dorsal hemisection lesion gaps	51869
@NP	numerous host cells	51933
@NP	the p75-NGF receptor	51964
@NP	the present study	51989
@NP	such a spontaneous response of endogenous tissue repair	52008
@NP	such a spontaneous response	52008
@NP	endogenous tissue repair	52039
@NP	the extent of the injury	52084
@NP	the extent	52084
@NP	the injury	52098
@NP	the dorsal half of the spinal cord over a distance of 2 mm	52139
@NP	the dorsal half	52139
@NP	the spinal cord over a distance of 2 mm	52158
@NP	the spinal cord	52158
@NP	a distance of 2 mm	52179
@NP	a distance	52179
@NP	2 mm	52193
@NP	Control animals , which did not receive a transplant ,	52199
@NP	Control animals	52199
@NP	a transplant	52238
@NP	only a minor penetration of NF-positive axons	52266
@NP	only a minor penetration	52266
@NP	NF-positive axons	52294
@NP	the lesion site	52317
@NP	This	52334
@NP	the lack of host cell infiltration	52359
@NP	the lack	52359
@NP	host cell infiltration	52371
@NP	the lesion site	52399
@NP	the contrary	52419
@NP	numerous NFpositive axons	52433
@NP	the graft/lesion site of OEC/ONFtransplanted animals	52470
@NP	the graft/lesion site	52470
@NP	OEC/ONFtransplanted animals	52495
@NP	OEC/ONF	52545
@NP	the surface area of the OEC/ONF -- biomatrix complexes upon transplantation	52574
@NP	the surface area of the OEC/ONF	52574
@NP	the surface area	52574
@NP	the OEC/ONF	52594
@NP	biomatrix complexes upon transplantation	52606
@NP	biomatrix complexes	52606
@NP	transplantation	52631
@NP	NF-positive axons	52648
@NP	the complex	52691
@NP	Many host cells	52704
@NP	Many host	52704
@NP	cells	52714
@NP	Schwann cells	52732
@NP	we	52750
@NP	immunoreactivity	52762
@NP	the p75 - NGF receptor	52783
@NP	the p75	52783
@NP	NGF receptor	52792
@NP	fibroblasts	52810
@NP	Bunge	52823
@NP	et al. , 1997 ; Pasterkamp et al. , 1999	52829
@NP	et al.	52829
@NP	1997 ; Pasterkamp et al.	52837
@NP	1997	52837
@NP	Pasterkamp et al.	52843
@NP	Pasterkamp	52843
@NP	et al.	52854
@NP	1999	52862
@NP	the biomatrix complexes	52890
@NP	growing within the pores of the biomatrix	52927
@NP	growing	52927
@NP	within the	52935
@NP	the biomatrix	52955
@NP	These invading host cells	52971
@NP	These	52971
@NP	host cells	52986
@NP	the stimulation of NF ingrowth	53013
@NP	the stimulation	53013
@NP	NF ingrowth	53032
@NP	the graft	53049
@NP	All the NF-positive axons	53060
@NP	the graft	53089
@NP	lesion site	53100
@NP	their	53148
@NP	nature	53175
@NP	the origin of these ingrowing axons	53192
@NP	the origin	53192
@NP	these ingrowing axons	53206
@NP	a CS and raphespinal origin	53244
@NP	these ingrowing axons	53302
@NP	these	53302
@NP	axons	53318
@NP	a peripheral origin -LRB- e.g.	53333
@NP	a peripheral origin	53333
@NP	CGRP	53359
@NP	immunoreactive axons	53364
@NP	immunoreactive	53364
@NP	axons	53379
@NP	a less severe injury model -LRB- Brook et al. , 2000 -RRB-	53423
@NP	a less severe injury model	53423
@NP	Brook	53451
@NP	et al. , 2000	53457
@NP	et al.	53457
@NP	2000	53465
@NP	OEC/ONF-transplanted animals	53488
@NP	a 10-fold increase	53524
@NP	NF-positive axon growth	53546
@NP	the graft/lesion site	53575
@NP	animals	53620
@NP	our transplantation strategy	53635
@NP	an argument	53683
@NP	the exact mechanisms	53712
@NP	neurofilamentpositive axon growth	53745
@NP	the transplanted OEC/ONF	53784
@NP	biomatrix complexes	53809
@NP	it	53833
@NP	the transplanted OEC/ONF or the biomatrix	53836
@NP	the transplanted OEC/ONF	53836
@NP	the biomatrix	53864
@NP	Pilot experiments by our group	53879
@NP	Pilot experiments	53879
@NP	our group	53900
@NP	a similar quantification procedure	53917
@NP	there	53965
@NP	no difference between the ingrowth of NF axons	53975
@NP	no difference	53975
@NP	the ingrowth of NF axons	53997
@NP	the ingrowth	53997
@NP	NF axons	54013
@NP	OEC/ONF -- biomatrix grafts or biomatrix grafts without OEC/ONF	54027
@NP	OEC/ONF	54027
@NP	biomatrix grafts or biomatrix grafts without OEC/ONF	54035
@NP	biomatrix grafts or biomatrix grafts	54035
@NP	OEC/ONF	54080
@NP	the biomatrix itself	54096
@NP	the biomatrix	54096
@NP	NF axon ingrowth	54156
@NP	the graft/lesion site	54178
@NP	This effect	54201
@NP	the host cells	54239
@NP	the biomatrix	54263
@NP	transplantation	54283
@NP	Survival and migration of transplanted OEC/ONF	54300
@NP	Survival and migration	54300
@NP	transplanted OEC/ONF	54326
@NP	no Hoechst-prelabeled-positive cells	54356
@NP	the spinal lesion gap , many prelabeled cells	54418
@NP	the spinal lesion gap	54418
@NP	many prelabeled cells	54441
@NP	the injection areas -LRB- Fig. 1 -RRB-	54484
@NP	the injection areas	54484
@NP	Fig. 1	54505
@NP	A minority of these cells	54514
@NP	A minority	54514
@NP	these cells	54528
@NP	the p75-NGF receptor	54550
@NP	the presence	54602
@NP	this receptor	54618
@NP	the OEC	54635
@NP	mixed OEC/ONF cultures -LRB- Li et al. , 1998 ; Deumens et al. , 2004 -RRB-	54646
@NP	mixed OEC/ONF cultures	54646
@NP	Li	54670
@NP	et al. , 1998 ; Deumens et al. , 2004	54673
@NP	et al.	54673
@NP	1998 ; Deumens et al.	54681
@NP	1998	54681
@NP	Deumens et al.	54687
@NP	Deumens	54687
@NP	et al.	54695
@NP	2004	54703
@NP	Hoechst	54719
@NP	leak	54731
@NP	transplanted cells	54743
@NP	host cells -LRB- Iwashita et al. , 2000 -RRB-	54772
@NP	host cells	54772
@NP	Iwashita	54784
@NP	et al. , 2000	54793
@NP	et al.	54793
@NP	2000	54801
@NP	the condensed presence of Hoechst-positive cells	54808
@NP	the condensed presence	54808
@NP	Hoechst-positive cells	54834
@NP	the p75-NGF receptor immunoreactivity in a subpopulation of Hoechst cells	54861
@NP	the p75-NGF receptor immunoreactivity	54861
@NP	a subpopulation of Hoechst cells	54902
@NP	a subpopulation	54902
@NP	Hoechst cells	54921
@NP	the Hoechst-positive cells within the injection areas	54949
@NP	the Hoechst-positive cells	54949
@NP	the injection areas	54983
@NP	transplanted OEC/ONF that survived	55007
@NP	transplanted OEC/ONF	55007
@NP	the injected OEC/ONF	55051
@NP	transplantation	55081
@NP	the injection areas	55102
@NP	they	55123
@NP	the injured spinal cord	55151
@NP	There	55176
@NP	some essential differences	55186
@NP	our study	55221
@NP	OEC / ONF migration and other studies	55239
@NP	OEC	55239
@NP	ONF migration and other studies	55244
@NP	ONF migration	55244
@NP	other studies	55262
@NP	migration of olfactory glia	55284
@NP	migration	55284
@NP	olfactory glia	55297
@NP	injection	55318
@NP	the injured spinal cord	55333
@NP	Li	55358
@NP	et al. , 1998 ; Ramon-Cueto et al. , 2000	55361
@NP	et al.	55361
@NP	1998 ; Ramon-Cueto et al.	55369
@NP	1998	55369
@NP	Ramon-Cueto et al.	55375
@NP	Ramon-Cueto	55375
@NP	et al.	55387
@NP	2000	55395
@NP	the specific olfactory glia culture and the injection procedures	55412
@NP	the specific olfactory glia culture	55412
@NP	the injection procedures	55452
@NP	the influence	55487
@NP	any of those factors on migration of the transplanted olfactory glia	55504
@NP	any	55504
@NP	those factors on migration of the transplanted olfactory glia	55511
@NP	those factors	55511
@NP	migration of the transplanted olfactory glia	55528
@NP	migration	55528
@NP	the transplanted olfactory glia	55541
@NP	The lack	55599
@NP	survival	55611
@NP	transplanted OEC/ONF on the biomatrices	55623
@NP	transplanted OEC/ONF	55623
@NP	the biomatrices	55647
@NP	the lack of migration of injected OEC/ONF	55667
@NP	the lack	55667
@NP	migration of injected OEC/ONF	55679
@NP	migration	55679
@NP	injected OEC/ONF	55692
@NP	CS axon regrowth	55726
@NP	no OEC/ONF continuum	55751
@NP	Pathological processes , like hemorrhage and inflammation ,	55785
@NP	Pathological processes	55785
@NP	hemorrhage and inflammation	55814
@NP	the injured spinal cord environment -LRB- Dusart and Schwab , 1994 -RRB-	55859
@NP	spinal cord environment -LRB- Dusart and Schwab , 1994 -RRB-	55871
@NP	spinal cord environment	55871
@NP	Dusart and Schwab , 1994	55896
@NP	Dusart	55896
@NP	Schwab , 1994	55907
@NP	Schwab	55907
@NP	1994	55915
@NP	The concentration of toxic substances released from such processes	55922
@NP	The concentration	55922
@NP	toxic substances released from such processes	55943
@NP	toxic substances	55943
@NP	such processes	55974
@NP	spinal lesions which are larger -LRB- Wagner et al. , 1978 -RRB-	56006
@NP	spinal lesions	56006
@NP	Wagner	56039
@NP	et al. , 1978	56046
@NP	et al.	56046
@NP	1978	56054
@NP	this	56072
@NP	the migration of the transplanted OEC/ONF within the host spinal tissue	56097
@NP	the migration	56097
@NP	the transplanted OEC/ONF within the host spinal tissue	56114
@NP	the transplanted OEC/ONF	56114
@NP	the host spinal tissue	56146
@NP	The lack of OEC/ONF migration within the host spinal tissue	56170
@NP	The lack	56170
@NP	OEC/ONF migration within the host spinal tissue	56182
@NP	OEC/ONF migration	56182
@NP	the host spinal tissue	56207
@NP	others	56251
@NP	OEC cultures	56284
@NP	the host spinal tissue close	56302
@NP	large spinal lesion gaps -LRB- Chuah et al. , 2004 -RRB-	56334
@NP	large spinal lesion gaps	56334
@NP	Chuah	56360
@NP	et al. , 2004	56366
@NP	et al.	56366
@NP	2004	56374
@NP	it	56388
@NP	multiple cell injections	56411
@NP	a continuum of these cells	56446
@NP	a continuum	56446
@NP	these cells	56461
@NP	spinal cords	56478
@NP	large lesion gaps	56496
@NP	this	56523
@NP	the lack of OEC/ONF survival within the large spinal lesion gap	56529
@NP	the lack	56529
@NP	OEC/ONF survival within the large spinal lesion gap	56541
@NP	OEC/ONF survival	56541
@NP	the large spinal lesion gap	56565
@NP	contrast with previous findings -LRB- Sasaki et al. , 2004 -RRB-	56599
@NP	contrast	56599
@NP	previous findings -LRB- Sasaki et al. , 2004 -RRB-	56613
@NP	previous findings	56613
@NP	Sasaki	56632
@NP	et al. , 2004	56639
@NP	et al.	56639
@NP	2004	56647
@NP	a combination of several causes	56658
@NP	a combination	56658
@NP	several causes	56675
@NP	the putative high concentration	56714
@NP	toxic substances released by pathological processes	56749
@NP	toxic substances	56749
@NP	pathological processes	56778
@NP	the survival of OEC/ONF-transplanted into these large lesion gaps	56819
@NP	the survival	56819
@NP	OEC/ONF-transplanted into these large lesion gaps	56835
@NP	these large lesion	56861
@NP	the OEC/ONF	56892
@NP	the biomatrix surface	56921
@NP	the injured spinal tissue	56950
@NP	the toxic substances	56977
@NP	these transplanted OEC / ONF	57024
@NP	these transplanted OEC	57024
@NP	ONF	57048
@NP	previous studies	57061
@NP	the survival	57096
@NP	transplanted cells	57112
@NP	identical large lesion gaps	57134
@NP	the cells	57167
@NP	collagen type I matrices	57194
@NP	collagen type	57194
@NP	I matrices	57208
@NP	the injured spinal cord environment -LRB- Joosten et al. , 2004 -RRB-	57262
@NP	the injured spinal cord environment	57262
@NP	Joosten	57299
@NP	et al. , 2004	57307
@NP	et al.	57307
@NP	2004	57315
@NP	the acutely injured spinal cord	57330
@NP	acutely injured spinal cord	57334
@NP	a negative effect	57385
@NP	OEC proliferation and increase OEC apoptosis	57406
@NP	OEC proliferation	57406
@NP	increase OEC apoptosis	57428
@NP	either uninjured or chronically injured spinal cord	57466
@NP	uninjured	57473
@NP	chronically injured spinal cord	57486
@NP	tissue -LRB- Woodhouse et al. , 2005 -RRB-	57518
@NP	tissue	57518
@NP	Woodhouse	57526
@NP	et al. , 2005	57536
@NP	et al.	57536
@NP	2005	57544
@NP	Third , optimal numbers of OEC/ONF	57551
@NP	Third	57551
@NP	optimal numbers of OEC/ONF	57558
@NP	optimal numbers	57558
@NP	OEC/ONF	57577
@NP	OEC/ONF	57618
@NP	biomatrix complexes during 4 days in vitro -LRB- Deumens et al. , 2004 -RRB-	57626
@NP	biomatrix complexes during 4 days in vitro	57626
@NP	biomatrix complexes	57626
@NP	4 days	57653
@NP	Deumens	57670
@NP	et al. , 2004	57678
@NP	et al.	57678
@NP	2004	57686
@NP	These numbers	57693
@NP	the survival	57759
@NP	the transplanted OEC/ONF	57775
@NP	the spinal lesion sites upon transplantation of these complexes	57807
@NP	the spinal lesion sites	57807
@NP	transplantation of these complexes	57836
@NP	transplantation	57836
@NP	these complexes	57855
@NP	there	57880
@NP	some differences between our study set-up	57895
@NP	some differences	57895
@NP	our study set-up	57920
@NP	Sasaki	57949
@NP	colleagues	57960
@NP	OEC survival , including a difference in lesion type ,	57990
@NP	OEC survival	57990
@NP	a difference in lesion type	58014
@NP	a difference	58014
@NP	lesion type	58030
@NP	time points	58051
@NP	injury	58069
@NP	cell preparation protocols	58081
@NP	the specific use	58118
@NP	poly	58138
@NP	lactide matrices to transplant OEC/ONF into the large spinal lesion gaps	58148
@NP	OEC/ONF	58179
@NP	the large spinal lesion gaps	58192
@NP	OEC/ONF survival	58250
@NP	Degradation of poly -LRB- D , L -RRB- - lactides	58268
@NP	Degradation	58268
@NP	poly -LRB- D , L -RRB- - lactides	58283
@NP	poly	58283
@NP	lactides	58293
@NP	example	58309
@NP	a lowering	58333
@NP	the pH -LRB- Mainil-Varlet et al. , 1997 -RRB-	58347
@NP	the pH	58347
@NP	Mainil-Varlet	58355
@NP	et al. , 1997	58369
@NP	et al.	58369
@NP	1997	58377
@NP	OEC / ONF survival	58401
@NP	OEC	58401
@NP	ONF survival	58406
@NP	biomaterials other than poly -LRB- D , L -RRB- - lactides	58427
@NP	biomaterials	58427
@NP	poly -LRB- D , L -RRB- - lactides	58451
@NP	poly -LRB- D , L -RRB-	58451
@NP	poly	58451
@NP	lactides	58461
@NP	combination	58487
@NP	OEC/ONF for their effects	58504
@NP	OEC/ONF	58504
@NP	their effects	58516
@NP	long-distance CS axon regrowth across large spinal lesion gaps	58533
@NP	long-distance CS axon regrowth	58533
@NP	large spinal lesion gaps	58571
@NP	Functional recovery The multifactorial transplantation strategy	58597
@NP	Functional recovery	58597
@NP	The multifactorial transplantation strategy	58617
@NP	modest recovery of fine locomotor parameters -LRB- Fig. 5 -RRB-	58672
@NP	modest recovery	58672
@NP	fine locomotor parameters -LRB- Fig. 5 -RRB-	58691
@NP	fine locomotor parameters	58691
@NP	Fig. 5	58718
@NP	The -LRB- incomplete -RRB- recovery	58727
@NP	locomotor functions -LRB- swing speed and stride length of the hind limb -RRB-	58756
@NP	locomotor functions	58756
@NP	swing speed and stride length of the hind limb	58777
@NP	swing speed and stride length	58777
@NP	the hind limb	58810
@NP	9 weeks	58841
@NP	injury , which may reflect an involvement of axonal regrowth	58855
@NP	injury	58855
@NP	an involvement of axonal regrowth	58881
@NP	an involvement	58881
@NP	axonal regrowth	58899
@NP	the current knowledge	58921
@NP	regrowth of individual axon tracts and functional recovery	58961
@NP	regrowth	58961
@NP	individual axon tracts and functional recovery	58973
@NP	individual axon tracts	58973
@NP	functional recovery	59000
@NP	Deumens et al. , 2005	59035
@NP	Deumens	59035
@NP	et al.	59043
@NP	2005	59051
@NP	an improvement in stride length as demonstrated in this study	59072
@NP	an improvement	59072
@NP	stride length as demonstrated in this study	59090
@NP	stride length	59090
@NP	this study	59123
@NP	enhanced regrowth	59177
@NP	injured CS axons	59198
@NP	a thoracic dorsal hemisection lesion site	59222
@NP	the caudal host tissue -LRB- Bregman et al. , 1995 -RRB-	59278
@NP	the caudal host tissue	59278
@NP	Bregman	59302
@NP	et al. , 1995	59310
@NP	et al.	59310
@NP	1995	59318
@NP	others	59338
@NP	a relation	59359
@NP	the CS tract and stride length	59378
@NP	the hind limbs -LRB- Starkey et al. , 2004 -RRB-	59412
@NP	the hind limbs	59412
@NP	Starkey	59428
@NP	et al. , 2004	59436
@NP	et al.	59436
@NP	2004	59444
@NP	our study	59454
@NP	no relation	59465
@NP	regrowth of the injured CS tract axons and recovery of stride length	59485
@NP	regrowth of the injured CS tract axons	59485
@NP	regrowth	59485
@NP	the injured CS tract axons	59497
@NP	recovery of stride length	59528
@NP	recovery	59528
@NP	stride length	59540
@NP	the effects on injured CS axons	59587
@NP	the effects	59587
@NP	injured CS axons	59602
@NP	responses	59637
@NP	other axon tracts	59650
@NP	the brain that are more likely to be linked with stride length	59684
@NP	the brain	59684
@NP	stride length	59733
@NP	this	59756
@NP	formation	59762
@NP	new intraspinal relay circuits	59775
@NP	others -LRB- Bareyre et al. , 2004 -RRB-	59822
@NP	others	59822
@NP	Bareyre	59830
@NP	et al. , 2004	59838
@NP	et al.	59838
@NP	2004	59846
@NP	The effect of our intervention on locomotion	59872
@NP	The effect	59872
@NP	our intervention on locomotion	59886
@NP	our intervention	59886
@NP	locomotion	59906
@NP	only a small subset of locomotor parameters	59934
@NP	only a small subset	59934
@NP	locomotor parameters	59957
@NP	This	59979
@NP	the spinal cord injury model	60019
@NP	we used.We	60053
@NP	we	60053
@NP	used.We	60056
@NP	behavioral impairments	60090
@NP	dorsal hemisection injury	60119
@NP	a highly detailed , objective ,	60168
@NP	a highly detailed	60168
@NP	objective	60187
@NP	sensitive manner using the CatWalk gait analysis	60202
@NP	sensitive manner	60202
@NP	the CatWalk gait analysis	60225
@NP	a behavioral level	60255
@NP	the CatWalk	60275
@NP	the control animals in our study	60299
@NP	the control animals	60299
@NP	our study	60322
@NP	The majority of locomotor parameters assessed in the CatWalk	60375
@NP	The majority	60375
@NP	locomotor parameters assessed in the CatWalk	60391
@NP	locomotor parameters	60391
@NP	the CatWalk	60424
@NP	these unaffected parameters	60463
@NP	the regularity index -LRB- RI -RRB- , which is strongly involved in coordination	60494
@NP	the regularity index	60494
@NP	RI	60516
@NP	coordination	60551
@NP	Implementation	60565
@NP	RI as an objective parameter for coordination into the BBB test	60583
@NP	RI	60583
@NP	an objective parameter for coordination into the BBB test	60589
@NP	an objective parameter	60589
@NP	coordination into the BBB test	60616
@NP	coordination	60616
@NP	the BBB test	60634
@NP	a significant increase of the BBB score of both transplanted and control animals	60659
@NP	a significant increase of the BBB score of	60659
@NP	a significant increase	60659
@NP	the BBB score of	60685
@NP	the BBB score	60685
@NP	transplanted and control animals	60707
@NP	a previous study of our group	60744
@NP	a previous study	60744
@NP	our group	60764
@NP	a spinal cord contusion injury	60780
@NP	RI implementation into the BBB	60812
@NP	RI implementation	60812
@NP	the BBB	60835
@NP	a strong enhancement	60850
@NP	the sensitivity of the BBB -LRB- Koopmans et al. , 2005 -RRB-	60874
@NP	the sensitivity	60874
@NP	the BBB -LRB- Koopmans et al. , 2005 -RRB-	60893
@NP	the BBB	60893
@NP	Koopmans	60902
@NP	et al. , 2005	60911
@NP	et al.	60911
@NP	2005	60919
@NP	a significant difference in BBB scores	60932
@NP	a significant difference	60932
@NP	BBB scores	60960
@NP	enriched housed animals as compared to normally housed animals	60991
@NP	enriched	60991
@NP	animals	61007
@NP	normally housed animals	61030
@NP	implementation of the RI	61065
@NP	implementation	61065
@NP	the RI	61083
@NP	the BBB -LRB- Koopmans et al. , 2005 -RRB-	61093
@NP	the BBB	61093
@NP	Koopmans	61102
@NP	et al. , 2005	61111
@NP	et al.	61111
@NP	2005	61119
@NP	the RI	61131
@NP	the BBB	61159
@NP	the present study	61170
@NP	the BBB scores of transplanted and control animals	61189
@NP	the BBB scores	61189
@NP	transplanted and control animals	61207
@NP	transplanted	61207
@NP	control animals	61224
@NP	a similar extent	61253
@NP	no inter-group difference	61282
@NP	This more sensitive and objective behavioral analysis	61327
@NP	the rather limited behavioral impairment	61398
@NP	dorsal hemisection injury	61445
@NP	an only very small window for functional recovery	61485
@NP	an only very small window	61485
@NP	functional recovery	61515
@NP	Conclusions Our multifactorial transplantation strategy	61536
@NP	Conclusions	61536
@NP	Our multifactorial transplantation strategy	61548
@NP	regrowth of injured CS axons	61623
@NP	regrowth	61623
@NP	injured CS axons	61635
@NP	large spinal lesion gaps	61659
@NP	an enhanced presence of injured CS axons	61694
@NP	an enhanced presence	61694
@NP	injured CS axons	61718
@NP	rostral	61757
@NP	the lesion gap	61768
@NP	the penetration of many axons	61808
@NP	the penetration	61808
@NP	many axons	61827
@NP	the graft	61843
@NP	modest locomotor recovery	61860
@NP	Future studies	61887
@NP	optimalization of the transplantation strategy	61915
@NP	optimalization	61915
@NP	the transplantation strategy	61933
@NP	issues	61982
@NP	the limited migration	62002
@NP	transplanted OEC/ONF	62027
@NP	the host tissue of spinal cords with large lesion gaps	62055
@NP	the host tissue	62055
@NP	spinal cords with large lesion gaps	62074
@NP	spinal cords	62074
@NP	large lesion gaps	62092
@NP	-LRB- 2 -RRB- the problems with OEC / ONF survival on poly -LRB- D , L -RRB-	62114
@NP	the problems	62118
@NP	OEC / ONF survival on poly -LRB- D , L -RRB-	62136
@NP	OEC / ONF survival on poly	62136
@NP	OEC	62136
@NP	ONF survival on poly	62141
@NP	ONF survival	62141
@NP	poly	62157
@NP	lactide matrices within large lesion gaps	62167
@NP	lactide matrices	62167
@NP	large lesion gaps	62191
@NP	we	62223
@NP	the combined use	62236
@NP	detailed and sensitive behavioral tests	62256
@NP	the CatWalk gait analysis and a spinal injury model	62304
@NP	the CatWalk gait analysis	62304
@NP	a spinal injury model	62334
@NP	a higher degree of behavioral impairment	62361
@NP	a higher degree	62361
@NP	behavioral impairment	62380
@NP	a much wider behavioral window for the determination of therapeutic effects	62419
@NP	a much wider behavioral window	62419
@NP	the determination of therapeutic effects	62454
@NP	the determination	62454
@NP	therapeutic effects	62475
@NP	Acknowledgments The authors thank Dr.	62496
@NP	Acknowledgments	62496
@NP	The authors	62512
@NP	Dr.	62530
@NP	Y.	62534
@NP	Li and Prof.	62537
@NP	Li	62537
@NP	Prof.	62544
@NP	Dr.	62550
@NP	G.	62554
@NP	Raisman	62557
@NP	their knowledge	62579
@NP	OEC/ONF culturing	62598
@NP	our laboratory and Marijke Lemmens and Dr.	62619
@NP	our laboratory	62619
@NP	Marijke Lemmens and Dr.	62638
@NP	Jos Prickaerts	62662
@NP	their assistance	62681
@NP	the immunohistochemical stainings and expertise	62703
@NP	picture processing , respectively	62761
@NP	picture processing	62761
@NP	The authors	62795
@NP	Lou Kirkels -LRB- IDEE , Maastricht -RRB- for his expertise with respect	62828
@NP	Lou Kirkels -LRB- IDEE , Maastricht -RRB-	62828
@NP	Lou Kirkels	62828
@NP	IDEE	62841
@NP	Maastricht	62847
@NP	his expertise with respect	62863
@NP	his expertise	62863
@NP	respect	62882
@NP	the injection procedures	62893
@NP	The RT97 monoclonal antibody , developed by Dr.	62919
@NP	The RT97 monoclonal antibody	62919
@NP	Dr.	62962
@NP	J.	62966
@NP	Wood	62969
@NP	the Developmental Studies	62993
@NP	Hybridoma Bank	63019
@NP	the auspices of the NICHD	63050
@NP	the auspices	63050
@NP	the NICHD	63066
@NP	The University of Iowa , Department of Biological Sciences ,	63094
@NP	The University	63094
@NP	Iowa , Department of Biological Sciences ,	63112
@NP	Iowa	63112
@NP	Department of Biological Sciences	63118
@NP	Department	63118
@NP	Biological Sciences	63132
@NP	Iowa City , IA 52242 , USA	63153
@NP	Iowa City	63153
@NP	IA 52242 , USA	63164
@NP	IA 52242	63164
@NP	USA	63174
@NP	This work	63179
@NP	the International Spinal Research Trust -LRB- ISRT ; STR057 to E.A.J.J. -RRB-	63203
@NP	the International Spinal Research Trust	63203
@NP	ISRT ; STR057 to E.A.J.J.	63244
@NP	ISRT	63244
@NP	STR057 to E.A.J.J.	63250
@NP	STR057	63250
@NP	E.A.J.J.	63260
@NP	References	63271
@NP	2004	63381
@VP	to stimulate CS axon regrowth across large lesion gaps	1206
@VP	stimulate CS axon regrowth across large lesion gaps	1209
@VP	to test the effects of this complete strategy	1593
@VP	test the effects of this complete strategy	1596
@VP	received injections with culture medium rostral and caudal to the lesion gap	1661
@VP	directly rostral to the lesion gap	1838
@VP	may be related to a lack of OEC/ONF survival on the biomatrices	2022
@VP	be related to a lack of OEC/ONF survival on the biomatrices	2026
@VP	related to a lack of OEC/ONF survival on the biomatrices	2029
@VP	was observed	2221
@VP	observed	2225
@VP	swing speed of the hind limbs	2318
@VP	was observed	2348
@VP	observed	2352
@VP	may be needed to stimulate repair of large spinal lesion gaps	2397
@VP	be needed to stimulate repair of large spinal lesion gaps	2401
@VP	needed to stimulate repair of large spinal lesion gaps	2404
@VP	to stimulate repair of large spinal lesion gaps	2411
@VP	stimulate repair of large spinal lesion gaps	2414
@VP	is rather limited	2539
@VP	to modulate this balance under experimental conditions	2963
@VP	modulate this balance under experimental conditions	2966
@VP	to be positively influenced by the presence of ONF -LRB- Raisman , 2001 -RRB-	3554
@VP	be positively influenced by the presence of ONF -LRB- Raisman , 2001 -RRB-	3557
@VP	positively influenced by the presence of ONF -LRB- Raisman , 2001 -RRB-	3560
@VP	to have a low regenerative response after injury -LRB- Joosten , 1997 -RRB-	4258
@VP	have a low regenerative response after injury -LRB- Joosten , 1997 -RRB-	4261
@VP	stimulated after transplantation of mixed OEC/ONF	4371
@VP	purified OEC cultures into the injured spinal cord tissue	4425
@VP	included small spinal lesion gaps	4522
@VP	may develop , requiring long-distance axon regrowth	4613
@VP	develop , requiring long-distance axon regrowth	4617
@VP	requiring long-distance axon regrowth	4626
@VP	is suggested to be associated by both OEC and ONF -LRB- Li et al. , 2005 -RRB-	4716
@VP	suggested to be associated by both OEC and ONF -LRB- Li et al. , 2005 -RRB-	4719
@VP	to be associated by both OEC and ONF -LRB- Li et al. , 2005 -RRB-	4729
@VP	be associated by both OEC and ONF -LRB- Li et al. , 2005 -RRB-	4732
@VP	associated by both OEC and ONF -LRB- Li et al. , 2005 -RRB-	4735
@VP	promote repair of injured CS axons across large spinal lesion gaps	4847
@VP	to bridge the lesion gap	5076
@VP	bridge the lesion gap	5079
@VP	to avoid the use of millions of autologous growthpromoting cells	5111
@VP	avoid the use of millions of autologous growthpromoting cells	5114
@VP	used to create an OEC/ONF continuum in rat spinal cords with large lesion gaps	5495
@VP	to create an OEC/ONF continuum in rat spinal cords with large lesion gaps	5500
@VP	create an OEC/ONF continuum in rat spinal cords with large lesion gaps	5503
@VP	used a 2-mm-long dorsal hemisection lesion	5736
@VP	have been shown to stimulate directional neurite growth in vitro	5823
@VP	been shown to stimulate directional neurite growth in vitro	5828
@VP	shown to stimulate directional neurite growth in vitro	5833
@VP	to stimulate directional neurite growth in vitro	5839
@VP	stimulate directional neurite growth in vitro	5842
@VP	were acutely transplanted into the 2-mmlong dorsal hemisection	5912
@VP	acutely transplanted into the 2-mmlong dorsal hemisection	5917
@VP	were injected rostral and caudal to the thoracic lesion site	6021
@VP	injected rostral and caudal to the thoracic lesion site	6026
@VP	has been previously reported	6159
@VP	been previously reported	6163
@VP	previously reported	6168
@VP	may then create a continuum of OEC/ONF in the injured spinal cord	6213
@VP	create a continuum of OEC/ONF in the injured spinal cord	6222
@VP	did not receive a graft within the lesion site	6425
@VP	receive a graft within the lesion site	6433
@VP	received culture medium injections rostral and caudal to the injury site	6476
@VP	were approved by the Committee on Animal Research of the Maastricht University	6967
@VP	approved by the Committee on Animal Research of the Maastricht University	6972
@VP	was made to minimize the number of animals and their suffering	7091
@VP	made to minimize the number of animals and their suffering	7095
@VP	to minimize the number of animals and their suffering	7100
@VP	minimize the number of animals and their suffering	7103
@VP	were capable of making three consecutive runs without hesitation	7367
@VP	making three consecutive runs without hesitation	7383
@VP	were behaviorally tested on the CatWalk to obtain preoperative CatWalk data	7468
@VP	behaviorally tested on the CatWalk to obtain preoperative CatWalk data	7473
@VP	to obtain preoperative CatWalk data	7508
@VP	obtain preoperative CatWalk data	7511
@VP	was performed at T11/T12	7591
@VP	performed at T11/T12	7595
@VP	were randomly divided into two groups	7629
@VP	divided into two groups	7643
@VP	did not receive transplants into the lesion site	7840
@VP	receive transplants into the lesion site	7848
@VP	received injections of culture medium into the rostral and caudal host stumps	7894
@VP	to label the CS tract	8153
@VP	label the CS tract	8156
@VP	was performed at 6 weeks after injury	8198
@VP	performed at 6 weeks after injury	8202
@VP	were sacrificed and processed for histological analysis	8271
@VP	sacrificed and processed for histological analysis	8276
@VP	were blind to the treatment	8414
@VP	containing syngeneic cells from the outer two glomerular layers of adult rat	8500
@VP	was identical to that described previously -LRB- Li et al. , 1998 -RRB-	8593
@VP	described previously -LRB- Li et al. , 1998 -RRB-	8615
@VP	were decapitated	8846
@VP	decapitated	8851
@VP	were dissected and cleared of meninges	8888
@VP	dissected and cleared of meninges	8893
@VP	were carefully dissected	8988
@VP	carefully dissected	8993
@VP	diced in small fragments	9029
@VP	was stopped by addition of culture medium	9194
@VP	stopped by addition of culture medium	9198
@VP	was the only culture	9501
@VP	used in this study	9529
@VP	was washed twice with culture medium and collected in 1 ml culture medium	9560
@VP	washed twice with culture medium and collected in 1 ml culture medium	9564
@VP	washed twice with culture medium	9564
@VP	collected in 1 ml culture medium	9601
@VP	was achieved by mechanical trituration	9666
@VP	achieved by mechanical trituration	9670
@VP	were grown for 4	9837
@VP	grown for 4	9842
@VP	was refreshed	9895
@VP	refreshed	9899
@VP	was refreshed every 2 days	9941
@VP	refreshed every 2 days	9945
@VP	containing both OEC and ONF	10023
@VP	will be named OEC/ONF cultures	10118
@VP	be named OEC/ONF cultures	10123
@VP	named OEC/ONF cultures	10126
@VP	was purchased from Purac Biochem -LRB- Gorinchem , The Netherlands -RRB-	10232
@VP	purchased from Purac Biochem -LRB- Gorinchem , The Netherlands -RRB-	10236
@VP	ca	10536
@VP	approximately 5000 , supplied by Sigma , Uithoorn , The Netherlands -RRB-	10540
@VP	supplied by Sigma	10560
@VP	were prepared from a mixture of PLA containing 10 wt	10621
@VP	prepared from a mixture of PLA containing 10 wt	10626
@VP	containing 10 wt	10657
@VP	described	10840
@VP	was dissolved in dimethylcarbonate to yield a 5 wt	10885
@VP	dissolved in dimethylcarbonate to yield a 5 wt	10889
@VP	to yield a 5 wt	10920
@VP	yield a 5 wt	10923
@VP	to induce solvent crystallization	11031
@VP	induce solvent crystallization	11034
@VP	was connected to a vacuum pump	11090
@VP	connected to a vacuum pump	11094
@VP	was removed by sublimation at − 10 °C and 10 − 2 Torr	11138
@VP	removed by sublimation at − 10 °C and 10 − 2 Torr	11142
@VP	was increased to 0 °C	11224
@VP	increased to 0 °C	11228
@VP	was continued	11268
@VP	continued	11272
@VP	were finally dried at room temperature	11293
@VP	dried at room temperature	11306
@VP	cut from the freeze-dried foams using a razor blade	11373
@VP	using a razor blade	11405
@VP	sterilized by UV exposure for 15 min	11429
@VP	were grown in vitro for 10 days -LRB- Days in vitro 10 ; DIV10 -RRB-	11527
@VP	grown in vitro for 10 days -LRB- Days in vitro 10 ; DIV10 -RRB-	11532
@VP	was stopped using culture medium	11745
@VP	stopped using culture medium	11749
@VP	using culture medium	11757
@VP	was resuspended in culture medium	11833
@VP	resuspended in culture medium	11837
@VP	grown on these substrates for 4 days	11998
@VP	described previously	12097
@VP	were prelabeled with Hoechst	12282
@VP	prelabeled with Hoechst	12287
@VP	were extensively washed with culture medium	12500
@VP	washed with culture medium	12517
@VP	was applied to the eyes to prevent drying during the operation	12992
@VP	applied to the eyes to prevent drying during the operation	12996
@VP	to prevent drying during the operation	13016
@VP	prevent drying during the operation	13019
@VP	drying during the operation	13027
@VP	overlying the operation area	13102
@VP	was shaved	13131
@VP	shaved	13135
@VP	was scrubbed with Bethadine	13155
@VP	scrubbed with Bethadine	13159
@VP	were sutured	13236
@VP	sutured	13241
@VP	were observed until awake and then returned to their home cages	13261
@VP	were observed until awake	13261
@VP	observed until awake	13266
@VP	then returned to their home cages	13291
@VP	received another i.p. injection with Buprenorfine	13374
@VP	was performed	13458
@VP	performed	13462
@VP	was exposed at T11/T12	13493
@VP	exposed at T11/T12	13497
@VP	was cut	13532
@VP	cut	13536
@VP	was incised at two spinal levels , 2 mm apart	13609
@VP	incised at two spinal levels , 2 mm apart	13613
@VP	Using an aspiration device	13655
@VP	was removed	13742
@VP	removed	13746
@VP	was 1.2 mm	13779
@VP	ascending dorsal column axons	14016
@VP	was then covered with DuraFilm	14207
@VP	covered with DuraFilm	14216
@VP	were done to control for possible damage induced by the injection procedure	14703
@VP	done to control for possible damage induced by the injection procedure	14708
@VP	to control for possible damage induced by the injection procedure	14713
@VP	control for possible damage induced by the injection procedure	14716
@VP	induced by the injection procedure	14744
@VP	did not receive a transplant into the lesion site	14800
@VP	receive a transplant into the lesion site	14808
@VP	make burr holes on both sides of the cranium overlying the sensorimotor cortices	14896
@VP	overlying the sensorimotor cortices	14941
@VP	was left in place for 1 min and was then gradually withdrawn	15309
@VP	was left in place for 1 min	15309
@VP	left in place for 1 min	15313
@VP	was then gradually withdrawn	15341
@VP	withdrawn	15360
@VP	At 9 weeks after SCI/3 weeks after CS tract tracing	15393
@VP	were removed	15682
@VP	removed	15687
@VP	buffered paraformaldehyde overnight	15721
@VP	was transferred to 10 % sucrose in PBS -LRB- 0.1 M ; pH 7.6 -RRB-	15788
@VP	transferred to 10 % sucrose in PBS -LRB- 0.1 M ; pH 7.6 -RRB-	15792
@VP	kept overnight at 4 °C	15846
@VP	were transferred to 25 % sucrose in PBS and kept for 3 days at 4 °C	15886
@VP	were transferred to 25 % sucrose in PBS	15886
@VP	transferred to 25 % sucrose in PBS	15891
@VP	kept for 3 days at 4 °C	15929
@VP	were frozen and stored at − 80 °C	16061
@VP	frozen and stored at − 80 °C	16066
@VP	Using a cryostat	16094
@VP	were serially cut -LRB- sagittal sections of 25 μm -RRB-	16135
@VP	cut -LRB- sagittal sections of 25 μm -RRB-	16149
@VP	were obtained per spinal cord	16226
@VP	obtained per spinal cord	16231
@VP	stored at − 20 °C	16378
@VP	used	16876
@VP	were diluted in 0.3 % Triton X-100 in Tris-buffered saline -LRB- TBS-T -RRB-	17310
@VP	diluted in 0.3 % Triton X-100 in Tris-buffered saline -LRB- TBS-T -RRB-	17315
@VP	were overnight at room temperature	17410
@VP	were 1.5 h at room temperature	17481
@VP	were used in a mixture	17566
@VP	used in a mixture	17571
@VP	preceded the incubation with the Alexalabeled secondary antibody	17655
@VP	washing steps	17868
@VP	involved three times 10 min TBS	17882
@VP	was used	18010
@VP	used	18014
@VP	stained for p75	18044
@VP	analyzed using an Olympus AX-70 microscope using epifluorescent illumination	18218
@VP	using an Olympus AX-70 microscope using epifluorescent illumination	18227
@VP	using epifluorescent illumination	18261
@VP	was equipped with a × 20 objective and a × 10 projection lens	18311
@VP	equipped with a × 20 objective and a × 10 projection lens	18315
@VP	using a MNG filter -LRB- Chroma Technology Corp , Rockingham , VT , USA -RRB-	18546
@VP	using a Sony Power HAD 3CCD Color Video Camera or an Olympus F-view	18795
@VP	cooled CCD camera -LRB- Paes , Zoeterwoude , The Netherlands -RRB-	18863
@VP	were analyzed with the image analyzing system analySIS Vers	18932
@VP	analyzed with the image analyzing system analySIS Vers	18937
@VP	analyzing system analySIS Vers	18961
@VP	Germany	19030
@VP	were analyzed	19116
@VP	analyzed	19121
@VP	were placed at four different locations in the spinal cord sections	19176
@VP	placed at four different locations in the spinal cord sections	19181
@VP	see also indications in Fig. 4	19245
@VP	placed in the dorsal gray/white matter at 2.5 -- 3 mm rostral to the injury site	19296
@VP	will be termed `` the rostral reference ''	19378
@VP	be termed `` the rostral reference ''	19383
@VP	termed `` the rostral reference ''	19386
@VP	was placed in the dorsal gray/white matter directly rostral to the injury site	19433
@VP	placed in the dorsal gray/white matter directly rostral to the injury site	19437
@VP	was placed in the gray matter underneath the lesion site	19527
@VP	placed in the gray matter underneath the lesion site	19531
@VP	were present underneath the lesion site	19606
@VP	was placed in the area where most BDA immunoreactivity was found	19655
@VP	placed in the area where most BDA immunoreactivity was found	19659
@VP	was found	19710
@VP	found	19714
@VP	could be found	19847
@VP	be found	19853
@VP	found	19856
@VP	were analyzed in all the sections containing BDA-labeled CS axons	20023
@VP	analyzed in all the sections containing BDA-labeled CS axons	20028
@VP	containing BDA-labeled CS axons	20057
@VP	was measured	20190
@VP	measured	20194
@VP	were summed	20243
@VP	summed	20248
@VP	tracing	20293
@VP	was highly variable among animals	20301
@VP	was taken as the 100 % reference value of BDA-labeled axons of each animal	20386
@VP	taken as the 100 % reference value of BDA-labeled axons of each animal	20390
@VP	were expressed relative to that of the rostral reference	20514
@VP	expressed relative to that of the rostral reference	20519
@VP	has been described previously by others -LRB- Goldshmit et al. , 2004 -RRB-	20604
@VP	been described previously by others -LRB- Goldshmit et al. , 2004 -RRB-	20608
@VP	described previously by others -LRB- Goldshmit et al. , 2004 -RRB-	20613
@VP	were sprouting/regrowing in the transplanted and/or control animals	20813
@VP	sprouting/regrowing in the transplanted and/or control animals	20818
@VP	was measured	21266
@VP	measured	21270
@VP	was used to correctly delineate the lesion / graft site	21294
@VP	used to correctly delineate the lesion / graft site	21298
@VP	to correctly delineate the lesion / graft site	21303
@VP	correctly delineate the lesion / graft site	21306
@VP	measured	21485
@VP	summed for all sections	21495
@VP	compared between transplanted and control animals	21524
@VP	were among the axons penetrating the graft/lesion site	21625
@VP	penetrating the graft/lesion site	21646
@VP	was performed	21717
@VP	performed	21721
@VP	assesses locomotor performance	21824
@VP	ranges from 0 to 21	21890
@VP	were blind to the treatment	22071
@VP	were averaged and taken as the BBB score of the animal	22144
@VP	averaged and taken as the BBB score of the animal	22149
@VP	swing / stance phases	22564
@VP	can be found elsewhere -LRB- Hamers et al. , 2001 ; Koopmans et al. , 2005 -RRB-	22616
@VP	be found elsewhere -LRB- Hamers et al. , 2001 ; Koopmans et al. , 2005 -RRB-	22620
@VP	found elsewhere -LRB- Hamers et al. , 2001 ; Koopmans et al. , 2005 -RRB-	22623
@VP	are trained for about 2 weeks to cross a glass runway without hesitation	22706
@VP	trained for about 2 weeks to cross a glass runway without hesitation	22710
@VP	to cross a glass runway without hesitation	22736
@VP	cross a glass runway without hesitation	22739
@VP	were motivated for the CatWalk test via a 12 g/day food restriction protocol	22821
@VP	motivated for the CatWalk test via a 12 g/day food restriction protocol	22826
@VP	were deprived of food	22935
@VP	deprived of food	22940
@VP	pellets PJPPP-0045 ; Sandown Chemical Ltd. , Hampton , UK	22994
@VP	were used as a reward	23089
@VP	used as a reward	23094
@VP	were used	23151
@VP	used	23156
@VP	described -LRB- Koopmans et al. , 2005 -RRB-	23200
@VP	obtained from the CatWalk , the regularity index -LRB- RI -RRB- ,	23262
@VP	can be implemented into the BBB scoring	23316
@VP	be implemented into the BBB scoring	23320
@VP	implemented into the BBB scoring	23323
@VP	scoring	23348
@VP	multiplied by four	23455
@VP	divided by the total number of paw placements	23475
@VP	multiplied by 100 %	23525
@VP	are considered coordinated	23618
@VP	considered coordinated	23622
@VP	coordinated	23633
@VP	runs is coordinated	23689
@VP	is coordinated	23694
@VP	coordinated	23697
@VP	Transplanted Hoechst-prelabeled OEC/ONF	23893
@VP	infiltrating host cells into the lesion site	23937
@VP	were prelabeled with Hoechst 33342	24025
@VP	prelabeled with Hoechst 33342	24030
@VP	immunostained	24071
@VP	are indicated	24229
@VP	indicated	24233
@VP	delineates the spinal cord	24419
@VP	is an enlargement of the box shown in panel B.	24554
@VP	shown in panel B.	24583
@VP	Transplanted	24605
@VP	are immunoreactive for p75-NGF receptor -LRB- red -RRB-	24709
@VP	indicate a few Hoechst-prelabeled cells with p75-NGF receptor immunoreactivity	24763
@VP	are labeled after sacrificing the animals	25073
@VP	labeled after sacrificing the animals	25077
@VP	sacrificing the animals	25091
@VP	is immunoreactive for p75-NGF receptor -LRB- red -RRB-	25245
@VP	are 200 μm	25319
@VP	is 100 μm	25352
@VP	was made -LRB- B -RRB-	25547
@VP	made -LRB- B -RRB-	25551
@VP	are indicated by arrowheads	25686
@VP	indicated by arrowheads	25690
@VP	was inserted into the lesion gap -LRB- C -RRB-	25756
@VP	inserted into the lesion gap -LRB- C -RRB-	25760
@VP	was stabilized by a Dura Film covering -LRB- not shown -RRB-	25807
@VP	stabilized by a Dura Film covering -LRB- not shown -RRB-	25811
@VP	covering	25837
@VP	not shown	25847
@VP	was delineated as indicated in the schematic representation in panel A	25949
@VP	delineated as indicated in the schematic representation in panel A	25953
@VP	indicated in the schematic representation in panel A	25967
@VP	represents the approximate location of the section shown in panel B.	26045
@VP	shown in panel B.	26096
@VP	was used to identify the border of the graft/lesion site	26134
@VP	used to identify the border of the graft/lesion site	26138
@VP	to identify the border of the graft/lesion site	26143
@VP	identify the border of the graft/lesion site	26146
@VP	pass the GFAP-IR tissue -LRB- arrow in panel B -RRB-	26242
@VP	grow into the graft/lesion site -LRB- B -RRB-	26289
@VP	also passed the GFAP-IR tissue	26370
@VP	then stayed at the outer circumferences of the lesion gap	26405
@VP	showed a 10-fold increase in transplanted versus control animals -LRB- C -RRB-	26541
@VP	indicated with an asterisk	26705
@VP	were observed to approach the graft/lesion site	26946
@VP	observed to approach the graft/lesion site	26951
@VP	to approach the graft/lesion site	26960
@VP	approach the graft/lesion site	26963
@VP	grew underneath the lesion and into the caudal host spinal cord	27013
@VP	penetrated the graft/lesion site	27109
@VP	represents the delineation of the spinal cord	27227
@VP	is visible within the lesion site	27304
@VP	represent the boxes used in the quantitative analysis	27354
@VP	used in the quantitative analysis	27374
@VP	stop rostral to the graft/lesion site	27656
@VP	indicates the graft/lesion site	27715
@VP	showing that labeled corticospinal axons rostral to the graft/lesion site	27823
@VP	labeled corticospinal axons rostral to the graft/lesion site	27836
@VP	are not GAP43 IR -LRB- D -RRB-	27897
@VP	is in the middle of the graft/lesion site	28008
@VP	indicates the graft/lesion site	28076
@VP	were only noted in one or two transplanted and control animals	28245
@VP	noted in one or two transplanted and control animals	28255
@VP	are 100 μm	28320
@VP	assessed in the CatWalk gait analysis	28587
@VP	swing speed of the hind limbs	28736
@VP	improved in transplanted versus control animals -LRB- C , D -RRB-	28785
@VP	were identical to those described previously -LRB- Li et al. , 1998 -RRB-	28897
@VP	described previously -LRB- Li et al. , 1998 -RRB-	28921
@VP	contained two main cell populations : the OEC and the ONF	28974
@VP	elongated , spindle-shaped cells co-expressing p75-NGF receptor and S100β	29061
@VP	co-expressing p75-NGF receptor and S100β	29093
@VP	expressed the GFAP protein , either diffusely or intensely	29152
@VP	expressed the GFAP protein	29152
@VP	diffusely or intensely	29187
@VP	consisted of multiple cell types with a flattened fibroblast-like morphology	29230
@VP	suggested the presence of fibroblasts and astrocytes , respectively	29372
@VP	decreased -LRB- Deumens et al. , 2004 -RRB-	29511
@VP	suggested	29749
@VP	stained -LRB- blue -RRB- nucleus -LRB- Fig. 1A -RRB-	30116
@VP	received a 2-mm-long dorsal hemisection injury at T11/T12 -LRB- Fig. 2 -RRB-	30188
@VP	completely filled the lesion gap -LRB- Fig. 2 -RRB-	30311
@VP	received culture medium injections at the same locations in the host tissue	30485
@VP	gained body weight in the weeks thereafter	30688
@VP	not shown	30864
@VP	were sacrificed	30999
@VP	sacrificed	31004
@VP	dissecting the paraformaldehyde-fixed spinal cords from the transplanted animals	31031
@VP	were clearly visible at the lesion sites	31145
@VP	covered the graft/lesion site	31233
@VP	taking the	31316
@VP	fixated spinal cord out of the animals	31327
@VP	was carried out with much care	31391
@VP	carried out with much care	31395
@VP	was to a large extent disconnected from the host spinal tissue in many animals	31520
@VP	disconnected from the host spinal tissue in many animals	31542
@VP	was often observed between the complex and the underlying host spinal tissue	31625
@VP	observed between the complex and the underlying host spinal tissue	31635
@VP	was noted in nearly all transplanted animals	31778
@VP	noted in nearly all transplanted animals	31782
@VP	suggesting partly complex degradation	31908
@VP	was devoid of any tissue	31983
@VP	Transplanted Hoechst-prelabeled OEC/ONF	32009
@VP	could easily be found at the levels of the rostral and caudal injection sites	32049
@VP	be found at the levels of the rostral and caudal injection sites	32062
@VP	found at the levels of the rostral and caudal injection sites	32065
@VP	could be detected on the biomatrix complexes	32137
@VP	be detected on the biomatrix complexes	32143
@VP	detected on the biomatrix complexes	32146
@VP	was immunoreactive for the p75-NGF receptor -LRB- Fig. 1D -RRB-	32788
@VP	were located at approximately 1 mm rostral and caudal to the lesion gap	33108
@VP	to investigate whether host cells migrated into the transplanted complexes	33403
@VP	investigate whether host cells migrated into the transplanted complexes	33406
@VP	migrated into the transplanted complexes	33437
@VP	invaded the biomatrix complexes -LRB- Fig. 1E -RRB-	33524
@VP	suggesting them to be invading Schwann cells -LRB- Fig. 1F -RRB-	33688
@VP	to be invading Schwann cells -LRB- Fig. 1F -RRB-	33704
@VP	be invading Schwann cells -LRB- Fig. 1F -RRB-	33707
@VP	invading Schwann cells -LRB- Fig. 1F -RRB-	33710
@VP	remains elusive	33791
@VP	focusing on axon regrowth per se	33860
@VP	to see whether axons penetrated the transplanted OEC/ONF -- biomatrix complex	33913
@VP	see whether axons penetrated the transplanted OEC/ONF -- biomatrix complex	33916
@VP	penetrated the transplanted OEC/ONF -- biomatrix complex	33934
@VP	performed a general neurofilament -LRB- NF -RRB- staining	34007
@VP	was occasionally an NF-positive fiber passing the GFAP-positive scar	34082
@VP	passing the GFAP-positive scar	34120
@VP	covering the grafts	34481
@VP	was performed	34532
@VP	performed	34536
@VP	was designed to completely fill up the lesion site	34567
@VP	designed to completely fill up the lesion site	34571
@VP	to completely fill up the lesion site	34580
@VP	completely fill up the lesion site	34583
@VP	filled up this lesion gap	34777
@VP	to delineate the graft/lesion site -LRB- Fig. 3A -RRB-	34834
@VP	delineate the graft/lesion site -LRB- Fig. 3A -RRB-	34837
@VP	demarcated by the GFAP-IR boundary	34919
@VP	not shown	35033
@VP	not shown	35409
@VP	was successful in nine out of ten transplanted animals	35467
@VP	in seven out of eight control animals	35526
@VP	observed to approach the graft/lesion site -LRB- Figs. 4A , C , D -RRB-	35599
@VP	to approach the graft/lesion site -LRB- Figs. 4A , C , D -RRB-	35608
@VP	approach the graft/lesion site -LRB- Figs. 4A , C , D -RRB-	35611
@VP	were observed to penetrate the graft in any of the animals	35775
@VP	observed to penetrate the graft in any of the animals	35780
@VP	to penetrate the graft in any of the animals	35789
@VP	penetrate the graft in any of the animals	35792
@VP	was observed underneath the graft/lesion site	35871
@VP	observed underneath the graft/lesion site	35875
@VP	was also the case caudal to the lesion site -LRB- Fig. 4E -RRB-	35978
@VP	varied among the animals	36077
@VP	was 12.3 % at maximum and 0.15 % at minimum	36149
@VP	were present between the two groups of animals	36256
@VP	was found -LRB- Group : F1 ,14 = 12.09 , P < 0.01 -RRB-	37021
@VP	found -LRB- Group : F1 ,14 = 12.09 , P < 0.01 -RRB-	37025
@VP	compared to control animals	37217
@VP	to control animals	37226
@VP	control animals	37229
@VP	approaching the host/graft interface	37515
@VP	were sprouting axons	37552
@VP	sprouting axons	37557
@VP	was performed	37602
@VP	performed	37606
@VP	were analyzed for GAP43	37719
@VP	analyzed for GAP43	37724
@VP	did we observe	37826
@VP	observe	37833
@VP	involves a reduced die-back	37969
@VP	resulted in functional impairment of the animals	38067
@VP	was extensive movements of the hip , the knee , and the ankle	38275
@VP	had plantar placement of the hind paws , many with weight support	38384
@VP	showed consistent weight supported plantar stepping -LRB- BBB score 11 -RRB-	38491
@VP	supported plantar stepping -LRB- BBB score 11 -RRB-	38516
@VP	stepping -LRB- BBB score 11 -RRB-	38534
@VP	were followed in the BBB locomotor test on a weekly basis	38715
@VP	followed in the BBB locomotor test on a weekly basis	38720
@VP	remained at a BBB score of 11 from the third week to the ninth week	38929
@VP	supported plantar stepping without coordination -LRB- Basso et al. , 1995 -RRB-	39055
@VP	stepping without coordination -LRB- Basso et al. , 1995 -RRB-	39073
@VP	can be regarded as an objective measure of coordination	39186
@VP	be regarded as an objective measure of coordination	39190
@VP	regarded as an objective measure of coordination	39193
@VP	are integrated into the BBB scores at 3 , 6 , and 9 weeks after injury	39284
@VP	integrated into the BBB scores at 3 , 6 , and 9 weeks after injury	39288
@VP	were dramatically increased -LRB- Fig. 5B -RRB-	39369
@VP	increased -LRB- Fig. 5B -RRB-	39387
@VP	Transplanted	39408
@VP	using a Student 's t test	39585
@VP	are statistically significant using a Student 's t test -LRB- P < 0.01 -RRB-	39874
@VP	using a Student 's t test -LRB- P < 0.01 -RRB-	39904
@VP	increased to a similar extent in	39962
@VP	crossing With respect to the CatWalk gait analysis	40249
@VP	crossing	40354
@VP	crossing in both animal groups when comparing the various locomotor parameters	40506
@VP	comparing the various locomotor parameters	40542
@VP	crossing	40781
@VP	was no further increase in runway crossing in both animal groups	40951
@VP	crossing in both animal groups	40985
@VP	crossing time	41392
@VP	was found between the two animal groups at any of the four time points	41406
@VP	found between the two animal groups at any of the four time points	41410
@VP	can be made at any given time point	41544
@VP	be made at any given time point	41548
@VP	made at any given time point	41551
@VP	was 148.1 ± 2.8 mm and 140.2 ± 2.6 mm , respectively -LRB- n.s. ; Fig. 5C -RRB-	41840
@VP	was observed between the two groups -LRB- Group : F1 ,16 = 6.11 , P < 0.05 -RRB-	42073
@VP	observed between the two groups -LRB- Group : F1 ,16 = 6.11 , P < 0.05 -RRB-	42077
@VP	crosses within one step cycle and the time	42515
@VP	takes	42578
@VP	were found for both stride length of the hind limbs	43197
@VP	found for both stride length of the hind limbs	43202
@VP	swing speed of the hind limbs	43253
@VP	not shown	43358
@VP	did not migrate from these areas	43972
@VP	migrate from these areas	43980
@VP	was not formed	44034
@VP	formed	44042
@VP	stimulated numerous axons to grow into the OEC/ONF -- biomatrix complex	44114
@VP	to grow into the OEC/ONF -- biomatrix complex	44140
@VP	grow into the OEC/ONF -- biomatrix complex	44143
@VP	was of CS or raphespinal origin	44204
@VP	did not enter the graft in any of the animals	44267
@VP	enter the graft in any of the animals	44275
@VP	rostral to the injury site	44413
@VP	was GAP43/B50 - positive	44608
@VP	used stimulated a recovery in stride length and swing speed of the hind limbs	44675
@VP	used stimulated a recovery in stride length	44675
@VP	stimulated a recovery in stride length	44680
@VP	swing speed of the hind limbs	44723
@VP	were transplanted into complete or incomplete transection sites , injured	45199
@VP	transplanted into complete or incomplete transection sites , injured	45204
@VP	injured	45264
@VP	regrowing across these small lesion gaps	45406
@VP	injured	45448
@VP	suggests a cooperation of the transplanted OEC with fibroblasts	45600
@VP	require long-distance axon regrowth	45731
@VP	to regrow around large spinal lesion gaps -LRB- Chuah et al. , 2004 -RRB-	45856
@VP	regrow around large spinal lesion gaps -LRB- Chuah et al. , 2004 -RRB-	45859
@VP	transplanted OEC	46115
@VP	were not able to stimulate long-distance regrowth of injured CS axons	46137
@VP	to stimulate long-distance regrowth of injured CS axons	46151
@VP	stimulate long-distance regrowth of injured CS axons	46154
@VP	has been quite unexplored	46371
@VP	been quite unexplored	46375
@VP	required in large spinal lesion gaps	46431
@VP	may be influence by at least three issues	46469
@VP	be influence by at least three issues	46473
@VP	Injured CS axons	46581
@VP	composed of immature astrocytes in a collagen matrix	46631
@VP	did not re-enter the caudal host	46688
@VP	re-enter the caudal host	46696
@VP	was influenced by the absence of transplanted cells in the host tissue	46830
@VP	influenced by the absence of transplanted cells in the host tissue	46834
@VP	transplanted into the large lesion gaps	46933
@VP	stimulate long-distance olfactory axon regeneration -LRB- Li et al. , 2005 -RRB-	47348
@VP	be beneficial to stimulate long-distance regrowth of axons severed by an SCI	47460
@VP	to stimulate long-distance regrowth of axons severed by an SCI	47474
@VP	stimulate long-distance regrowth of axons severed by an SCI	47477
@VP	severed by an SCI	47519
@VP	were addressed	47609
@VP	addressed	47614
@VP	cultured on biomatrices	47708
@VP	described previously	47843
@VP	may then create an OEC/ONF continuum	47883
@VP	create an OEC/ONF continuum	47892
@VP	are known to stimulate directional neurite outgrowth in vitro	47973
@VP	known to stimulate directional neurite outgrowth in vitro	47977
@VP	to stimulate directional neurite outgrowth in vitro	47983
@VP	stimulate directional neurite outgrowth in vitro	47986
@VP	were transplanted into the lesion gaps	48059
@VP	transplanted into the lesion gaps	48064
@VP	were used	48129
@VP	used	48134
@VP	has rendered two main histological outcomes	48188
@VP	rendered two main histological outcomes	48192
@VP	directly rostral to the spinal lesion gap -LRB- Fig. 4 -RRB-	48291
@VP	seemed to have an aligned phenotype	48472
@VP	to have an aligned phenotype	48479
@VP	have an aligned phenotype	48482
@VP	were immunonegative for GAP43/B50	48658
@VP	normally starts directly after injury	48722
@VP	propose three possibilities involved in the contrasting results	49229
@VP	involved in the contrasting results	49257
@VP	survived in small lesion gaps -LRB- Li et al. , 1997 , 1998 , 2003 -RRB-	49329
@VP	transplanted into the large lesion gap -LRB- see below -RRB-	49483
@VP	see below	49523
@VP	differed from ours	49590
@VP	differed , i.e. high cervical vs. low thoracic	49634
@VP	to regrow	49713
@VP	regrow	49716
@VP	defined lesion of the CS tract vs. 2 - mm-wide dorsal hemisection injury	49899
@VP	simply injecting OEC/ONF suspensions -LRB- Li et al. , 1998 -RRB-	50074
@VP	may consist of growth-promoting cells and biodegradable matrices	50325
@VP	consist of growth-promoting cells and biodegradable matrices	50329
@VP	see also below	50645
@VP	may require more than the 9 weeks	50748
@VP	require more than the 9 weeks	50752
@VP	showing CS axons present almost exclusively rostral to the injury site	50916
@VP	is not the determining factor in the CS axon regrowth response	51023
@VP	were infiltrated by numerous host cells expressing the p75-NGF receptor	51913
@VP	infiltrated by numerous host cells expressing the p75-NGF receptor	51918
@VP	expressing the p75-NGF receptor	51953
@VP	taking out the dorsal half of the spinal cord over a distance of 2 mm	52128
@VP	did not receive a transplant	52222
@VP	receive a transplant	52230
@VP	had only a minor penetration of NF-positive axons into the lesion site	52262
@VP	may be explained by the lack of host cell infiltration into the lesion site	52339
@VP	be explained by the lack of host cell infiltration into the lesion site	52343
@VP	explained by the lack of host cell infiltration into the lesion site	52346
@VP	penetrated the graft/lesion site of OEC/ONFtransplanted animals	52459
@VP	were observed throughout the complex	52666
@VP	observed throughout the complex	52671
@VP	observed immunoreactivity for the p75 - NGF receptor	52753
@VP	pores of the biomatrix	52946
@VP	invading host cells	52977
@VP	may account for the stimulation of NF ingrowth into the graft	52997
@VP	account for the stimulation of NF ingrowth into the graft	53001
@VP	were GAP43/B50-positive , confirming their regrowing	53112
@VP	confirming their regrowing	53137
@VP	regrowing	53154
@VP	sprouting nature	53165
@VP	is yet unclear	53228
@VP	could be excluded	53272
@VP	be excluded	53278
@VP	excluded	53281
@VP	ingrowing axons	53308
@VP	may have a peripheral origin -LRB- e.g.	53324
@VP	have a peripheral origin -LRB- e.g.	53328
@VP	has been described previously	53390
@VP	been described previously	53394
@VP	described previously	53399
@VP	compared to control animals	53600
@VP	to control animals	53609
@VP	control animals	53612
@VP	is multifactorial	53664
@VP	stimulating neurofilamentpositive axon growth into the transplanted OEC/ONF	53733
@VP	is it the transplanted OEC/ONF or the biomatrix	53830
@VP	using a similar quantification procedure	53911
@VP	be sufficient to stimulate NF axon ingrowth into the graft/lesion site	54129
@VP	to stimulate NF axon ingrowth into the graft/lesion site	54143
@VP	stimulate NF axon ingrowth into the graft/lesion site	54146
@VP	invading the biomatrix after transplantation	54254
@VP	could be detected within the spinal lesion gap , many prelabeled cells	54393
@VP	be detected within the spinal lesion gap , many prelabeled cells	54399
@VP	detected within the spinal lesion gap , many prelabeled cells	54402
@VP	were observed within the injection areas -LRB- Fig. 1 -RRB-	54463
@VP	observed within the injection areas -LRB- Fig. 1 -RRB-	54468
@VP	stain host cells -LRB- Iwashita et al. , 2000 -RRB-	54766
@VP	are transplanted OEC/ONF that survived	55003
@VP	survived	55033
@VP	survived transplantation into the injection areas	55072
@VP	did not migrate within the injured spinal cord	55128
@VP	migrate within the injured spinal cord	55136
@VP	showing migration of olfactory glia after injection into the injured spinal cord	55276
@VP	remains to be determined	55573
@VP	to be determined	55581
@VP	be determined	55584
@VP	determined	55587
@VP	may have impeded CS axon regrowth because no OEC/ONF continuum was created	55709
@VP	have impeded CS axon regrowth because no OEC/ONF continuum was created	55713
@VP	impeded CS axon regrowth because no OEC/ONF continuum was created	55718
@VP	was created	55772
@VP	created	55776
@VP	released from such processes	55960
@VP	be higher in spinal lesions which are larger -LRB- Wagner et al. , 1978 -RRB-	55993
@VP	are larger	56027
@VP	to create a continuum of these cells with spinal cords with large lesion gaps	56436
@VP	create a continuum of these cells with spinal cords with large lesion gaps	56439
@VP	is in contrast with previous findings -LRB- Sasaki et al. , 2004 -RRB-	56593
@VP	may be involved	56690
@VP	be involved	56694
@VP	involved	56697
@VP	released by pathological processes	56766
@VP	have affected the survival of OEC/ONF-transplanted into these large lesion gaps	56805
@VP	affected the survival of OEC/ONF-transplanted into these large lesion gaps	56810
@VP	were cultured on the biomatrix surface facing the injured spinal tissue	56904
@VP	cultured on the biomatrix surface facing the injured spinal tissue	56909
@VP	facing the injured spinal tissue	56943
@VP	are directly available to these transplanted OEC / ONF	56998
@VP	were embedded in collagen type I matrices and were thereby	57177
@VP	were embedded in collagen type I matrices	57177
@VP	embedded in collagen type I matrices	57182
@VP	were thereby	57223
@VP	during 4 days in vitro	57646
@VP	are relatively low	57707
@VP	studied time points after injury	58043
@VP	to transplant OEC/ONF into the large spinal lesion gaps	58165
@VP	transplant OEC/ONF into the large spinal lesion gaps	58168
@VP	may have negatively affected OEC/ONF survival	58221
@VP	have negatively affected OEC/ONF survival	58225
@VP	negatively affected OEC/ONF survival	58230
@VP	may impair OEC / ONF survival	58390
@VP	impair OEC / ONF survival	58394
@VP	stimulated modest recovery of fine locomotor parameters -LRB- Fig. 5 -RRB-	58661
@VP	may reflect an involvement of axonal regrowth	58869
@VP	reflect an involvement of axonal regrowth	58873
@VP	directly linking regrowth of individual axon tracts and functional recovery	58944
@VP	is impossible -LRB- Deumens et al. , 2005 -RRB-	59020
@VP	demonstrated in this study	59107
@VP	could be determined	59554
@VP	be determined	59560
@VP	determined	59563
@VP	descending from the brain that are more likely to be linked with stride length	59668
@VP	are more likely to be linked with stride length	59699
@VP	to be linked with stride length	59715
@VP	be linked with stride length	59718
@VP	linked with stride length	59721
@VP	described by others -LRB- Bareyre et al. , 2004 -RRB-	59809
@VP	can not be excluded	59852
@VP	be excluded	59859
@VP	excluded	59862
@VP	is restricted to only a small subset of locomotor parameters	59917
@VP	using the CatWalk gait analysis	60219
@VP	were not as severely impaired as expected	60332
@VP	expected	60365
@VP	assessed in the CatWalk	60412
@VP	remained unaffected	60436
@VP	is	60491
@VP	is strongly involved in coordination	60527
@VP	involved in coordination	60539
@VP	using a spinal cord contusion injury	60774
@VP	housed animals as compared to normally housed animals	61000
@VP	was implemented into the BBB in the present study	61138
@VP	implemented into the BBB in the present study	61142
@VP	increased to a similar extent	61240
@VP	could be observed	61308
@VP	be observed	61314
@VP	observed	61317
@VP	leaving open an only very small window for functional recovery	61472
@VP	stimulating regrowth of injured CS axons across large spinal lesion gaps	61611
@VP	focus on optimalization of the transplantation strategy	61906
@VP	have a much wider behavioral window for the determination of therapeutic effects	62414
@VP	thank Dr.	62524
@VP	developed by Dr.	62949
@VP	developed under the auspices of the NICHD	63034
@VP	maintained by The University of Iowa , Department of Biological Sciences ,	63080
